1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41
row_id,oMIM_ID,oMIM_ID__via_disease_name,omim_number_prefix,omim_number,omim_title_preferred,omim_title_alternative,omim_title_included,disease_name,disease_comments,gene_affected__orig,gene_affected__csv,enzyme_or_protein_detected,enzyme_or_protein_detected__sha256,uniprotids_and_or_ecnumbers_gene_product__orig,ec_number__csv,uniprot_ID__csv,regimen_name,regimen_comments,drug_IDs__orig,drug_ID2,drug_ID2__sha256,drug_ID__ORed__csv,drugbank_ID__ORed__csv,chEBI_ID__ORed__csv,wHOCC_ID__ORed__csv,drug_ID__ANDed__csv,drugbank_ID__ANDed__csv,chEBI_ID__ANDed__csv,wHOCC_ID__ANDed__csv,study_type_evidence_codes__orig,study_type_evidence_code__csv,mutation_improved_by_treatment__csv,mutation_not_improved_by_treatment__csv,regimen_mechanism_of_action__csv,regimen_mechanism_of_action_abbreviation__csv,phenotype_improved_by_treatment__csv,phenotype_ID__csv,phenotype_improved_by_treatment_comments,treatment_manuscript_reference__csv,XML/RDF
1,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,Hydrocortisone,,DB00741,DB00741,d55f242360bccc5155198cd6643f9c51065254fd32e5c26b3016071ac1965000,DB00741,DB00741,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Abnormal plasma aldosterone,HP:0040085,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337,https://www.ncbi.nlm.nih.gov/pubmed/18458702",
2,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Abnormality of potassium homeostasis,HP:0011042,,,
3,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Abnormal circulating renin,HP:0040084,,,
4,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Hypertension,HP:0000822,,,
5,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,Dexamethasone,,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Abnormal plasma aldosterone,HP:0040085,,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,
6,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",
7,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Abnormal circulating renin,HP:0040084,,,
8,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",
9,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Bone massÂ loss,NA,,,
10,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,Testosterone,,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Puberty and gonadal disorders,HP:0008373,,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,
11,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,"Estrogen replacement (                                                             
Estradiol)",,DB00783,DB00783,102bf3a48f5629450533d490b6f3cdafd4acafc04910d4d17440e7aa962a1c8d,DB00783,DB00783,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Puberty and gonadal disorders,HP:0008373,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",
12,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,Cyclic medroxyprogesterone,,DB00603,DB00603,a234730cb907c7cbc30f1d06491247dca9bcee6c19ee863a6a46f31a1859ca56,DB00603,DB00603,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Puberty and gonadal disorders,HP:0008373,,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,
13,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Amenorrhea,HP:0000141,,,
14,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,Pioglitazone,,DB01132,DB01132,b480a29fbdfeb3ae6ee3a43c7963906cce5e34d9d28da69bf7c49540c1f2f6b6,DB01132,DB01132,,,,,,,ECO:0007121 /ECO:0000352,"ECO:0007121,ECO:0000352",,,Supportive (C),C,Insulin resistance,HP:0000855,,"https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php?lng=EN&data_id=38680&ClinicalTrialName=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&title=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&search=ResearchTrials_ClinicalTrials_Simple,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",
15,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1 gene,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,,,,,,,,,,,,,,,,,,,Hypertension,HP:0000822,,,
16,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,Riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Cognitive impairment,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/22391998,
17,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,https://www.ncbi.nlm.nih.gov/pubmed/24321868,
18,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,Poor motor coordination,HP:0002275,,https://www.ncbi.nlm.nih.gov/pubmed/24321868,
19,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,Flavin adenine dinucleotide + levocarnitine chloride.,,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B)+Supportive (C),B+C,defected  L-2-HGDH enzyme activity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998",
20,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998",
21,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,Leukodystrophy,HP:0002415,,,
22,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,dystonia,HP:0001332,,,
23,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,Neurological impairment,HP:0000707,,https://n.neurology.org/content/70/13/1051,
24,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,FAD+Riboflavin,,DB03147+DB00140,DB03147 + DB00140,4b5bf2ddcc7a779a722942c2cd15bf316ab54c01c6bdfed05011f301fa318a51,,,,,"DB03147,DB00140","DB03147,DB00140",,,ECO:0000352,ECO:0000352,,,Direct interaction >>> activity modification,B,Neurological impairment,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",
25,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,,,,,,,,,,,,,,,,,,,,,,,
26,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,Magnesium,,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Status epilepticus,,,https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,
27,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
28,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
29,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
30,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
31,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,Citrate treatment,,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (Mechanistic B),B,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/24687295,
32,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,,,,,,,,,,,,,,,,,,,D-2-hydroxyglutaric aciduria,HP:0012321,,,
33,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,,,,,,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,,
34,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,,,,,,,,,,,,,,,,,,,low urinary excretion of TCA cycle intermediates malate and succinate,,,,
35,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,,,,,,,,,,,,,,,,,,,Hypocitraturia,HP:0012405,,,
36,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,Benzhexol,,DB00376,DB00376,9bd438fb7ce723e5b6b6831690d700f1ff2b5deea66023810bd5ce522026558d,DB00376,DB00376,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tremor,HP:0001337,,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,
37,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,,,,,,,,,,,,,,,,,,,dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,
38,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,Vigabatrin,,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,seizures,HP:0001250,,"http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985,https://www.ncbi.nlm.nih.gov/pubmed/11102558",
39,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,levodopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/30013934,
40,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,carbidopa,,DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tremor,HP:0001337,,https://www.ncbi.nlm.nih.gov/pubmed/30013934,
41,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,cefoperazone sodium,,DB01329,DB01329,69098c55654437667604f916e5d7dd4edfd33469799a94712a877f90391da29b,DB01329,DB01329,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal inflammatory response,HP:0012647,,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,
42,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,tazobactam sodium,,DB01606,DB01606,bc8be247387bc1fdd57acef1e85b75b700eebfb8304ff98db9adb3ba61cb9b01,DB01606,DB01606,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal inflammatory response,HP:0012647,,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,
43,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,B vitamins,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormality of the nervous system,HP:0000707,,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,
44,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,creatine phosphate sodium,,DB13191,DB13191,8c5d446d48c0426cf1e66e63a0d9c479682d29dcaf4e6354cf7b4b54b71a3b7a,DB13191,DB13191,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormality of cardiovascular system physiology,HP:0011025,,,
45,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,Carbamazepine,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/22132097,
46,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,Carnitine,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal muscle physiology,HP:0011804,,https://www.ncbi.nlm.nih.gov/pubmed/22132097,
47,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,,,,,,,,,,,,,,,,,,,,,,,
48,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,,,,,,,,,,,,,,,,,,,,,,,
49,610006,610006,Number Sign,610006,2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,2-METHYLBUTYRYL GLYCINURIA;; SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD,,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSBÂ gene,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,00c7809543aa8a8bfefd5f2daf283c2a80b3dc1de6b593d6cbc7ea68f7478b31,1.1.1.178,1.1.1.178,,L-Carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormality of muscle physiology,HP:0011804,,"http://www.babysfirsttest.org/newborn-screening/conditions/2-methylbutyrylglycinuria,https://www.newbornscreening.info/Parents/organicaciddisorders/2MBC.html#4",
50,610006,610006,Number Sign,610006,2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,2-METHYLBUTYRYL GLYCINURIA;; SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD,,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSBÂ gene,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,00c7809543aa8a8bfefd5f2daf283c2a80b3dc1de6b593d6cbc7ea68f7478b31,1.1.1.178,1.1.1.178,,,,,,,,,,,,,,,,,,,,,Elevated serum toxic intermediates in isoleucine pathway,HP:0001939,,,
51,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,Biotin,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,ECO:0000352,ECO:0000352,MCCA-R385S(heterozygote mutation),MCCB-(IVS16Ã¾1G>A)/ MCCB-missense mutation E99Q Homozygous mutation,Functional interaction(Mechanistic B),B,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",
52,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,"""heterozygote missense mutation, MCCA-R385S""",,,,Organic aciduria,HP:0001992,,,
53,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,EEG abnormality,HP:0002353,,,
54,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,Hypsarrhythmia,HP:0002521,,https://www.ncbi.nlm.nih.gov/pubmed/16773504,
55,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,vigabatrin,,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/16773504,
56,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,Increased 3-hydroxyisovaleric acid excretion,NA,,,
57,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,Increased 3-methylcrotonylglycine excretion,NA,,,
58,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,abnormal Biotinidase activity in plasma,NA,,,
59,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,EEG abnormality,HP:0002353,,,
60,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,L-Carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Abnormality of muscle physiology,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/10485305,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055",
61,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,secondary carnitine deficiency,HP:0003234*,,https://www.ncbi.nlm.nih.gov/pubmed/8831079,
62,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,elevated serum toxic intermediates (,HP:0001939,,,
63,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,Glycine,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,defected excertion of 3- MCG,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079",
64,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,HP:0001939 *,,,
65,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,Glycine +L-Carnitine,,DB00145Â +DB00583,DB00145 + DB00583,3b944267403c33e88c1ec7983b17d0d2af8877b8be5653fb334888feee30467e,,,,,"DB00145,DB00583","DB00145,DB00583",,,ECO:0000352,ECO:0000352,,,,,Acute metabolic crisis ( Metabolism abnormality)*,HP:0001939 *,,https://link.springer.com/article/10.1007/BF00710419,
66,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,,,,,,,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,HP:0001939 *,,"https://link.springer.com/article/10.1007/BF00710419,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948",
67,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,secondary carnitine deficiency,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948",
68,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,high  short chain acyl-carnitine metabolite level,HP:0001939,,,
69,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Muscle weakness,HP:0001324,,https://link.springer.com/article/10.1023%2FA%3A1024031714659?LI=true,
70,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,vitamin E supplements,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Abnormality of peripheral nerves,HP:0045010,,https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,
71,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Neuropathy,HP:0009830,,,
72,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,Triheptanoin,,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Myalgia,HP:0003326,,"https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/",
73,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Abnormal cardiac function,HP:0011025,,,
74,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Fatigue,HP:0011025,,,
75,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,Prednisone,,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352,ECO:0000352,,,,,Fatigue,HP:0011025,,"https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F",
76,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Impaired nerve conduction,HP:0040129,,,
77,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Defected mucle plasma membrane,,,,
78,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,,,,,,,,,,,,,,,,,,,,Defected neuronal plasma membrane,,,,
79,236795,236795,Percent,236795,3-HYDROXYISOBUTYRIC ACIDURIA,,,3-Hydroxyisobutyric aciduria,,ALDH6A1 gene,ALDH6A1,3-hydroxyisobutyrate dehydrogenase,96a7c136253464a3a84f7709f116ef98d6a3e4b4a291cec9a46a1d22484f4a89,1.1.1.31,1.1.1.31,,Carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,acidemia,HP:0001941,,http://eknygos.lsmuni.lt/springer/365/81-92.pdf,
80,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUHÂ gene,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new",
81,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUHÂ gene,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,,,,,,,,,,,,,,,,,,,,Abnormality of movement,HP:0100022,,,
82,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUHÂ gene,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,,,,,,,,,,,,,,,,,,,,Metabolic Decompensation,HP:0001939,,https://www.ncbi.nlm.nih.gov/pubmed/11400757/,
83,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUHÂ gene,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,,,,,,,,,,,,,,,,,,,,Delayed Growth,HP:0001510,,,
84,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,Sapropterin,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,Functional interaction( Mechanistic B),B,Behavioral abnormality,HP:0000708,,https://www.ncbi.nlm.nih.gov/pubmed/19323589,
85,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Personality disorder,HP:0012075,,,
86,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,HP:0004923,,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,
87,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,Antisense morpholino oligonucleotides (AMOs),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,"""c.84â322A>T, c.163 + 695_163 + 751del57, or c.164â712A>T""",,Direct interaction (Mechanistic A),A,pseudoexon activation,NA,,https://www.ncbi.nlm.nih.gov/pubmed/21542064,
88,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,BH4+L-Dopa+5HTP,,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",
89,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,HP:0012535,,https://www.ncbi.nlm.nih.gov/pubmed/25304915,
90,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/25304915,
91,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormality,HP:0012759,,https://www.ncbi.nlm.nih.gov/pubmed/25304915,
92,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Intellectual disability,HP:0001249,,https://www.ncbi.nlm.nih.gov/pubmed/25304915,
93,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Delayed CNS mylinaton,HP:0002188,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879",https://www.ncbi.nlm.nih.gov/pubmed/16601879,
94,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,Oxitriptan,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Abnormality of neurotransmitter metabolism,HP:0012535,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879","https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879",
95,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Abnormality in serotonin turnover (Abnormality of circulating hormone level),HP:0003117,,,
96,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,levodopa (L-dopa),"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRDâplus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of lâdopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879",
97,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Paroxysmal movements,HP:0007166,,,
98,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Movement disorder,HP:0100022,,,
99,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,carbidopa,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879",
100,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,pramipexole + L- dopa,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",DB00413+DB01235,DB00413 + DB01235,7595e126d2990dac6112bbf564594e94ac729fdf3635748cc9c255c7e0df00ae,,,,,"DB00413,DB01235","DB00413,DB01235",,,ECO:0007121,ECO:0007121,,,Functional interaction( Mechanistic B),B,Movement Disability,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879",
101,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,High prolactin level,HP:0000870,,,
102,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Behavioural Disability,HP:0000708,,,
103,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,,,,,,,,,,,,,,,,,,,,Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*,NA,,,
104,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,selective monoamine oxidase (MAO) B inhibitor,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",DB01247,DB01247,f9b43a00b76b73233eb21ecbe37b0b4ea50b8b79310d1c2d90628c6f5473068a,DB01247,DB01247,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,allows for lower doses of neurotransmitter precursor to avoid their side effects.,NA,,"https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/",
105,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,folinic acid,,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Abnormal serum folate,HP:0040087,,,
106,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,BH4,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Elevated Phe level in blood,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/",
107,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,,
108,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,BH4+L-dopa+5-hydroxytryptophan,,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Elevated blood phenylalanine concentration,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986",
109,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,HP:0012535,,,
110,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,,
111,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,,DB00360+DB01235+DB02959+DB03256,DB00360 + DB01235 + DB02959 + DB03256,19db2fce0e879d3ee2f4f7d58588f280ddd7cfc17d9c0d4fbb52645399aa8f57,,,,,"DB00360,DB01235,DB02959,DB03256","DB00360,DB01235,DB02959,DB03256",,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Developmental delay,HP:0001263,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,
112,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Delayed receptive language,HP:0010863,,,
113,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Neurological impairment,HP:0000707,,,
114,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,HP:0004923,,,
115,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,folinic acid,,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Progressive basal ganglia calcification,HP:0002135,,"https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346",
116,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Subcortical calcification,HP:0007346,,,
117,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,Seizure,HP:0001250,,,
118,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,,,,,,,,,,,,,,,,,,,,,,,,
119,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,"The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038",MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,vitamin E therapy,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,nervous system abnormalities,HP:0002011,,"https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038",
120,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,,,,,,,,,,,,,,,,,,,,neurologic dysfunction,HP:0000707,,,
121,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,,,,,,,,,,,,,,,,,,,,Retinopathy,HP:0000488,,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,
122,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,medium-chain fatty acid supplements,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Growth impairment,HP:0008897,,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,
123,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,Vitamin K,,CHEBI:28384,CHEBI:28384,ecb601251a789dcf3deca6380d185812b577fddd0923e2054edf04a013beef8f,CHEBI:28384,,CHEBI_28384,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,HP:0002630,,https://www.ncbi.nlm.nih.gov/pubmed/26396722,
124,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,Vitamin D,,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,HP:0002630,,,
125,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,vitamin A+ Vitamin E,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Retinal degeneration,HP:0000546,,"https://www.ncbi.nlm.nih.gov/pubmed/11767031,https://www.ncbi.nlm.nih.gov/pubmed/30731125",
126,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,https://www.ncbi.nlm.nih.gov/pubmed/14749227,
127,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,DB13959 + DB00162 + DB11094 + DB00163 + CHEBI:28384,c642fea6ddbc185bb2eb49ab478df353841ffddc084150ddba0a6f4df2f17523,,,,,"DB13959,DB00162,DB11094,DB00163,CHEBI:28384","DB13959,DB00162,DB11094,DB00163",CHEBI_28384,,ECO:0000352,ECO:0000352,,,Supportive (C),,Neurological abnormalities,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/24288038,
128,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,,,,,,,,,,,,,,,,,,,,Disease progression (Progressive),HP:0003676,,,
129,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,Progesteron,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",DB00396,DB00396,443360a06525a0b3f190045706807cee5cf695a7a3bd5cd542dd2d9d76fdcf4c,DB00396,DB00396,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Female infertility,HP:0008222,,,
130,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,Vitamin B12+iron,,DB00115+DB01592,DB00115 + DB01592,42f42dfa1280bac5c92e5c3a432ac2ea405fd34ce350d7ef4c3b47fd3e022f07,,,,,"DB00115,DB01592","DB00115,DB01592",,,ECO:0000352,ECO:0000352,,,,,Anemia,HP:0001903,,,
131,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTPÂ gene,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,levothyroxine,,DB00451,DB00451,55499b3bcef6fb6f5029a1d7616498410a2edcee934df2555522c03ff686047b,DB00451,DB00451,,,,,,,ECO:0000352,ECO:0000352,,,,,subclinical hypothyroidism,HP:0000821,,"https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/17132287/",
132,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CPÂ gene,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,Deferasirox,,DB01609,DB01609,ece99e5185fe01b151ec6d8a32883b6ba773b80b7652158782d72699831f7b57,DB01609,DB01609,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,high serum ferritin concentration,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/",
133,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CPÂ gene,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,,,,,,,,,,,,,,,,,,,,high brain and liver iron stores,HP:0003281*,,,
134,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CPÂ gene,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,vitamin E+ Zinc,,DB00163Â +DB01593,DB00163 + DB01593,978c4fc248d12906503cf88dc8e31cc73b4a29fc630db814476e7ec27ca34bcd,,,,,"DB00163,DB01593","DB00163,DB01593",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tissue damage,NA,,,
135,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CPÂ gene,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,,,,,,,,,,,,,,,,,,,,Liver dysfunction,HP:0001410,,,
136,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CPÂ gene,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,,,,,,,,,,,,,,,,,,,,pancreatic dysfunction,HP:0001738,,,
137,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,L-Carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,fasting ketogenesis,"HP:0001946,HP:0025212",,,
138,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,,,,,,,,,,,,,,,,,,,,cardiac dysfunction,HP:0011025,,,
139,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,,,,,,,,,,,,,,,,,,,,Delayed growth,HP:0001510,,,
140,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,,,,,,,,,,,,,,,,,,,,cognitive impairment,HP:0100543,,,
141,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,zinc,,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,skin inflammation,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477",
142,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,Alopecia,HP:0001596,,,
143,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,Agitation,HP:0000713,,,
144,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,irritability,HP:0000737,,,
145,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,diarrhea,HP:0002014,,,
146,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,emotional disturbances,HP:0000712,,,
147,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,Zinc+ linoleic acid,,DB01593+DB14104,DB01593 + DB14104,b8bd26246c91a48785bb0cad4932c0b92154691812754cc3e082b9db68408b7e,,,,,"DB01593,DB14104","DB01593,DB14104",,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,,HP:0000712,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298/,
148,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,Diiodoquinoline,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",DB09115,DB09115,b40e358518c02414cf504cb64c2212cb23371f763a623218585a1f0d8675ceea,DB09115,DB09115,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,Acrodermatitis (Dermatitis)*,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520",
149,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,Diarrhea,HP:0002014,,,
150,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,Alopecia,HP:0001596,,,
151,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,Perioral dermatitis,HP:0040181,,,
152,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,Clioquinol,,DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,Dermatitis,HP:0011123,,https://www.ncbi.nlm.nih.gov/pubmed/375935,
153,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,
154,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,
155,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,Zn-DTSM (zinc ionophore),"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",,,,,,,,,,,,ECO:0001565/ ECO:0005542,"ECO:0001565,ECO:0005542",,,Functional interaction ( Mechanistic B),B,,,,https://www.ncbi.nlm.nih.gov/pubmed/30669644,
156,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,
157,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,
158,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,
159,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,Glucose,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*,HP:0010472,,"https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201",
160,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,"""(abdominal pain, nausea, vomiting)""","HP:0002027, HP:0002017",,,
161,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,Mild attack,HP:0012825,,https://www.ncbi.nlm.nih.gov/pubmed/23605132/,
162,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,Panhematin,,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",,,Functional interaction(Mechanistic B),B,pain,HP:0012531,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201",
163,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,hypertension,HP:0000822,,,
164,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,tachycardia,HP:0001649,,,
165,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,abnormal mental status,HP:0100543,,,
166,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,Acute attack,HP:0011009,,,
167,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,rh-HMBS,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct intercation (Mechanistic A),,Accumulated  plasma porphobilinogen,HP:0011009,,https://www.ncbi.nlm.nih.gov/pubmed/17375984/,
168,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,Accumulated  urine porphobilinogen,HP:0012217,,,
169,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,rhPBGD,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct intercation (Mechanistic A),,Eevated porphyrin precursors porphobilinogen,HP:0012217,,https://www.ncbi.nlm.nih.gov/pubmed/15208740/,
170,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,rAAV8-mediated gene therapy expressing murine HMB-synthase,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct intercation (Mechanistic A),,Hepatic metabolic abnormalities ( Metabolism abnormality)*,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/19861948,
171,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,,,,,,,,,,,,,,,,,,,,Abnormal neuromotor function,HP:0002333,,,
172,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBSÂ gene,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,AAV2/5-PBGD,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct intercation (Mechanistic A),,Low PBGD expression in liver,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pubmed/24933563",
173,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,allopurinol,,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0007121,ECO:0007121,,,Functional intearction ( Mechanistic B),B,urolithiasis,HP:0000787,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594",
174,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,crystalline nephropathy,HP:0000112,,,
175,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Hematuria,HP:0000790,,,
176,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Dysuria,HP:0100518,,,
177,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Recurrent urinary tract infections,HP:0000010,,,
178,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Chronic kidney disease,HP:0012622,,,
179,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,
180,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Kidney stones,,,,
181,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,febuxostat,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction( Mechanistic B),B,urolithiasis,HP:0000787,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594",
182,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,crystalline nephropathy,HP:0000112,,,
183,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Hematuria,HP:0000790,,,
184,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Dysuria,HP:0100518,,,
185,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Recurrent urinary tract infections,HP:0000010,,,
186,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Chronic kidney disease,HP:0012622,,,
187,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,,,,,,,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,
188,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),,DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (Mechanistic A),A,lymphopenia,HP:0001888,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies",
189,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,hepatosplenomegaly,HP:0001433,,,
190,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Elevated liver enzyme levels,HP:0002910,,,
191,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Low weight,HP:0004325,,,
192,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Abnormal eosinophil counts,HP:0001879,,,
193,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Hemolysis,HP:0001878,,,
194,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Thyroid antibodies (autoimmunity)*,HP:0002960,,,
195,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Abnormal immune function,HP:0010978,,"https://adisinsight.springer.com/trials/700243447,https://clinicaltrials.gov/ct2/show/NCT01420627,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html",
196,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,dermatitis,HP:0011123,,,
197,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,Pegademase bovine ((PEG-ADA)),"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (Mechanistic A),A,Abnormal immune function,HP:0010978,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,
198,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Recurrent infection,HP:0002719,,,
199,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,,
200,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Abnormal lymphocyte counts,HP:0040088,,,
201,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,Abnormal number of b cells,HP:0010975,,,
202,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,,,,,,,,,,,,,,,,,,,,,,,,
203,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA gene,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,Immune Globulin Human,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,DB00028,DB00028,b4a020967fdfce429d858a0849d50d3228b8294a28110560a624ebc67aa6811e,DB00028,DB00028,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Recurrent infection,HP:0002719,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,
204,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,D- Ribose,,DB02053,DB02053,eabda4f8b44a13a741f0afd53711a1dcc4bdbe6cff37bf638ddb81e693d39610,DB02053,DB02053,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Exercise-induced muscle fatigue,HP:0009020,,https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,
205,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,Exercise-induced myalgia,HP:0003738,,,
206,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,Limb muscle weakness,HP:0003690,,,
207,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,Muscle cramps,HP:0003394,,,
208,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,Lorenzo's oil(Terminated),"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",DB12528,DB12528,ff0f6cb97866beeedb0199181a2fbc05ccd6ae32f2efa71c269742fa5e0a326f,DB12528,DB12528,,,,,,,ECO:0007121,ECO:0007121,,,Supportive (C),C,Disease progression,HP:0003678,,"https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.myelin.org/lorenzos-oil/",
209,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,Abnormal elevated level of VLCFA in plasma,HP:0003455,,,
210,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,Lenti-D geneÂ therapy(advanced self-inactivating lentiviral vector TYF-ABCD1),,,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction ( Mechanistic A),A,Functional disability(Constitutional symptom)*,HP:0025142,,"https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4,https://www.myelin.org/tag/lenti-d/,https://www.ncbi.nlm.nih.gov/pubmed/28976817",
211,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,Sobetirome (NV1205),The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,DB07425,DB07425,fa24e3f98b6f364249dcdf28690475c06594501bb1e056954ecd570ce03b01c9,DB07425,DB07425,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,Functional interaction (Mechanistic B),B,Elevated long chain fatty acids,HP:0003455,,"https://www.ncbi.nlm.nih.gov/pubmed/28200172,https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/28976817",
212,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,Lovastatin,,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352/ECO:0001565/ECO:0007121,"ECO:0000352,ECO:0001565,ECO:0007121",,,Symptomatic (C),C,High plasma level of very-long-chain fatty acids,HP:0003455,,"https://www.ncbi.nlm.nih.gov/pubmed/16949688,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986",
213,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,High plasma levels of hexacosanoic acid,NA,,https://www.ncbi.nlm.nih.gov/pubmed/10870849,
214,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,interferon beta + thalidomide,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",DB00060+DB01041,DB00060 + DB01041,c793f24520a844a8b9ad79caa145585b6ebe90fdfd3570f13ca2b6dc711d6cb2,,,,,"DB00060,DB01041","DB00060,DB01041",,,ECO:0007121,ECO:0007121,,,Supportive (C),C,NO revealed clinical benefit,NA,,"https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects",
215,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,,,,,,,,,,,,,,,,,,,,,,,,
216,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1Â gene,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,Triheptanoin,,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,muscle pain,HP:0003326,,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,
217,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1Â gene,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,,,,,,,,,,,,,,,,,,,,defective heart function,HP:0011025,,,
218,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1Â gene,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,,,,,,,,,,,,,,,,,,,,Lack of energy,HP:0012378,,,
219,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglycerides,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,High blood ammonia level,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/29651749,https://www.ncbi.nlm.nih.gov/pubmed/26427088",
220,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Relapse of hyperammonemic encephalopathy,HP:0001298*,,,
221,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,High plasma citrulline levels,HP:0011966,,,
222,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,low plasma glutamine levels,HP:0010903,,,
223,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,L-Arginine,,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315",
224,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,
225,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Encephalopathy,HP:0001298,,https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article,
226,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Pyruvic acid,,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/books/NBK1181/",
227,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,L-Arginine+Pyruvic acid,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,anorexia,HP:0002039,,https://www.ncbi.nlm.nih.gov/pubmed/18958581,
228,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,lethargy,HP:0001254,,,
229,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,fatigue,HP:0012378,,,
230,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Poor growth,HP:0001510,,,
231,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,hyperammonemia,HP:0001987,,,
232,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Elevated plasma citrulline level,HP:0011966,,,
233,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*,HP:0004337*,,,
234,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,,,,,,,,,,,,,,,,,,,,Elevated serum pancreatic secretory trypsin inhibitor,NA,,,
235,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,D-mannitol,"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956",DB00742,DB00742,6901ce517b0e556bdf0e1512436665e7cacf116fb1a39fbd50503cf07b13f38d,DB00742,DB00742,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Brain oedema,HP:0002181,,https://www.ncbi.nlm.nih.gov/pubmed/16449956,
236,612953,,Number Sign,612953,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14","DYSTONIA-PARKINSONISM, ADULT-ONSET",,Adult-onset dystonia-parkinsonism,,PLA2G6,PLA2G6,Phospholipase A(2),02f5ac6177812aaaa701b880f4919006662bf03727daa1d08e827b15844dd3c8,3.1.1.4,3.1.1.4,,Pergolide,It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,parkinsonism,HP:0001300,,https://www.ncbi.nlm.nih.gov/pubmed/24613933,
237,612953,,Number Sign,612953,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14","DYSTONIA-PARKINSONISM, ADULT-ONSET",,Adult-onset dystonia-parkinsonism,,PLA2G6,PLA2G6,Phospholipase A(2),02f5ac6177812aaaa701b880f4919006662bf03727daa1d08e827b15844dd3c8,3.1.1.4,3.1.1.4,,L- dopa,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/25660576/,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503",
238,615395,,Number Sign,615395,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16,,,Combined oxidative phosphorylation deficiencyÂ 16,,MRPL44,MRPL44,MITOCHONDRIAL RIBOSOMAL PROTEIN L44,a7b6822329646a27ebeff35ed519d80b78777b54ba5a01db37bb12b716c034f5,Q9H9J2,,Q9H9J2,creatine,,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Low physical capacity (Constitutional symptom)*,HP:0025142,,https://www.ncbi.nlm.nih.gov/pubmed/25797485,
239,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,cholic acid,,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction ( Mechanistic B),B,Hepatic Biochemical abnormalities (Laboratory abnormality)*,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/11067870,
240,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,HP:0500014,,,
241,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,progression of the disease (Rapidly progressive)*,HP:0003678*,,,
242,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Bile flow defect,HP:0001396,,,
243,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,synthesisÂ of atypicalÂ bileÂ acids,NA,,,
244,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,production of toxic intermediates,HP:0001939*,,,
245,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,,
246,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,chenodeoxycholic acid,,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction ( Mechanistic B),B,Abnormal liver function tests,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pubmed/11067870",
247,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Pruritus,HP:0000989,,https://www.ncbi.nlm.nih.gov/pubmed/11067870,
248,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Abnormal urinary steroids levels(Abnormality of urine hormone level)*,HP:0012029,,,
249,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,ursodeoxycholic acid,,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,Abnormal liver function tests,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/7915305,
250,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,Glycocholic Acid,,DB02691,DB02691,03e89641534d0243274641dac3fb206495468eca87b614a8ecaafafcf4a5128f,DB02691,DB02691,,,,,,,ECO:0007121,ECO:0007121,,,,,Failure to thrive,HP:0001508,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,
251,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,,
252,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,VitaminA+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,DB00162 + DB11094 + DB01022 + DB00163 + DB01586 + DB06777,027f257b129714df32be1a781a1235287ee1ddb1c47e1c41ff0c0230a74fcd92,,,,,"DB00162,DB11094,DB01022,DB00163,DB01586,DB06777","DB00162,DB11094,DB01022,DB00163,DB01586,DB06777",,,ECO:0000352,ECO:0000352,,,Symptomatic (C) + Functional interaction( Mechanistis B),,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,
253,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Abnormal gait,HP:0001288,,,
254,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,,,,,,,,,,,,,,,,,,,,Muscle weakness,HP:0001324,,,
255,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,cholic acid,,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,biochemical abnormalities,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/8225213,
256,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Histologic abnormalities in liver(Abnormal test result)*,HP:0500014,,,
257,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,,
258,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Bile flow defect,HP:0001396,,,
259,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,synthesisÂ of atypicalÂ bileÂ acids,NA,,,
260,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,production of bile acid toxic intermediates,HP:0001939*,,,
261,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption (Fat malabsorption)*,HP:0002630*,,,
262,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,Chenodeoxycholic acid + cholic acid.,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),,Abnormal liver function tests,HP:0002630*,,https://www.ncbi.nlm.nih.gov/pubmed/8707100,
263,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Liver biopsy abnormalities,,,,
264,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Abnormal bilirubin level,,,,
265,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,Chenodeoxycholic acid,,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),,Abnormal liver function,,,https://www.ncbi.nlm.nih.gov/pubmed/28697823,
266,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,Hepatomegaly,,,,
267,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,,,,,,,,,,,,,,,,,,,,,,,,
268,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,Nitisinone,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction ( Mechanistic B),B,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",
269,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,,,,,,,,,,,,,,,,,,,,ochronosis,HP:0030764,,https://www.ncbi.nlm.nih.gov/pubmed/26891864,
270,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,,,,,,,,,,,,,,,,,,,,High circulating HGA (homogentisic acid)level,NA,,https://www.ncbi.nlm.nih.gov/pubmed/26891864,
271,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,,,,,,,,,,,,,,,,,,,,Joint disesae,HP:0001367,,,
272,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,N-ACETYL-CYSTEINE,,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,apoptosis induced in chondrocytes,NA,,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alkaptonuria,
273,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,ASCORBIC ACID,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal chondrocyte growth,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/9718357/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",
274,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,
275,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGDÂ gene,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,,,,,,,,,,,,,,,,,,,,abnormality of proteoglycan metabolism,HP:0004355,,,
276,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,ARC-AAT,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,,HP:0004355,,"https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23527792,https://clinicaltrials.gov/ct2/show/NCT02900183",
277,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,Recombinant alpha 1-antitrypsin (rAAT),,DB05481,DB05481,03d5b47c3fbfa1dc8708cfe9a116f75eab13122951fd3cb99b8f661fa25cdc6b,DB05481,DB05481,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Progressive emphysema,HP:0002097,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/",
278,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,,,,,,,,,,,,,,,,,,,,Decreased lung function,HP:0005952,,,
279,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,,,,,,,,,,,,,,,,,,,,Recurrent infection,HP:0002719,,,
280,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,Retinoic acid,,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,ECO:0005542,ECO:0005542,,,Symptomatic(C),,Alveoli damage ( interstitial pulmonary abnormality)*,HP:0006530,,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,
281,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,Beta2-agonists +corticosteroids + anti-cholinergics,,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),,Difficulty breathing,HP:0002098,,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,
282,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,,,,,,,,,,,,,,,,,,,,Lung inflammation (Abnormality of respiratory system),HP:0002086,,,
283,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,Lamazym(rhLAMAN),,DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Reduced pulmonary function,HP:0005952,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",
284,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,Low FVC%,HP:0030878*,,,
285,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,High NFL (neurofilament light signature ) in CSF,NA,,,
286,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,Elevated GFAP(Glial fibrillary acidic protein) level in CSF,NA,,,
287,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,Elevated Tau-p level in CSF,NA,,,
288,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,High CSF MAN2-oligosaccharides,,,,
289,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,,,,,,,,,,,,,,,,,,,,cognitive deficits,HP:0100543,,,
290,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,AAV1vector expressing Î±-Mannosidase,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A),A,Neurological abnormalities,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode,
291,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Glycerol phenylbutyrate,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,DB08909,DB08909,2586da7dbf2d6a945d5981b8b8b7394f72544f04b5a969e4b658667ef0e87e30,DB08909,DB08909,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,low quality of life(Constitutional symptom )*,HP:0025142*,,"https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/",
292,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,AEB1102(Pegzilarginase) â Co-ArgI-PEG modified human Arginase I,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Elevated blood arginine levels( Abnorality in arginie metabolism)*,HP:0010909*,,"https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771",
293,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,,,,,,,,,,,,,,,,,,,,Unstable neurological function (Abnormality of the nervous system)*,HP:0000707*,,,
294,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,,
295,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,sodium benzoate,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title",
296,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,sodium phenylbutyrate,,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperammonemia,HP:0001987,,https://www.ncbi.nlm.nih.gov/pubmed/11148549,
297,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,AAV-based gene therapy,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,neurotoxicity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25474440,https://www.ncbi.nlm.nih.gov/pubmed/23388701,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813",
298,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,,,,,,,,,,,,,,,,,,,,neurological abnormalities,HP:0000707,,,
299,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,,
300,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Nitric oxide supplement,,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,ECO:0005542,ECO:0005542,,,Symptomatic (C),C,hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub",
301,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,absence of flow-mediated dilatation of brachial artery,NA,,,
302,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,endothelial dysfunction,NA,,,
303,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,Cardiac hypertrophy,,,,
304,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,,,,,
305,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,,,,,
306,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Sodium citrate,,DB09154,DB09154,7dfb3c751c48770217688e4602f154f80add9e9a472388e4dd0bad634fbbddb3,DB09154,DB09154,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal renal nitrogen elimination,HP:0004364,,https://www.ncbi.nlm.nih.gov/pubmed/8582405,
307,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,keto-analogues of essential amino acids,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,seizure,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/668730,
308,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,High blood ammonia levels,HP:0001987,,,
309,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,Defective argininosuccinic acid excretion,HP:0001939*,,,
310,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Sodium Phenylbutyrate +Arginin,,DB06819+DB00125,DB06819 + DB00125,861d80de6bb5c57448657264b826026526cff1506651818b5ddd2b8e8f42cc64,,,,,"DB06819,DB00125","DB06819,DB00125",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Hyperammonemia,HP:0001987,,"https://clinicaltrials.gov/ct2/show/NCT00345605,https://www.ncbi.nlm.nih.gov/pubmed/8582405",
311,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Arginine,,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,abnormal hepatic function tests,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521",
312,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,Low plasma arginine levels,HP:0005961,,,
313,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASLÂ gene,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,,,,,,,,,,,,,,,,,,,,Acute hyperammonemia,HP:0008281,,,
314,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,AAV2-hAADC ( Gene therapy),,,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,motor malperformance,HP:0002275,,"https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/",
315,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,increased dopamine and serotonin levelsÂ (neurotransmitter levels),HP:0012654,,,
316,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Bromocriptine,,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hypokinesia,HP:0002375,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,
317,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,axial hypotonia,HP:0008936,,,
318,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,limb hypertonia,HP:0002509,,,
319,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,dystonia,HP:0001332,,,
320,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,choreoathetosis,HP:0001266,,,
321,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Poor head control,HP:0002421,,,
322,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Oculogyric crises,HP:0010553,,,
323,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Abnormalitilty in voluntary movements(Abnormality of movement)*,HP:0100022*,,,
324,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,,
325,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Pyridoxine,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),A,boost residual AADC activity with a cofactor excess,NA,,,
326,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Pyrodixal 5 phosphate,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),A,boost residual AADC activity with a cofactor excess,,,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,
327,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,pramipexole,,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,ECO:0000352,ECO:0000352,,,"Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https:,www.ncbi.nlm.nih.gov,pubmed,25001633",C,Hypotonia,HP:0001290,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,
328,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,,
329,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Poor head control,HP:0002421,,,
330,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities(Abnormality of movement)*,HP:0100022*,,,
331,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,,
332,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Rotigotine,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/",
333,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,,
334,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Poor head control,HP:0002421,,,
335,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,HP:0100022*,,,
336,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,,
337,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Pergolide,,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypotonia,HP:0001290,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,
338,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,,
339,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Poor head control,HP:0002421,,,
340,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,HP:0100022*,,,
341,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,,,,,,,,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,,
342,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,cerebral folate depletion,HP:0012446,,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,
343,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDCÂ gene,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Pargyline,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",DB01626,DB01626,d111c3960f6beafd424461e2aa35d0bca282e8427b5c5a16b077bc71ade82e7f,DB01626,DB01626,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypotonia,HP:0001290,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,
344,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,S-adenosylmethionine,,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,low levels of purines,HP:0004369,,"https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896",
345,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,Progression of retinal degeneration ( Rapidly Progressive)*,HP:0003678*,,,
346,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,Ataxia Progression(Rapid progression),HP:0002719,,https://www.ncbi.nlm.nih.gov/pubmed/23190330,
347,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,Recurrent infection,HP:0002719,,,
348,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,frequent hospital admission,NA,,,
349,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,Hearing impairment progression(Rapid progression)*,HP:0003678*,,,
350,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1Â gene,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,,,,,,,,,,,,,,,,,,,,Noctornal difficulty breathing,HP:0002098,,,
351,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,"As by 2016 Banning et al. mentioned ""Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years",AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,Amlexanox,"Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. ""This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. "" It posses the ability to cross the BBB. ""Our data show for the first time that Amlexanox might provide a valid therapy for AGU."" https://www.ncbi.nlm.nih.gov/pubmed/29247835",DB01025,DB01025,80f15884cb03a9796fc7107d6ffcf92d0754edc547a1c163cd778ad25649d5e5,DB01025,DB01025,,,,,,,ECO:0001565,ECO:0001565,Ser72Pro/Trp168X,,Direct interaction ( Mechanistic A),A,Low AGA activity,NA,,"https://www.semanticscholar.org/topic/amlexanox/510418,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.ncbi.nlm.nih.gov/pubmed/29247835",
352,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,betaine,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",DB06756,DB06756,a8f65864591a4e53f7884308c647c506d5d939fadb78576e1a1f21a5c6e4a5af,DB06756,DB06756,,,,,,,ECO:0001565,ECO:0001565,T122K,,Direct interaction ( Mechanistic A),A,Low AGA activity,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/",
353,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,Unstable AGA enzyme,NA,,,
354,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,Misfolded AGA,NA,,,
355,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,Abnormal AGA processing,NA,,,
356,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,Glycine,,DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,,,,,Direct interaction ( Mechanistic A),A,Low AGA activity,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pubmed/23601642",
357,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,Recombinant human Aspartylglucosamidase,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,pathology in many somatic tissues,HP:0000924*,,"https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/27906067",
358,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,accumulating substance aspartylglucosamine from ( Metaboic abnormality)*,HP:0001939*,,,
359,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*,HP:0001939*,,,
360,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*),HP:0001939*,,,
361,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,Gene therapy (wild-type Ad-AGA),"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,Low expression of AGA enzyme,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,
362,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,Liver lysosomal storage abnormality,,,,
363,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,Brain lysosomal storage disease,,,,
364,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGAÂ gene,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,,,,,,,,,,,,,,,,,,,,ipsilateral brain neuronal storage abnormalities,,,https://www.ncbi.nlm.nih.gov/pubmed/16518877/,
365,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,vitamin E,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pubmed/20301317,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/books/NBK1241/,https://www.ncbi.nlm.nih.gov/pubmed/15300460",
366,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,,,,,,,,,,,,,,,,,,,,Abnormal vitamin E level(Vitamin E deficiency)*,HP:0100513*,,,
367,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,,,,,,,,,,,,,,,,,,,,Ataxia,HP:0001251,,"https://www.ncbi.nlm.nih.gov/pubmed/9931538,https://www.ncbi.nlm.nih.gov/pubmed/11554913",
368,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,,,,,,,,,,,,,,,,,,,,Neurological abnormalitis,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/15300460",
369,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,RRR-Î±-tocopherol,,DB14002,DB14002,92900224055cbadcf6c80003489a230f3c28a1ecaf594d0dc3a0c5fe40be77c6,DB14002,DB14002,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*,HP:0030390*,,"https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15300460",
370,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPAÂ gene,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,,,,,,,,,,,,,,,,,,,,Abnormal H50 (The erythrocyte resistance to oxidative stress),NA,,,
371,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,myo-inositol,,DB13178,DB13178,ced8fe513f10e1fefbed4496ffa213252995e3da39b86b760f3efded57a1716f,DB13178,DB13178,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,neurological malfunction,HP:0000707,,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,
372,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,immune dysfunctions,HP:0002715,,,
373,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,Alpha lipoic acid,,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Neuronal death,HP:0002529,,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,
374,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,,
375,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,nicotinamide,,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal levels of urine total alkanes,NA,,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,
376,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,,
377,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,Alpha-lipoic acid + nicotinamide,,DB00166+DB02701,DB00166 + DB02701,06ec7c35b99dd3cb38e5758cbbd01898caead5f074f39ed2013492b0e6df3155,,,,,"DB00166,DB02701","DB00166,DB02701",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Abnormal serum fast ORAC(oxygen reduced absorbance capacity),NA,,,
378,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Abnormal lymphocyte counts,HP:0040088,,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,
379,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,Immunoglobulin replacement therap,,DB00028,DB00028,b4a020967fdfce429d858a0849d50d3228b8294a28110560a624ebc67aa6811e,DB00028,DB00028,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Recurrent infection,HP:0002719,,https://www.ncbi.nlm.nih.gov/pubmed/28318010,
380,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,amantadine,,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Ataxia,HP:0001251,,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,
381,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,involuntary movements,HP:0004305,,,
382,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,parkinsonism,HP:0001300,,,
383,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,clonazepam,,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,myoclonuic Jerk,HP:0001336,,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,
384,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Poor fine motor skills,HP:0007010,,,
385,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Voice tremor,HP:0012477,,,
386,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,,,,,,,,,,,,,,,,,,,,Poor intelligibility,HP:0001249,,,
387,208920,,Number Sign,208920,"ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH","ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA;; ATAXIA-OCULOMOTOR APRAXIA 1; AOA1;; ATAXIA-TELANGIECTASIA-LIKE SYNDROME;; CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HA","ATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED",Ataxia-oculomotor apraxia type 1,,APTXÂ gene,APTX,Aprataxin,ff454d93c31ed6f6d09999cd7b6d59974b0256a21cbad59406de89b358f45b15,3.1.12.2,3.1.12.2,,CoQ10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,lack of strenght,HP:0003750,,https://www.ncbi.nlm.nih.gov/pubmed/28277561,
388,208920,,Number Sign,208920,"ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH","ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA;; ATAXIA-OCULOMOTOR APRAXIA 1; AOA1;; ATAXIA-TELANGIECTASIA-LIKE SYNDROME;; CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HA","ATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED",Ataxia-oculomotor apraxia type 1,,APTXÂ gene,APTX,Aprataxin,ff454d93c31ed6f6d09999cd7b6d59974b0256a21cbad59406de89b358f45b15,3.1.12.2,3.1.12.2,,,,,,,,,,,,,,,,,,,,,seizures,HP:0001250,,,
389,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TFÂ gene,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,Human apotransferrin,,CHEBI:2786,CHEBI:2786,e70c6b5799bf1f6b401efc912a9b7d33a0088c1a818b232bc81928673fc6a533,CHEBI:2786,,CHEBI_2786,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,hypochromic anemia,HP:0001931,,"https://clinicaltrials.gov/ct2/results?cond=Atransferrinemia%C2%A0&term=&cntry=&state=&city=&dist=,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1682235/",
390,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TFÂ gene,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,Deferoxamine,,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,hypochromic anemia,HP:0001931,,"https://www.ncbi.nlm.nih.gov/pubmed/8187613,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1682235/",
391,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TFÂ gene,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,Ferrous sulfate,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrinâbound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",DB13257,DB13257,a8ed5c403d6017336ca159660834c6338855cddd0b2d2bbad95e3670d7a93bcf,DB13257,DB13257,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Decreased hemoglobin,HP:0001903,,https://www.ncbi.nlm.nih.gov/pubmed/28895280,
392,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TFÂ gene,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,,,,,,,,,,,,,,,,,,,,High ferritin level,HP:0003281,,,
393,162350,,Number Sign,162350,"CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B","KUFS DISEASE, AUTOSOMAL DOMINANT;; CEROID LIPOFUSCINOSIS, NEURONAL, PARRY TYPE",,Autosomal dominant neuronal ceroid lipofuscinosis 4B,,DNAJC5A,DNAJC5A,DnaJ homolog subfamily C member 5(cysteine string PROTEIN),2330e114db5b1f7d3e1e424c05947a90eb56cc4bdf430d6885d98ca253788a18,Q9H3Z4,,Q9H3Z4,No treatment avilable in DDIEM,"Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management",,,,,,,,,,,,,,,,Symptomatic (C),C,,HP:0003281,,https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management,
394,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,Cystagon,Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction ( Mechanistic B),B,progression of neurodegeneration,HP:0002344,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",
395,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,N-Acetylcysteine+cysteamine bitartrate,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",DB06151+DB00847,DB06151 + DB00847,73f604cfaf3993a0200b6dad4a2b89b2bebda7797c491467b08d1a8f943e296d,,,,,"DB06151,DB00847","DB06151,DB00847",,,ECO:0007121,ECO:0007121,,,Functional interaction ( Mechanistic B),B,granular osmiophilic deposits (GROD),HP:0003657,,https://www.ncbi.nlm.nih.gov/pubmed/24997880,
396,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,,,,,,,,,,,,,,,,,,,,irritability,HP:0000737,,,
397,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,,,,,,,,,,,,,,,,,,,,Defected alertness,HP:0004372,,,
398,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,,,,,,,,,,,,,,,,,,,,Isoelectric electroencephalogram,HP:0002353,,,
399,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,Î´-tocopherol (DT),,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction ( Mechanistic B),B,cognitive deficits,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/29631617,
400,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,hydroxypropyl-Î²-cyclodextrin (HPBCD),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction ( Mechanistic B),B,brain atrophy,HP:0012444,,,
401,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,Î´-tocopherol (DT) + hydroxypropyl-Î²-cyclodextrin (HPBCD),A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction ( Mechanistic B),B,Lipid accumulation( Abnorality in lipid meabolism)*,HP:0003119*,,,
402,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,,,,,,,,,,,,,,,,,,,,Lysosomal enlargment (Abnormality of lysosomal metabolism)*,HP:0004356*,,,
403,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,Recombinant human palmitoyl-protein thioesterase 1 ( PPT1),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction ( Mechanistic A),A,Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*,HP:0004356*,,,
404,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,Mycophenolate mofetil,,DB00688,DB00688,c4034355ca9cb7c4b5e332b5578e3df223e6dd710880dbeffbd730080f3abbed,DB00688,DB00688,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,Symptomatic (C),C,The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated,HP:0004356*,,"https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1,https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/,https://link.springer.com/chapter/10.1007%2F8904_2018_113",
405,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,carbenoxolone,,DB02329,DB02329,de2101a8c9f2a03505d41ef6199bdbc99ab73ca91ac891d0a0d03f1af1e0d247,DB02329,DB02329,,,,,,,ECO:0005542,ECO:0005542,,,Symptomatic (C),C,Blood-brain barrier (BBB) impairment,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/,https://link.springer.com/chapter/10.1007%2F8904_2018_113",
406,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,,,,,,,,,,,,,,,,,,,,Low cell autofluorescence,NA,,,
407,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,,,,,,,,,,,,,,,,,,,,membrane fluidity alterations,NA,,,
408,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,,,,,,,,,,,,,,,,,,,,extended G1 interval,HP:0011018,,,
409,601780,,Number Sign,601780,"CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6","CEROID LIPOFUSCINOSIS, NEURONAL, 6, VARIABLE AGE AT ONSET;; NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, VARIANT; vLINCL;; CEROID LIPOFUSCINOSIS, NEURONAL, 6 (Kufs type);; CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE, FORMERLY; CLN4A, FORMERLY",,Late infantile neuronal ceroid lipofuscinoses CLN6,,CLN6,CLN6,"CLN6, transmembrane ER protein",2772bfaf86ea57a692429f41141a8131888aee9c0d0c0d9de629f38a2f979710,id,,"NO,Human,id",scAVV9.CB.CLN6,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,,HP:0011018,,"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=168491,https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14",
410,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,cerliponase alfa,,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,Functional interaction ( Mechanistic B),B,neurologic deficits,HP:0000707,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",
411,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,,
412,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,brain atrophy,HP:0012444,,,
413,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,loss of ambulation,HP:0002540,,,
414,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
415,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
416,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
417,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
418,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
419,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,,,,,
420,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,AAVrh.10CUhCLN2,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,,,,https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8,
421,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,AAV2CUhCLN2,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,,,,"https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9,https://emedicine.medscape.com/article/1178391-treatment",
422,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,Î´-tocopherol (DT),,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction ( Mechanistic B),B,cognitive deficits,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",
423,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,hydroxypropyl-Î²-cyclodextrin (HPBCD),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction ( Mechanistic B),B,brain atrophy,HP:0012444,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/,
424,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,recombinant human tripeptidyl peptidase-1 (rhTPP1),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction ( Mechanistic A),A,neurological disease,HP:0000707,,"https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease-300635669.html,https://www.ncbi.nlm.nih.gov/pubmed/24938720",
425,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,BMN 190 (cerliponase alfa),,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,neurologic deficits,HP:0000707,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720",
426,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,,
427,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,brain atrophy,HP:0012444,,,
428,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,,,,,,,,,,,,,,,,,,,,loss of ambulation,HP:0002540,,,
429,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,CoQ10(ubiquinone),,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0007121,ECO:0007121,comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24],,Functional interaction ( Mechanistic B),B,tremor,HP:0001298,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873",
430,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,Drawing inabiliity,MP:0004144,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,
431,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,Myoclonus,HP:0002180,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873",
432,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873",
433,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,Hetero c.[1541AâG] + [1750_1752 delACC],,,,exercise intolerance,HP:0012211,,https://www.ncbi.nlm.nih.gov/pubmed/18319074,
434,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,
435,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,hyperlactatemia,HP:0003128,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,
436,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,Homozygous deletion (c.504del_CT),,,,Speech problem,HP:0002167,,https://www.ncbi.nlm.nih.gov/pubmed/26818466,
437,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,Gait abnormality,HP:0001288,,,
438,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,Neurological abormalities,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/26818466,
439,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs),,,,Fatigue,HP:0012378,,https://www.ncbi.nlm.nih.gov/pubmed/29159460,
440,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,High ataxia score ( Ataxia)*,HP:0001251*,,,
441,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A,,,,Myoclonic abnormalities(Myoclouns)*,HP:0001336*,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524",
442,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,ataxic gait,HP:0002066,,,
443,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,,,,,,,,,,,,,,,,,,,,dysarthric speech,HP:0001260,,,
444,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,idebenone,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0000352,ECO:0000352,,,,,,HP:0001260,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,
445,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,Sodium Valproate,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,,Symptomatic (C),,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,
446,607091,,Number Sign,607091,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D",CDG IId; CDGIId,,B4GALT1-CDG (CDG-IId),,GALT1Â gene,GALT1,"beta-1,4-galactosyl transferase.",c4dcaf42b8042b735f0768ac89f9085c112da2f2028922247817bedd4576c4b4,2.4.1.274,2.4.1.274,,galactose supplementation,Drug name: Treatment is under trial.,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://clinicaltrials.gov/ct2/show/NCT02955264",
447,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,mannose supply,,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (Mechanistic B),B,Metabolism abnormality,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558",
448,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,hypoproteinemia,MP:0005567,,,
449,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,blood coagulation,HP:0001928,,,
450,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,protein-losing enteropathy,HP:0002243,,,
451,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,hypoglycaemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/10484808,
452,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,Hypoglycosylation of serum glycoproteins,NA,,https://www.ncbi.nlm.nih.gov/pubmed/9525984,
453,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,,,,,,,,,,,,,,,,,,,,urinary tract infection,HP:0000010,,,
454,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,D- Galactose,,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (Mechanistic B),B,Abnormal aPTT level,HP:0003645,,https://www.ncbi.nlm.nih.gov/pubmed/28617415,
455,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,Abnormal AST level (Abnormal liver enzymes)*,HP:0002910,,,
456,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,Abnormal ALT level(Abnormal liver enzymes)*,HP:0002910,,,
457,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,Abnormal Antithrombin-III levels,HP:0001976,,,
458,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,,,,,
459,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,fucose therapy,,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction (B),B,Abnormal Golgi located fucosylation,NA,,"http://www.jbc.org/content/282/14/10762.long#ref-14,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,""espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.""",
460,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,Abnormal fucosylation state of glycoconjugates.,NA,,,
461,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,,,,,,,,,,,,,,ECO:0005542,ECO:0005542,,,,,Abnormal selectin ligand function,NA,,http://www.bloodjournal.org/content/94/12/3976.abstract?ijkey=201ceaaf5f2f21a180c7df639f863d067551bca5&keytype2=tf_ipsecsha,
462,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,,,,,,,,,,,,,,ECO:0005542,ECO:0005542,,,,,Neutropenia,HP:0001875,,http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,
463,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Asfotase Alfa,,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),A,Abnormal developmental milestones,HP:0012759,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",
464,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,deteriorating pulmonary function,HP:0005952,,,
465,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Decreased physical function,HP:0025142,,,
466,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,failure-to-thrive,HP:0001508,,,
467,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Dental Defects,HP:0000164,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124/,
468,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPLÂ gene,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,pyridoxal,,DB00147,DB00147,e4e9653857187889e123957c2167ebd6d98261a31e548707bc2e1bd7002fda38,DB00147,DB00147,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,epilepsy,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia",
469,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,simvastatin,,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),B,Accumulation of toxic metabolites in cholesterol biosynthetic pathway,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,
470,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,ichthyosiform erythematous plaques,HP:0008064,,,
471,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,waxy scaling plaques,HP:0040189*,,,
472,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,inflammation,MP:0001845,,,
473,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,skin thickening,HP:0100725,,,
474,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,lovastatin+cholesterol,,DB00227+DB04540,DB00227 + DB04540,aea53ff37491f6c9dd3f41d1b8f8a80053b307fce2d3823a311fa5693405e27a,,,,,"DB00227,DB04540","DB00227,DB04540",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Cutaneous abnormalities,MP:00011911,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,
475,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,Ichthyosiform erythroderma,HP:0007431,,,
476,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,ketoconazole,,DB01026,DB01026,b60b0b8ef6aa34242467e4ddc87ad1d2845091eb8c05f056e84054c684c4717b,DB01026,DB01026,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Cutaneous abnormalities,MP:0001191,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,
477,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,simvastatin+cholesterol,,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Ichthyosiform erythroderma,HP:0007431,,,
478,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,Itchy skin,HP:0000989,,,
479,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,Scaling Skin,HP:0040189,,,
480,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,Erythema,HP:0010783,,,
481,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,Verruciform plaques(verruciform xanthomas)*,HP:0031517*,,https://www.ncbi.nlm.nih.gov/pubmed/29341259,
482,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,,,,,,,,,,,,,,,,,,,,VXâlike lesions,NA,,,
483,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Retinoids,,CHEBI:26537,CHEBI:26537,75cede199dcabebdeb1685d362d37882b001179a89276267737877c5557ba548,CHEBI:26537,,CHEBI_26537,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Scaling Skin,HP:0040189,,https://www.ncbi.nlm.nih.gov/pubmed/29392821,
484,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL gene,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Glycolic acid+lovastatin+cholesterol,,DB03085+DB00227+DB04540,DB03085 + DB00227 + DB04540,256d4592b76615e3a3522ef56a90d4b2aaa1f417ee97a69498fb6e6308adcb46,,,,,"DB03085,DB00227,DB04540","DB03085,DB00227,DB04540",,,ECO:0000352,ECO:0000352,,,,,verruciform xanthomas,HP:0031517,,,
485,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Emollients +acitretin,,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Ichthyosis,HP:0008064,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+ChanarinâDorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170",
486,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Erythroderma,HP:0001019,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,
487,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Diffuse scaling(Skin Scaling)*,HP:0040189*,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,
488,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*,HP:0007479*,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,
489,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Erythema,HP:0010783,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,
490,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Scaling,HP:0040189,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,
491,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Emollients,,A06AA,A06AA,b64fe70b67eafd88c09ed6cf397a9a5aa41284ea532408db8746b7f4d1da793b,A06AA,,,A06AA,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,erythema,HP:0010783,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,
492,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Ichthyosis,HP:0008064,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,
493,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,Pruritis,HP:0000989,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,
494,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,scaling,HP:0040189,,,
495,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Ursodeoxycholic acid,,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,steatohepatitis,HP:0001397,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,
496,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5 gene,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,vitamin E,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,steatohepatitis,HP:0001397,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,
497,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,chenodeoxycholic acid,,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,neurological dysfunctions,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,
498,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,lovastatin,,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,cataracts,HP:0000518,,,
499,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,chronic diarrhoea,MP:0001665,,,
500,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,Elevated serum cholesterol,HP:0003124,,,
501,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,EEG abnormalities,HP:0002353,,,
502,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,abnormal gait,HP:0001288,,,
503,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,Cognitive impairment,HP:0100543,,,
504,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,,,,,,,,,,,,,,,,,,,,seizure,HP:0001250,,,
505,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,muscle weakness,HP:0001324,,https://rarediseases.info.nih.gov/diseases/5622/cerebrotendinous-xanthomatosis,
506,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,FOLR1,FOLR1,Folate receptor alpha,fa9795212e8a989c55c4de3574c5b43b124e273a023f2ed8866563ecd092d22e,P15328,,P15328,folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Impaired social interaction,HP:0000735,,,
507,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,FOLR1,FOLR1,Folate receptor alpha,fa9795212e8a989c55c4de3574c5b43b124e273a023f2ed8866563ecd092d22e,P15328,,P15328,,,,,,,,,,,,,,,,,,,,Movement disorder,HP:0100022,,,
508,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,seizure,HP:0001250,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/,
509,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Myoclonic seizures,HP:0002123,,https://academic.oup.com/brain/article/135/7/2002/357230,
510,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,astatic seizures,HP:0010819,,,
511,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Desmopressin,,DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,polyuria,HP:0000103,,https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1,
512,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Vasopressin,,DB00067,DB00067,e9fc4af7bd908224aefe167a2729421282bcbc25ae28d9836f3fb71ea8e4f799,DB00067,DB00067,,,,,,,,,,,Direct Interaction (A),A,polydipsia,MP:0001426,,https://academic.oup.com/jcem/article/98/10/3958/2833930,
513,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,thirst,HP:0001959,,,
514,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,chlorpropamide,,DB00672,DB00672,1b02186f4830609aa0bcaa3357749eab2002066fff689e8c09ab10999fd61209,DB00672,DB00672,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Polyurea,HP:0000103,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999/,
515,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Chlorpropamide + carbamazepine,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,DB00672+DB00564,DB00672 + DB00564,5f627ab82a019d8d70f1356bfdde1f0c27621081b1f295a1fac632661a08104c,,,,,"DB00672,DB00564","DB00672,DB00564",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,chlorpropamide-induced hypoglycaemia (Hypoglycemia)*,HP:0001943*,,https://www.ncbi.nlm.nih.gov/pubmed/1220254,
516,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Polyuria,HP:0000103,,,
517,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,chlorpropamide+Hydrochlorothiazide,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,DB00672+DB00999,DB00672 + DB00999,d8e42848b73e0dfb5b2d04e2a21327383f3d381a26b44714c75300e58f81cd96,,,,,"DB00672,DB00999","DB00672,DB00999",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Ployuria,HP:0000103,,,
518,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,
519,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,
520,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Pitressin tannate in oil,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Direct Interaction (A),A,Ployuria,HP:0000103,,https://www.ncbi.nlm.nih.gov/pubmed/3940717,
521,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Clofibrate,,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Ployuria,HP:0000103,,https://academic.oup.com/jcem/article/98/10/3958/2833930,
522,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Hyposthenuria,HP:0003158,,,
523,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Indapamide,,DB00808,DB00808,a63d31f207a29b8421e497c08b97b156d768c7caeebc62299eca3b05e749e92e,DB00808,DB00808,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,High serum osmolality,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800",
524,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Ployuria,HP:0000103,,,
525,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Reduced urinary osmolality,HP:0003158,,,
526,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,dDAVP (1-Desamino-8-D Arginine Vasopressin),"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),A,Increased urine output,HP:0000103,,https://www.ncbi.nlm.nih.gov/pubmed/626447,
527,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,
528,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,
529,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,Medium-chain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,developmental delay,HP:0001263,,https://rarediseases.info.nih.gov/diseases/1123/carnitine-acylcarnitine-translocase-deficiency,
530,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,epilepsy,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/17508264,Abstract",
531,601987,,Asterisk,601987,"CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B","CPT IB;; CPT I, MUSCLE;; MCCPT1; MCPT1;; KIAA1670",,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1BÂ gene,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",bc205fb2ae3c455e166c24e1b4a9407dada6712431ab5bc61e38cf0159829dda,2.3.1.21,2.3.1.21,,Medium-chain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,neurological damage,HP:0000707,,https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle,
532,601987,,Asterisk,601987,"CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B","CPT IB;; CPT I, MUSCLE;; MCCPT1; MCPT1;; KIAA1670",,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1BÂ gene,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",bc205fb2ae3c455e166c24e1b4a9407dada6712431ab5bc61e38cf0159829dda,2.3.1.21,2.3.1.21,,,,,,,,,,,,,,,,,,,,,hypoglycemia,HP:0001943,,,
533,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,Triheptanoin,,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,muscle pain,HP:0003326,,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/08/WC500192013.pdf,
534,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,,,,,,,,,,,,,,,,,,,,rhabdomyolysis,HP:0003201,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676979/,PMC2676979",
535,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,,,,,,,,,,,,,,,,,,,,abnormal SF-36 physical composite scores,NA,,,
536,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,cornstarch,,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/15669684,
537,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,,,,,,,,,,,,,,,,,,,,Low growth rate (Abnormal growth)*,HP:0001507*,,,
538,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1Â gene,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,N-Carbamylglutamate,,DB06775,DB06775,4232311e92dd47c3fa1cd15c2af2c63ef49708a80c82e3cc943e86fc4cfdfaf2,DB06775,DB06775,,,,,,,,,,,Direct Interaction (A),A,hyperammonaemia,MP:0005309,,https://www.ncbi.nlm.nih.gov/pubmed/28281899,
539,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1Â gene,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,N-acetyl-l-glutamate,,DB04075,DB04075,bf808123779c3bb0479cf5a2353df9114c277f7c8fb112b3984c6296307d02dd,DB04075,DB04075,,,,,,,,,,,Direct Interaction (A),A,Acidemia,HP:0001941,,https://www.ncbi.nlm.nih.gov/pubmed/23649895,
540,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1Â gene,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,Gene Therapy ??,,DB04075,DB04075,bf808123779c3bb0479cf5a2353df9114c277f7c8fb112b3984c6296307d02dd,DB04075,DB04075,,,,,,,,,,,Direct Interaction (A),A,hyperammonaemia,MP:0005309,,http://medcraveonline.com/JPNC/JPNC-07-00273.php,
541,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTDÂ gene,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,ORL-1B,,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,,,,,Symptomatic (C),C,seizure,HP:0001250,,https://trialbulletin.com/lib/entry/ct-03269045,
542,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTDÂ gene,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,baclofen,,DB00181,DB00181,283d4a5ab576ae808a0995e16fe21d81a8a4de4f3d61614edd1975a48037e4c1,DB00181,DB00181,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,dystonia,HP:0001332,,https://emedicine.medscape.com/article/942055-treatment,
543,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTDÂ gene,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,,,,,,,,,,,,,,,,,,,,Spasticity,HP:0001257,,,
544,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",Biotin+thiamine,,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy",
545,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",,,,,,,,,,,,,,,,,,Symptomatic (C),C,encephalopathy,HP:0001298,,"https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777",
546,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",,,,,,,,,,,,,,,,,,,,signal abnormality of the cortex,HP:0030178,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,
547,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",,,,,,,,,,,,,,,,,,,,Abnormal movement,HP:0100022,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,
548,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",,,,,,,,,,,,,,,,,,,,Dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,
549,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",,,,,,,,,,,,,,,,,,,,Abnormal reflexes,HP:0001347,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,
550,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3Â gene,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available",L-dopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/24260777,Abstract",
551,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1Â gene,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,glucose,,DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Ketosis,HP:0001946,,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x,
552,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1Â gene,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Organic aciduria,HP:0001992,,https://www.sciencedirect.com/science/article/pii/S1110863016300763,
553,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1Â gene,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,Bicitra,,DB09154,DB09154,7dfb3c751c48770217688e4602f154f80add9e9a472388e4dd0bad634fbbddb3,DB09154,DB09154,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Acidosis,HP:0001941,,http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency,
554,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,spironolactone+potassium+ACE-inhibitor,,DB00421+DB14500+C09A,DB00421 + DB14500 + C09A,2c1de8c0d712f2c71cdce34819cb42813e8b5c5d01001db2b81dffd21f5761b8,,,,,"DB00421,DB14500,C09A","DB00421,DB14500",,C09A,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,electrolyte disturbances,HP:0003111,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707/,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391",
555,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,Acetazolamide,,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,EC:0007121,EC:0007121,,,Symptomatic (C),,Metabolic alkalosis,HP:0200114,,"https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391",
556,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,,,,,,,,,,,,,,,,,,,,Hypokalemia Metabolic Alkalosis,HP:0002900,,,
557,241200,,Number Sign,241200,"BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 2, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 2",,Bartter Syndrome 2,,KCNJ1,KCNJ1,ATP-sensitive inward rectifier potassium channel 1,7874457d65b7a0e39ed008d10aa44e47f4fb3cf2b60362a5281b740a6e1d42d7,P48048,,P48048,,,,,,,,,,,,,,,,,,,,hypomagnesemia,HP:0002917,,https://www.ncbi.nlm.nih.gov/pubmed/2646391,
558,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,Tanespimycin,,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction ( Mechanistic B),B,Low plasma membrane expression of R8Lin kidney,NA,,https://www.ncbi.nlm.nih.gov/pubmed/24189473,
559,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,Hypokalemia,HP:0002900,,,
560,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,Metabolic alkalosis,HP:0200114,,,
561,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,Sensorineural hearing impairment,HP:0000407,,,
562,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,ER-associated degradation of R8L,NA,,,
563,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,Mislocalization of R8L,NA,,,
564,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,Potassium Chloride,,DB00761,DB00761,67f1e0b55afe5c60ce17dcb742c8ee747c1e0593a6d968a63548f2028bdaab68,DB00761,DB00761,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hypokalemia,HP:0002900,,https://www.ncbi.nlm.nih.gov/books/NBK442019/,
565,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,Naproxen,,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hypokalemia,HP:0002900,,https://www.nejm.org/doi/full/10.1056/NEJM197807132990214,
566,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,Niflumic acid,,DB04552,DB04552,5713f2b6a75cfae35e3aa40027d972812579f1da3c3e790f8d66dda705bb2029,DB04552,DB04552,,,,,,,ECO:0001565,ECO:0001565,L155/ G345/ A349,G167A / F213A,Functional interaction (Mechanistic B),B,Abnormal ClC-Ka function,NA,,https://www.ncbi.nlm.nih.gov/pubmed/20649569/,
567,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,"""L155A, G345S and A349E""",,,,,,,,
568,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,,,,,
569,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,,,,,,,,,,,,,,,,,,,,,,,,
570,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,POTASSIUM-SPARING AGENTS,,C03D,C03D,2149b82adae974abae88f3e4f4af9dc52149787611ba4b9ef4ee0e21e49f385e,C03D,,,C03D,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Deleterious prognosis,NA,,https://www.ncbi.nlm.nih.gov/pubmed/30387909,
571,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Decreased life expectancy,NA,,,
572,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Salt wasting,HP:0000127,,,
573,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Growth retardation,HP:0001510,,,
574,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Indomethacin,,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Deleterious prognosis,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract",
575,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Decreased life expectancy (Mortality)*,HP:0040006*,,,
576,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Salt wasting,HP:0000127,,,
577,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Growth hormone,,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report",
578,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Decreased serum IGFâ1,HP:0030353,,,
579,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Failure to thrive,HP:0001508,,,
580,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Potassium,,DB14500,DB14500,e125cfa968fc61758afee8060f8f001728433f4e42edde1b8995f33e02470fe8,DB14500,DB14500,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hypokalemia,HP:0002900,,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,
581,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Magnesium,,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hypomagnesemia,HP:0002917,,https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub,
582,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Sodium,,DB09395,DB09395,a2e90a7e24334a5ed20abf64752128f167cc038382ad998c3b313a690ed639d0,DB09395,DB09395,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hyponatremia,HP:0002902,,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,
583,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Aminoglycoside (Geneticin),,DB04263,DB04263,cd2dbb29480b68e7de99d5788d9ff351b31bfb1079109d60285c8ed6195afa7b,DB04263,DB04263,,,,,,,ECO:0001565,ECO:0001565,W610X,,Direct Interaction,A,Defected ClC-Kb expression,NA,,https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract,
584,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Potassium+IndomethacinÂ±Spironolactone,,DB14500+DB00328+ DB00421,DB14500 + DB00328 + DB00421,74018c025b92f10cc55009de38eb9e0ce8552cf86ae4a3142d4755fb71953df2,,,,,"DB14500,DB00328,DB00421","DB14500,DB00328,DB00421",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Short stature,HP:0004322,,https://www.ncbi.nlm.nih.gov/pubmed/28288174,
585,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,Nonsteroidal anti-inflammatory drugs,,M01AX,M01AX,1d07c4e8d775e1b7a83076b8032adfa28e035bca5f842078d3bf8b2ea7e2f329,M01AX,,,M01AX,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Elevated prostaglandin E2,HP:0003566,,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,
586,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Hypokalemia,HP:0002900,,,
587,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,,,,,,,,,,,,,,,,,,,,High calcium excretion in urine,HP:0002150,,,
588,300971,300971,Number Sign,300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5","Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084",MAGED2,MAGED2,Melanoma-associated antigen D2,b00da096e8725d8e2fe515eee3945d5e88ccec5481d88723a0c03654cb906c2f,Q9UNF1,,Q9UNF1,Electrolytes,,B05BB01,B05BB01,6f47b13d3c6f83aad8615713775b60e6109d75b86612e998d531873f4a032bf0,B05BB01,,,B05BB01,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Renal salt wasting,HP:0000127,,https://www.ncbi.nlm.nih.gov/pubmed/27120771,
589,300971,300971,Number Sign,300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,MAGED2,MAGED2,Melanoma-associated antigen D2,b00da096e8725d8e2fe515eee3945d5e88ccec5481d88723a0c03654cb906c2f,Q9UNF1,,Q9UNF1,Indomethacin,,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,,,,,
590,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Elamipretide,,DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,oxidative stress,HP:0025464,,"https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome/,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1",
591,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,abnormal energy production in damaged mitochondria,HP:0003287,,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,
592,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Fatigue,HP:0012378,,,
593,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Granulocyte colony stimulating factor (GâCSF),,DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/15098233/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031",
594,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Recurrent infection,HP:0002719,,https://www.ncbi.nlm.nih.gov/pubmed/23432031,
595,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Digoxin,,DB00390,DB00390,f2bdf23583ba341ca8bdca42235e68f59c1808a47ae96e50a7735ba79978f392,DB00390,DB00390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Low ejection fraction,HP:0012664,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,
596,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Tricusped incompetence,HP:0005180,,,
597,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Mitral incomptence,HP:0001653,,,
598,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Pantothenic acid,,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Low myocardial function,HP:0001638,,https://www.ncbi.nlm.nih.gov/pubmed/7833193,
599,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,T wave abnormalities,HP:0005135,,,
600,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Delayed Growth,HP:0001510,,,
601,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,hypocholesterolaemia,HP:0003146,,,
602,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,hyperuricaemia,HP:0002149,,,
603,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Neutropenia,HP:0001875,,,
604,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics,,C09A/C09CA/C07/C03,C09A / C09CA / C07 / C03,67ec8dbfcc290dba514a279b4dc29f123750523946fc607fb885132a4a49ca67,"C09A,C09CA,C07,C03",,,"C09A,C09CA,C07,C03",,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Heart failure,HP:0001635,,https://www.ncbi.nlm.nih.gov/pubmed/31239752,
605,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate,,C09A/C09CA/C07/C04+B01A,C09A / C09CA / C07 / C04 + B01A,47112a2b783bbdf9bce71ba82cf2f0bf6749d691fbd8b49a4923f0837bd88ddd,"C09A,C09CA,C07,C04",,,"C09A,C09CA,C07,C04",B01A,,,B01A,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Atrial fibrillation,HP:0005110,,https://www.ncbi.nlm.nih.gov/pubmed/31239752,
606,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Bezafibrate,,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0005542,ECO:0005542,,,,,Cardiac dysfunction,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/",
607,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Exercise intolerance,HP:0003546,,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,
608,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",AAV9-TAZ,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction ( Mechanistic A),A,Abnormal cardiac protein (TAZ) expression,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30788385/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/",
609,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Mitochondrial dysfunction,HP:0003287,,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,
610,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Mueculoskeletal dysfunction,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,
611,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",Digoxin+furosemide+captopril,,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Cardiomegaly,HP:0001640,,https://www.ncbi.nlm.nih.gov/pubmed/20981509,
612,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Reduced ejection fraction,HP:0012664,,https://www.ncbi.nlm.nih.gov/pubmed/20981509,
613,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Developmetal delay,HP:0001263,,https://www.ncbi.nlm.nih.gov/pubmed/20981509,
614,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,Abormal liver size,HP:0002240,,https://www.ncbi.nlm.nih.gov/pubmed/20981509,
615,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ gene,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available",,,,,,,,,,,,,,,,,,,,,,,,
616,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,sebelipase alfa,,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542",,,Direct Interaction ( Mechanistic A),A,High plasma cholesterol level*,HP:0003107,,"https://rarediseases.org/rare-diseases/cholesteryl-ester-storage-disease/,https://www.ncbi.nlm.nih.gov/pubmed/27878737",
617,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,hypertriglycemia,HP:0002155,,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,
618,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,,
619,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Dyslipidemia,HP:0003119,,,
620,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,,,,,
621,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,fenofibrate,,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,ECO:0005542,ECO:0005542,,,Symptomatic (C),C,Increased plasma triglycerides,HP:0002155,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/,
622,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Simvastatin,,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hyperlipidemia,HP:0003077,,https://www.ncbi.nlm.nih.gov/pubmed/16848116,
623,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Lovastatin,Treatment success with statins has been mixed.,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Increased LDL cholesterol,HP:0003141,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,
624,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Increased plasma triglycerides,HP:0002155,,,
625,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Increased total cholesterol,HP:0003124,,,
626,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Elevated urine mevalonate levels,NA,,,
627,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Colestyramine+Simivastatin,,DB01432+DB00641,DB01432 + DB00641,ee4abff46f2607086d159b62a84c245332bf66d6dd105ab45ba06d83ef7b39f1,,,,,"DB01432,DB00641","DB01432,DB00641",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Dyslipidemia,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101",
628,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,,
629,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Ezetimibe,,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Dyslipidemia,HP:0003119,,https://www.ncbi.nlm.nih.gov/pubmed/29374495,
630,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,,
631,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,,,,,
632,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,,,,,
633,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,,,,,,,,,,,,,,,,,,,,,,,,
634,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Colchicine(COL),"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",DB01394,DB01394,1993a504d61ce758a9a5be3048f2dc6a7dd5154ce9a2be3f3b79121e71e9ce07,DB01394,DB01394,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Arthritis,HP:0001369,,"https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/",
635,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Arthralgia,HP:0002829,,,
636,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,prednisone,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",,,Symptomatic (C),C,Arthritis,HP:0001369,,"https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/27790033/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/",
637,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,naproxen sodium,,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,,,,,Symptomatic (C),C,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/",
638,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Recurrent repisode of flares (Recurrent)*,HP:0025303,,,
639,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Anakinra/canakinuma,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",DB00026/DB06168,DB00026 / DB06168,8da5bac4d209298507ef0e3267481c0112e66a975848f515c7cfd8b1e52cc48b,"DB00026,DB06168","DB00026,DB06168",,,,,,,ECO:0007121/ ECO:0000352,"ECO:0007121,ECO:0000352",,,Symptomatic (C),C,Recurrent repisode of flares (Recurrent)*,HP:0025303,,"https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pubmed/19289295,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",
640,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Arthritis,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pubmed/23022422,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract",
641,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Refractory Arthritis,HP:0031375,,https://www.ncbi.nlm.nih.gov/pubmed/22658375,
642,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Synovitis,HP:0100769,,https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract,
643,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,rilonacept,,DB06372,DB06372,333591c7ae0fc057cca9ea7dbb86a8f4cd537758e3df888c094e1f0a470a4c07,DB06372,DB06372,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Recurrent repisode of flares (Recurrent)*,HP:0025303,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,
644,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,methotrexate,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",DB00563,DB00563,ad15fbb18adebcf2b1ad9bf875bb79f89bf8334ac3b7ee462dedaabaf303964b,DB00563,DB00563,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,swollen joint,HP:0001386,,"https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.nature.com/articles/nrrheum.2010.182",
645,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Arthralgia,HP:0002829,,,
646,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Hydroxychloroquine,,DB01611,DB01611,f77095ab6907cedf6f841df612e5949c6a03afd4e8f75a8a4379e876c8c1130f,DB01611,DB01611,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,swollen joint,HP:0001386,,"https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.nature.com/articles/nrrheum.2010.182",
647,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Arthralgia,HP:0002829,,,
648,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Arthropathy,HP:0003040,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,
649,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Probenecid,,DB01032,DB01032,2eaf2c7a70dc6dbae04804ddaf804322045de4d452b206ddf563c955877393ec,DB01032,DB01032,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction( Mechanistic B),,Abnormality of phosphate homeostasis,HP:0100529,,"https://www.ncbi.nlm.nih.gov/pubmed/7520501,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/",
650,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,,,,,
651,118610,118610,NULL,118610,CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION,FAMILIAL APATITE DISEASE,,Chondrocalcinosis due to apatite crystal deposition,,ANKHÂ gene,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,NSAIDs,,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,acute arthritis,HP:0001369,,https://www.ncbi.nlm.nih.gov/pubmed/17541659,
652,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,vitamin E,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,neurological abnormalities,HP:0012638,,"https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770",
653,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,Alpha-tocopherol,,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,,,,,Symptomatic (C),C,neurological abnormalities,HP:0012638,,"https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770",
654,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Abnormal Adipose tissue tocopherol level.,NA,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/,
655,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,Tocofersolan,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",DB11635,DB11635,7608df18269ce24297436b4d5fd42d34fbc0c143fddc55d4b9d419f47d5cd202,DB11635,DB11635,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,No Studies were done on this drug.,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/27520363,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",
656,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,Vitamin A+ Vitamin E,,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Minor visual abnormalities,HP:0000505,,"https://www.ncbi.nlm.nih.gov/pubmed/19285442/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",
657,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Neurological abnormality,HP:0012638,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
658,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Muscular abnormality,HP:0012638,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
659,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,vitamin D,,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,osteopenia,HP:0000938,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
660,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Vitamin D insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
661,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,vitamin K,,DB01022,DB01022,053b7d961fb9916bcb2c1470e66df9490330721eaeb4caa1dfc3314164fb34ca,DB01022,DB01022,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Bleeding tendency,HP:0001892,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
662,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Vitamin K insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
663,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,medium-chain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,"Low weight,growth",HP:0004325,,https://www.sciencedirect.com/science/article/pii/S0929693X16302044?via%3Dihub,
664,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Diarrhea,HP:0002014,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
665,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,,,,,,,,,,,,,,,,,,,,Malnutrition,HP:0004395,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,
666,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,fat emulsion,,DB09422,DB09422,c5cc20af31e840d8cb75f3f1083525f9d9d5bcaa36e6dfa2a1bc66069d2a803c,DB09422,DB09422,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Fat malabsorption,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",
667,215720,215720,NULL,215720,CITRULLINE TRANSPORT DEFECT,,,Citrulline transport defect,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,No Treatment available in DDIEM,,DB09422,DB09422,c5cc20af31e840d8cb75f3f1083525f9d9d5bcaa36e6dfa2a1bc66069d2a803c,DB09422,DB09422,,,,,,,,,,,,,,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",
668,611209,,Number Sign,611209,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G",CDG IIg; CDGIIg;; CDGII/COG1 CEREBROCOSTOMANDIBULAR-LIKE SYNDROME,,COG1-CDG (CDG-IIg),,COG1,COG1,component of oligomeric golgi complex 1,3df5aa58aa53109ad9018723d40ec1cbd78cf5bcaacc8b5992db8463691f54e8,Q9HCJ1,,Q9HCJ1,No Treatment available in DDIEM,,DB09422,DB09422,c5cc20af31e840d8cb75f3f1083525f9d9d5bcaa36e6dfa2a1bc66069d2a803c,DB09422,DB09422,,,,,,,,,,,,,,HP:0001324,,"https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.2010.05840.x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",
669,615395,,Number Sign,615395,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16,,,Combined oxidative phosphorylation deficiency 16,,MRPL44,MRPL44,mitochondrial ribosomal protein L44,0051cb8730a139212747dc7ecedfd46ad21198c07c5c7cdd9f7c8b5c577401d8,Q9H9J2,,Q9H9J2,l-carnitineÂ +propranolol,,DB00583+DB00571,DB00583 + DB00571,378f46f7743b389bc94209f52906555d449a160e4f81a4e80d0e03888546a542,,,,,"DB00583,DB00571","DB00583,DB00571",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,low physical capacity,HP:0012378,,"https://link.springer.com/article/10.1007%2Fs10048-015-0444-2,https://www.ncbi.nlm.nih.gov/pubmed/25797485",
670,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,Cholic acid,,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Atypical bile acids,NA,,"https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",
671,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,,,,,,,,,,,,,,,,,,,,Defected bile flow,HP:0001396,,https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2,
672,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,,,,,,,,,,,,,,,,,,,,Cirrhosis,HP:0001394,,"https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/",
673,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,chenodeoxycholic acid,,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/",
674,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,,,,,,,,,,,,,,,,,,,,Abnormal urinary steroid level,HP:0012030,,https://www.ncbi.nlm.nih.gov/pubmed/2072042,
675,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,,,,,,,,,,,,,,,,,,,,Ill-being (Constitutional symptoms)*,HP:0025142*,,,
676,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,Ursodeoxycholic acid,,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,,,,HP:0025142*,,,
677,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,Cholic acid,,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Liver biochemical abnormalitiesÂ (Laboratory abnormalities)*,HP:0001939,,https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,
678,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,Histological abnormalitiesÂ (Abnormal test result)*,HP:0500014,,,
679,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,,
680,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,Defected bile flow(Cholestasis)*,HP:0001396,,,
681,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,fat soluble vitamin malabsorption*,HP:0002630,,,
682,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,Atypical bile acid synthesis,NA,,,
683,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,production of toxic bile acid metabolic intermediates,NA,,,
684,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,chenodeoxycholicÂ acid,,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,abnormal liver function,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/28697823,
685,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,hepatomegaly,HP:0002240,,,
686,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,interferon Î±-2a,,DB00034,DB00034,6acbf91f3d728fdb4641adedec9508e8123689c18890640525e6a12ed5ef6454,DB00034,DB00034,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,low hemoglobin concentration,HP:0001931,,"https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract",
687,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,,,,,,,,,,,,,,,,,,,,Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*,HP:0011031*,,,
688,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,deferoxamine,,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,high plasma ferritin,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/",
689,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,deferiprone,,DB08826,DB08826,ecac33e809e84cbd68c4ad875f2d52e72c6fc8367bdeabc70a344a6582d0858a,DB08826,DB08826,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Elevated serum ferritin concentrations,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pubmed/16141353",
690,220120,,Number Sign,220120,D-GLYCERIC ACIDURIA,D-GLYCERIC ACIDEMIA;; GLYCERATE KINASE DEFICIENCY,,D-glycericacidemia,,GLYCTK,GLYCTK,d-glycerateÂ kinase,bdf5b0f4fde0a1db11335b73d7193512c015dbca0a59c41e205517e262913975,2.7.1.31,2.7.1.31,,Sodium bicarbonate,,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/26247153,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652015005050021&lng=en&nrm=iso&tlng=en,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract",
691,261515,261515,Number Sign,261515,D-BIFUNCTIONAL PROTEIN DEFICIENCY,17-BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY;; DBP DEFICIENCY;; PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY;; PBFE DEFICIENCY,,D-bifunctional protein deficiency,"No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/",HSD17B4,HSD17B4,17Î²-hydroxysteroid dehydrogenase type 4,71ecb46f2ff29b43d552e82b83eecd08adbf8ed63bd14e093c300a4022496830,2.7.1.31,2.7.1.31,,chenodeoxycholic acid+cholic acid,,DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,ECO:0007121,ECO:0007121,,,Supportive (C),C,The study was terminated,HP:0001942,,"https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract",
692,261515,261515,Number Sign,261515,D-BIFUNCTIONAL PROTEIN DEFICIENCY,17-BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY;; DBP DEFICIENCY;; PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY;; PBFE DEFICIENCY,,D-bifunctional protein deficiency,,HSD17B4,HSD17B4,17Î²-hydroxysteroid dehydrogenase type 4,71ecb46f2ff29b43d552e82b83eecd08adbf8ed63bd14e093c300a4022496830,2.7.1.31,2.7.1.31,,cholic acid+ursodiol,,DB02659Â +DB14555,DB02659 + DB14555,d90e7fd11b2e5d24821872fb692d884f540cf9eb1111c6df8e170f11f43c6d61,,,,,"DB02659,DB14555","DB02659,DB14555",,,ECO:0007121,ECO:0007121,,,Supportive (C),C,The study was terminated,,,,
693,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,L- carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,DNA damage (Abnormality of DNA repair)*,HP:0003254*,,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,
694,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,,,,,,,,,,,,,,,,,,,,oxidative injury*,HP:0025463,,,
695,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,,,,,,,,,,,,,,,,,,,,Protein oxidation,NA,,,
696,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,,,,,,,,,,,,,,,,,,,,lipid peroxidation,NA,,,
697,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,Valproic acid,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/22149023,
698,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,carbamazepine,,DB00593,DB00593,8f6c6cd8e7b651a924326a65216d6a6f55ed8cd6902c293f9a6f333d852da414,DB00593,DB00593,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
699,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,phenobarbital,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
700,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,phenytoin,,DB00252,DB00252,7355ede4950f929c039e58163d1daf16e75b5ea0f0e2193086b6c3e613e23110,DB00252,DB00252,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
701,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,oxcarbazepine,,DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
702,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,vigabatrin,,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
703,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,gabapentin,,DB00996,DB00996,8c05f551ff6c46816ab7d5744ebfe36a01784a399e682aa2f8482ee68150a544,DB00996,DB00996,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
704,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,topiramate,,DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
705,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,zonisamide,,DB00909,DB00909,18de586f793c8d7432d331c9afe6dfcf1fcb41f7152cad42ef308d101c3060c9,DB00909,DB00909,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
706,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,ethosuximide,,DB00593,DB00593,8f6c6cd8e7b651a924326a65216d6a6f55ed8cd6902c293f9a6f333d852da414,DB00593,DB00593,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
707,219750,,Number Sign,219750,"CYSTINOSIS, ADULT NONNEPHROPATHIC","CYSTINOSIS, OCULAR NONNEPHROPATHIC;; CYSTINOSIS, BENIGN NONNEPHROPATHIC",,"Cystinosis, ocular nonnephropathic",,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,cysteamine,,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0005542/ECO:0007121,"ECO:0005542,ECO:0007121",,,Functional interaction ( Mechanistic B),B,corneal crystals,HP:0000531,,"https://www.ncbi.nlm.nih.gov/pubmed/12370309/,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12488257/,https://www.ncbi.nlm.nih.gov/pubmed/1929112/",
708,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,cysteamine,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542",,,Functional interaction ( Mechanistic B),B,corneal crystals,HP:0000531,,"https://www.ncbi.nlm.nih.gov/pubmed/11001803,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",
709,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Photophobia,HP:0000613,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,
710,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Kidney disease progression ( Progressive disorder)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/",
711,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,development of extra-renal pathologies ( Progressive disorder)*,HP:0003678*,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/",
712,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,hypothyroidism,HP:0000821,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,
713,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Delayed growth,HP:0001510,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253",
714,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,cystine accumulation in muscle parenchyma,HP:0003358,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,
715,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,shorter life expectancy,NA,,,
716,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Reduction of WBC cystine levels,NA,,,
717,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,renal function declines,HP:0012622,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,
718,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism),HP:0010918*,,https://www.ncbi.nlm.nih.gov/pubmed/23416144,
719,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,glomerular damage,HP:0000095*,,,
720,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,indomethacin,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,polyuria,HP:0000103,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,
721,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,weight gain,HP:0004324,,,
722,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,proximal tubule salt lossesÂ (Proximal tubular defect),HP:0000114,,,
723,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,renal salt wasting,HP:0000127,,,
724,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Bicarbonate+potassium supplements,,DB01390+DB01345,DB01390 + DB01345,8fe6f9a7e240a8467a633c2992e62e3ee42ae6ab67a7d5a310585f6687ae4db3,,,,,"DB01390,DB01345","DB01390,DB01345",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,acidosis,HP:0001941,,,
725,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,neutral phosphate+Vitamin D,,DB14502 orDB09449 +DB11094,DB14502 or DB09449 + DB11094,418faa3c57dfedc8d5e738a454d7f9610ff7779297d6a0981897e792402555f0,"DB14502,DB09449","DB14502,DB09449",,,DB11094,DB11094,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Phosphate imbalance (Abnormality of phosphate homeostasis),HP:0100529,,https://www.ncbi.nlm.nih.gov/pubmed/27102039,
726,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Thiazide,,DB01324,DB01324,220a0c5acbf784f3ffab6250232a8f228a59e8fdd431a6ae0acc2e73ec19d03b,DB01324,DB01324,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,low proximal tubular reabsorption of bicarbonates,HP:0004910*,,,
727,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,growth hormone,,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,retarded growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/",
728,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,low phosphate reabsorption,HP:0000117,,,
729,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Thyroxine,,DB00451,DB00451,55499b3bcef6fb6f5029a1d7616498410a2edcee934df2555522c03ff686047b,DB00451,DB00451,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hypothyroidism,HP:0000821,,,
730,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,ACE inhibitors,,DB01348,DB01348,e1dec09af2974110d81151f593a251bbda4fdcfa89d6f9ac483ea8803a766e9e,DB01348,DB01348,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,glomerular proteinuria,HP:0000100,,,
731,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Albuminuria,HP:0012592,,https://www.ncbi.nlm.nih.gov/pubmed/14690254/,
732,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Testosterone,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Low serum testosterone levels,HP:004017,,https://www.ncbi.nlm.nih.gov/pubmed/19217094/,
733,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2","Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,phenobarbital,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,Direct Interaction (A),A,high serum bilirubin level,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/23162302/,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",
734,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,orlistat,,DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,high plasma level of unconjugated bilirubin concentration,HP:0008282,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",
735,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,increased fecal fat excretion,HP:0002570,,,
736,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*,HP:0008282*,,,
737,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,AT342,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,High serum  bilirubin concentration,HP:0002904,,https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3,
738,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,GNT0003,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,High serum  bilirubin concentration,HP:0002904,,"https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/",
739,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,hypericum extract,,DB01323,DB01323,7299029353133dbaf5d6253ef3ae989f77790dd9f2eb93e893d60bfc552a4174,DB01323,DB01323,,,,,,,ECO:0000352,ECO:0000352,,,Direct Interaction (A),A,,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/",
740,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,AAV-mediated gene therapy,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/",
741,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,High serum  bilirubin concentration,HP:0002904,,,
742,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Increased inflammatory response,HP:0012649,,,
743,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,Abnormality of metabolism,HP:0001939,,,
744,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Chlofibrate,,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,High serum  bilirubin concentration,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/7483726,https://www.ncbi.nlm.nih.gov/pubmed/19752526/",
745,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Fenofibrate,,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Drug wasn't effective (Insignificant effect),,,https://www.ncbi.nlm.nih.gov/pubmed/16830281,
746,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Calcium,,DB01373,DB01373,752f5e1d8a1808aa3274b10279d52abd2d2cb5fbd6901891efde70a9e3eb0a58,DB01373,DB01373,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Calcium makes phototherapy more efficient,,,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,
747,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,,,,,,,,,,,,,,,,,,,,,,,,
748,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Tin-protoporphyrin,The drug is effective in conjuction with phototherapy,DB02285,DB02285,a3ce67a332f4f19482d5635c9d0a88ffbb869428c5cf4a370a9284554a66ea58,DB02285,DB02285,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,High serum bilirubin level,HP:0002904,,"https://www.nature.com/articles/pr1989488,http://pediatrics.aappublications.org/content/86/1/152,https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome",
749,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,orlistat,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,Symptomatic (C),C,high plasma level of unconjugated bilirubin concentration,HP:0008282,,"https://www.ncbi.nlm.nih.gov/pubmed/17957158,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662",
750,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,AT342,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,Study was suspended based on Sponsor Decision.,HP:0002904,,"https://clinicaltrials.gov/ct2/show/NCT03223194,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662",
751,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,GNT0003,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),,Study is still recruiting,,,https://clinicaltrials.gov/ct2/show/NCT03466463,
752,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Ad5/CMV/hUG-Br1,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),A,Hyperbilirubinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/9525311/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292",
753,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Chimeric oligonucleotide(oligonucleotide-based gene therapy),,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),,UDP-glucuronosyltransferase gene defect,NA,,https://www.ncbi.nlm.nih.gov/pubmed/10468611/,
754,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Retrovirus,,,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),,Hyperbilirubinemia,HP:0002904,,https://www.ncbi.nlm.nih.gov/pubmed/9457971/,
755,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Ad-hBUGT1,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),,Hyperbilirubinemia,HP:0002904,,https://www.ncbi.nlm.nih.gov/pubmed/8900123/,
756,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,sodium benzoate,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/12948744,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub",
757,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,sodium phenylacetate,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",DB09269,DB09269,b4d195b67707744e24c0b704d907ac0beea0eca42d2d3f7f6360e3b5f86d036d,DB09269,DB09269,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,https://www.ncbi.nlm.nih.gov/pubmed/12948744,
758,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,CoQ,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Abnormal liver function,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/12948744,
759,121270,121270,NULL,121270,"COPPER DEFICIENCY, FAMILIAL BENIGN",,,"Copper deficiency, familial benign",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,copper,,DB09130,DB09130,5507c2652d23e5ac96b92e36d181679beb34dd7987e8c695ab1a85505fe86fa4,DB09130,DB09130,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,hypocupraemia,HP:0010836,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,
760,121270,121270,NULL,121270,"COPPER DEFICIENCY, FAMILIAL BENIGN",,,"Copper deficiency, familial benign",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,,,,,,,,,,,,,,,,,,,,seizures,HP:0001250,,,
761,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROSÂ gene,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,bortezomib,,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,Functional interaction (B),B,high porphyrin accumulation in circulating RBCs,HP:0012187,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442",
762,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROSÂ gene,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,,,,,,,,,,,,,,,,,,,,skin photosensitivity,HP:0000992,,,
763,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROSÂ gene,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,,,,,,,,,,,,,,,,,,,,premature degradation of misfolded UROS mutants,NA,,https://www.ncbi.nlm.nih.gov/pubmed/28334762,
764,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROSÂ gene,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,,,,,,,,,,,,,,,,,,,,abnormal porphyrin accumulation in urine,HP:0010473,,,
765,610198,,Number Sign,610198,"3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5","CARDIOMYOPATHY, DILATED, WITH ATAXIA; DCMA;; MGA, TYPE V; MGA5",,"DCMA syndromeÂ (3-methylglutaconic aciduria, type V)",,DNAJC19,DNAJC19,DnaJ heat shock protein family (Hsp40) member C19,5d69fff92ceebbdfaa7868a0560025b09c62f8db0af410b4e7096aec3f5d6528,Q96DA6,,Q96DA6,Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide,,C09C+DB00390+DB00695,C09C + DB00390 + DB00695,90c0a3658738c46c75da5391ab80a802bdb6c8aa2d0dbeb83c445eefd868a16a,,,,,"C09C,DB00390,DB00695","DB00390,DB00695",,C09C,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Low ejection fraction,HP:0010473,,"https://www.ncbi.nlm.nih.gov/pubmed/27928778,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/",
766,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,Dextrothyroxine,,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,ECO:0007121,ECO:0007121,,,,,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/",
767,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,,,,,,,,,,,,,,,,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/280544,
768,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/280544,
769,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,,,,,,,,,,,,,,,,,,,,Mild asymptomatic hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/280544,
770,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,Complex Carbohydrates,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
771,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,,,,,,,,,,,,,,,,,,,,Short Stature,HP:0004322,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
772,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,Complex carbohydrates+Beneprotein+Low fats,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
773,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,Uncooked cornstarch+ Beneprotein+Low fats diet,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
774,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,Uncooked cornstarch+ Beneprotein,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
775,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,,,,,,,,,,,,,,,,,,,,Failure to thrive,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
776,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,Uncooked cornstarch,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
777,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,,,,,,,,,,,,,,,,,,,,Failure to thrive,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
778,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate),,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,"On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.",https://www.ncbi.nlm.nih.gov/pubmed/25266922,
779,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,CoCarbs + HPro,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
780,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,Uncooked cornstarch+ Beneprotein,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Elevated hepatic transaminases,HP:0002910,Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/12930917",
781,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,,,,,,,,,,,,,,,,,,,,Hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/12930917,
782,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,,,,,,,,,,,,,,,,,,,,,,,,
783,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,,,,,,,,,,,,,,,,,,,,,,,,
784,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver","GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,Glycosade,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Nocturnal Hypoglycemia(Hypoglycemia)*,HP:0001943*,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/29223626",
785,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,,,,,,,,,,,,,,,,,,,,Poor sleep quality(Sleep disturbance)*,HP:0002360*,,https://www.ncbi.nlm.nih.gov/pubmed/29223626,
786,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,Cornstarch,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,,,MorningHypoglycemia (Hypoglycemia)*,HP:0012051,,https://www.ncbi.nlm.nih.gov/pubmed/12794686,
787,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,,,,,,,,,,,,,,,,,,,,Ketosis,HP:0001946,,,
788,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,,,,,,,,,,,,,,,,,,,,,,,,
789,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,,,,,,,,,,,,,,,,,,,,,,,,
790,611881,,Number Sign,611881,GLYCOGEN STORAGE DISEASE XII; GSD12,"GSD XII;; ALDOLASE A DEFICIENCY;; ALDOA DEFICIENCY;; ALDOLASE DEFICIENCY, RED CELL;; RED CELL ALDOLASE DEFICIENCY",,Glycogen storage disease type 12,,ALDOA,ALDOA,"aldolase, fructose-bisphosphate A",765e3f734fb51fe756a52b5fc92eb554299da15770d33cbf0de1d803bc460696,4.1.2.13,4.1.2.13,,No treatment available,,,,,,,,,,,,,,,,,,,,done,,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,
791,612932,,Number Sign,612932,GLYCOGEN STORAGE DISEASE XIII; GSD13,GSD XIII;; ENOLASE 3 DEFICIENCY;; ENOLASE-BETA DEFICIENCY,,Glycogen storage disease type 13,,ENO3,ENO3,enolase 3,b8821d4006d3d4ef72ac65052dd7252623400ecb5fc8291514ac714627f1a465,4.2.1.11,4.2.1.11,,No treatment available,,,,,,,,,,,,,,,,,,,,done,,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,
792,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,DTX401,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,"""The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level.""",done,,"https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20163245",
793,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,FIV-hAAT-G6Pase,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),A,Hypoglycemia,done,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,https://www.ncbi.nlm.nih.gov/pubmed/20163245",
794,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Ad-mG6Pase,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),A,Growth retardation,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
795,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
796,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hyperuricemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
797,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hyperlipidemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
798,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Enlarged kidney,HP:0000105,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
799,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,
800,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,AAV-cG6PGH,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),A,Growth Failure,HP:0002240,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,
801,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hyperlipidemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128",
802,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hypoglycemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128",
803,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,HDAd-G6Pase,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct Interaction (A),A,Hypoglycemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/17505475,https://www.ncbi.nlm.nih.gov/pubmed/17430128",
804,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Glycosade,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",
805,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,"Sleep disturbance,Poor sleep quality",HP:0002360,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862",
806,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,,
807,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,l-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0007764,ECO:0007764,,,Symptomatic (C),C,mitochondrial dysfunction,HP:0003287,,"http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract,https://www.nature.com/articles/srep44408",
808,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Tempol,,DB12449,DB12449,b6f511b8dda4a7374a265acd57094467915d8b79768f706f3fac644c5bf034a7,DB12449,DB12449,,,,,,,ECO:0005242,ECO:0005242,,,Symptomatic (C),,Abnormal renal function,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pubmed/20195241,https://www.nature.com/articles/srep44408",
809,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Renal disease progression( Progressive disorder)*,HP:0003676*,,https://www.ncbi.nlm.nih.gov/pubmed/20195241,
810,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Nephropathy,HP:0000112,,https://www.ncbi.nlm.nih.gov/pubmed/20195241,
811,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,ACEâinhibitors,,C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Glomerular hyperfilteration (Abnormal glomerular filtration rate),HP:0012212,,"https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006",
812,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Antioxidant + ACE inhibitors,,DB12449+C09C,DB12449 + C09C,efbd842276f530133b1a9e0b5437448a7d861f01bd4344a83118634d4a160bfb,,,,,"DB12449,C09C",DB12449,,C09C,ECO:0007764,ECO:0007764,,,Symptomatic (C),,Nephropathy,HP:0000112,,"https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006",
813,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Glucose,,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/",
814,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Uncooked cornstarch,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),,Hypoglycemia,HP:0001943,,"https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,https://www.ncbi.nlm.nih.gov/pubmed/20975743/",
815,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Allopurinol,,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,High plasma uric acid levels,HP:0002149,,https://www.ncbi.nlm.nih.gov/pubmed/26835382,
816,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Calcium+ vitamin D3,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,DB01373+DB00169,DB01373 + DB00169,6ce9cd0a5e5edd83421774b5d0464c1727779801a14fcec589dfa00a065b3f18,,,,,"DB01373,DB00169","DB01373,DB00169",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Osteoporosis,HP:0000939,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,
817,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,medium chain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperuricemia,HP:0002149,,https://www.ncbi.nlm.nih.gov/pubmed/20357432,
818,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/20357432,
819,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,Growth failure,HP:0001510,,https://www.ncbi.nlm.nih.gov/pubmed/20357432,
820,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,,,,,,,,,,,,,,,,,,,,,,,,
821,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Human granulocyte-colony-stimulating-factor,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,DB00099,DB00099,df8f4f7cffc198cc131ab66c85b0c27934125ec41a478c68ad5cf2e48ad87507,DB00099,DB00099,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956",
822,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,Recurrent bacterial infection,HP:0002718,,"https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.sciencedirect.com/science/article/abs/pii/S0022347605802902",
823,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.sciencedirect.com/science/article/abs/pii/S0022347605802902",
824,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,GâCSF + 5âaminosalicylic acid,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",DB00099+DB00244,DB00099 + DB00244,fbc15a36027247fdc87df3f319b1ce0c1ed359a9a52ca7d13fb7bc7356ab0c18,,,,,"DB00099,DB00244","DB00099,DB00244",,,ECO:0000352,ECO:0000352,,,,,Neutropenia with IBD,HP:0001875+HP:0002037,,"https://www.ncbi.nlm.nih.gov/pubmed/12373585,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498",
825,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Adalimumab,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,GSD-associated enterocolitis(enterocolitis),HP:0004387,,https://www.ncbi.nlm.nih.gov/pubmed/18172743,
826,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Glycosade,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",
827,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,"Sleep disturbance,Poor sleep qaulity",HP:0002360,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862",
828,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,,
829,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,rAAV-GPE-G6PT,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct Interaction (A),A,hyperlipidemia,HP:0003077,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
830,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,hypoglycemia,HP:0001943,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
831,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,hyperuricemia,HP:0002149,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
832,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,lactic acidemia,HP:0003128,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
833,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,age-related insulin resistance(Insulin resistance)*,HP:0000855*,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
834,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,obesity,HP:0001513,,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,
835,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,galactose+Uridine,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",DB11735+DB02745,DB11735 + DB02745,5f525431b12ec66e372ad1e76a90015d7b1bbf5e6e800c87d3557e2396b087a3,,,,,"DB11735,DB02745","DB11735,DB02745",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Partial correction of neutrophil dysfunction,HP:0011990,"In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract",http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract,
836,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,vitamin E,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,neutropenia,HP:0001875,,https://www.ncbi.nlm.nih.gov/pubmed/19066956,
837,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,https://www.ncbi.nlm.nih.gov/pubmed/19066956,
838,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,testosterone,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,decreased male libido,HP:0040306,,https://www.ncbi.nlm.nih.gov/pubmed/28160246,
839,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,low physical activity,HP:0025142,,,
840,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,decrease muscle strenght,HP:0001324,,,
841,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,medium chain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperurecemia,done,,https://www.ncbi.nlm.nih.gov/pubmed/20357432,
842,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,Hypertriglycerdemia,,,,
843,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,,,,,,,,,,,,,,,,,,,,Growth failure,,,,
844,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,Cornstarch,,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,linear growth velocity(Abnormality of body height)*,HP:0000002*,,"https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482",
845,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,hypoglycemic seizures,HP:0002173,,,
846,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,Enlarged size of the liver,HP:0002240,,,
847,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,calcium and vitamin D,,DB01373 + DB11094,DB01373 + DB11094,7885d7e836e075132866496ac09834e338f19bebfe3771d77d34ec43420f0f84,,,,,"DB01373,DB11094","DB01373,DB11094",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Osteoporosis,HP:0000939,,,
848,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,Glycosade,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432",
849,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,Sleep disturbance,HP:0002360,,https://www.ncbi.nlm.nih.gov/pubmed/29223626,
850,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,Rapamycin,,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a defective protein by inhibition,B,high glycogen levels in muscles,HP:0009051,,https://www.ncbi.nlm.nih.gov/pubmed/24509886,
851,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,liver fibrosis progression,HP:0001395,,https://www.ncbi.nlm.nih.gov/pubmed/24509886,
852,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,fructose,,DB04173,DB04173,0f3d4d64e17c3caea0a67312f04920172569a615afacf6f1c21a6f4b824eb673,DB04173,DB04173,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,exercise intolerance,HP:0003546,,https://www.ncbi.nlm.nih.gov/pubmed/25832663,
853,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,high protein diet,,NA,,,,,,,,,,,,,,,Symptomatic (C),C,delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377",
854,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,myopathy,HP:0003198,,,
855,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,cardiomyopathy,HP:0001638,,,
856,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,Modified Atkins diet,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,abnormal blood levels of ketone bodies,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/",
857,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,Abnormal blood levels of  fatty acids,HP:0004359,,,
858,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,high creatine kinase,HP:0003236,,,
859,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,cardiomyopathy,HP:0001638,,,
860,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,low energetic state of heart(Abnormality of cardiovascular system physiology)*,HP:0011025*,,,
861,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,low energetic state of skeletal muscle,HP:0011804,,,
862,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,Increased creatine kinase activity,HP:0003236,,,
863,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,,,,,,,,,,,,,,,,,,,,,,,,
864,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,Sodium Valproate,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,,done,,"http://euromacregistry.eu/portal1/content.asp?contentid=1207,https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569",
865,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,Triheptanoin,,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,abnormal fat metabolism,HP:0004359,,"https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1",
866,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,abnormal carbohydrate metabolism*,HP:0011013,,,
867,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,creatine,,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/25391139,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf",
868,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,sucrose,,DB02772,DB02772,315878de726debaf51db4155574061556fa558a7791b78bbca31f9a90bfde016,DB02772,DB02772,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,exercise intolerance,HP:0003547,,"http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25391139,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",
869,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,vitamin B6,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,insufficient anaerobic glycolysis of skeletal muscle,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Confirmation+of+the+efficacy+of+vitamin+B6+supplementation+for+McArdle+disease+by+followâup+muscle+biops,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf",
870,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,exercise intolerance,HP:0003546,,,
871,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,abnormal muscle phosphorylase activity,NA,,,
872,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,ramipril,,DB00178,DB00178,619aea6ef0e92c91d7d8591df28d34f3d7e8c3131e655d93aad7947ddf784744,DB00178,DB00178,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,disability(Functional motor problems)*,HP:0004302*,,"https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/",
873,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Abnormal exercise physiology,HP:0009020,,,
874,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,GENTAMICIN,,DB04729,DB04729,d2bb23a9527e496109b0e1ea6cc9907f90b9339c059a5bd86c4a54d7ecc50c98,DB04729,DB04729,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,,HP:0009020,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract",
875,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,Cornstarch(Uncooked),,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.sciencedirect.com/science/article/pii/S1096719214002959?via%3Dihub",
876,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Abnormal blood glucose concentration,HP:0011015,,https://www.ncbi.nlm.nih.gov/pubmed/20301760,
877,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Low energy level(Tiredness)*,HP:0012378,,https://www.ncbi.nlm.nih.gov/pubmed/20301760,
878,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Failure to thrive,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
879,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Elevated Hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
880,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,Beneprotein,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://m.ufhealth.org/sites/default/files/media/GSD/General-Nutrition-Guidelines-For-Glycogen-Storage-Disease-Type-VI.pdf",
881,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,Uncooked cornstarch+Beneprotein,,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,Functional interaction (B),,Elevated Hepatic transaminases,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,
882,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,D-Thyroxine,,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),,Hepatomeglay,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087",
883,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Elevated Hepatic transaminases,HP:0002910,,,
884,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Failure to thrive,HP:0001508,,,
885,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Increased erythrocyte glycogen content,HP:0001939,,,
886,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,,
887,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,,,,,
888,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,,,,,,,,,,,,,,,,,,,,,,,,
889,232800,,Number Sign,232800,GLYCOGEN STORAGE DISEASE VII; GSD7,GSD VII;; MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY;; PFKM DEFICIENCY;; TARUI DISEASE,,Glycogen storage disease type 7,"The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272",PFKM,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",09f803234edd9c4360e283983e38b2ef63ee950038d3eeac6b4833679a83e11b,2.7.1.11,2.7.1.11,,Triheptanoin,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",,,,,,,,,,,,ECO:0007121,ECO:0007121,,,,,Trial is still in the Recruiting stage.,,,https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,
890,232800,,Number Sign,232800,GLYCOGEN STORAGE DISEASE VII; GSD7,GSD VII;; MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY;; PFKM DEFICIENCY;; TARUI DISEASE,,Glycogen storage disease type 7,,PFKM,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",09f803234edd9c4360e283983e38b2ef63ee950038d3eeac6b4833679a83e11b,2.7.1.11,2.7.1.11,,,,,,,,,,,,,,,,,,,,,,,,,
891,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,"Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.",GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,Nicotinamide,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction(Mechanistic B),B,Liver steatosis,HP:0001397,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268",
892,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,,,,,,,,,,,,,,,,,,,,Fatty liver,HP:0001397,,,
893,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,,,,,,,,,,,,,,,,,,,,Liver fibrosis,HP:0001395,,,
894,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,,,,,,,,,,,,,,,,,,,,DNA hypermethylation,NA,,,
895,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,OTZÂ (L-2-oxothiazoline-4-carboxylic acid,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction (B),B,low intracellular cysteine*,HP:0010918,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,
896,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,,,,,,,,,,,,,,,,,,,,behavioral abnormalities,HP:0000708,,,
897,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,,,,,,,,,,,,,,,,,,,,GSH deficiency,HP:0003343,,,
898,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,N-acetylcysteine,,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction (B),B,Delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/,https://www.ncbi.nlm.nih.gov/pubmed/20868666",
899,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,,,,,,,,,,,,,,,,,,,,Cataract,HP:0000518,,https://www.ncbi.nlm.nih.gov/pubmed/11095909,
900,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,,,,,,,,,,,,,,,,,,,,low reproductive capacity (infertility),HP:0000144,,https://www.ncbi.nlm.nih.gov/pubmed/11089562,
901,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,ascorbic acid,,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/8301428/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852094/",
902,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,Ascorbate + N-acetylcysteine,,DB00126+DB06151,DB00126 + DB06151,91c2381c97f0b05c7f238d2769f7c96c9ac8c3d0f9b258ead7f86a09688a9e23,,,,,"DB00126,DB06151","DB00126,DB06151",,,ECO:0000352,ECO:0000352,,,,,High erythrocyte turnover(Abnormality of erythrocytes)*,HP:0001877*,,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,
903,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,Polycitra (citric acid +potassium citrate + sodium citrate)+vitamin C+vitamin E+selenium,,DB11135,DB11135,22f5abc3eb662b8283f23aa7fa4f08c4926ae913337d99d99f4d250de779d6fa,DB11135,DB11135,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,oxidative stress,HP:0025464,,http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract,
904,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,alpha-tocopherol,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,abnormal microtubule assembly,NA,,https://books.google.com.sa/books?id=s5LmBwSwwGsC&pg=PA555&lpg=PA555&dq=alpha-tocopherol+in+treating+abnormal+microtubule+assembly%C2%A0&source=bl&ots=4aMlvmEp6z&sig=4RJAuvv04-5ZSQQWo2OOGLf5LYg&hl=en&sa=X&ved=2ahUKEwjrut3GkqHeAhUJJ1AKHUwSBiYQ6AEwBXoECAQQAQ#v=onepage&q=alpha-tocopherol%20in%20treating%20abnormal%20microtubule%20assembly%C2%A0&f=false,
905,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Short erythrocyte survival (Abnormality of erythrocytes)*,HP:0001877*,,https://www.ncbi.nlm.nih.gov/pubmed/29340523,
906,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,abnormal polymorphonuclear leukocyte function,HP:0001874,,,
907,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Neutropenia,HP:0001875,,,
908,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Susceptibility to Bacterial infection,HP:0002718,,,
909,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,retinal dystrophy,HP:0000556,,https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,
910,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,CNS damage progression,HP:0007367,,,
911,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,L-carnitine+vitamin E+vitamin B1+ cobalamin,,DB00583+DB00163+DB00152+DB14098+DB01390,DB00583 + DB00163 + DB00152 + DB14098 + DB01390,b1d3dacceb6ae2c16a9d8eb6e987d5ba702ea95658a905f29847e3ed88694343,,,,,"DB00583,DB00163,DB00152,DB14098,DB01390","DB00583,DB00163,DB00152,DB14098,DB01390",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hypersomnia,HP:0100786,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
912,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Jaundice,HP:0000952,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
913,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Carnitine deficiency,HP:0003234,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
914,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Hypotonia,HP:0001290,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
915,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,DB00583 + DB00163 + DB00152 + DB00140 + DB01390 + DB00126 + DB00115,d45ec54952c5d410109fb89d77997c093924fd1033baf758b19082f4d37fa234,,,,,"DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115","DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Metabolic acidosis,HP:0001942,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
916,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
917,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Elevated urine 5-oxoproline,NA,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
918,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Decreased blood free carnitine,HP:0008315,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
919,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,L-carnitine+ vitamin B1+B12+C + E,,DB00583+DB00152+DB00115+DB00126+DB00163,DB00583 + DB00152 + DB00115 + DB00126 + DB00163,7af2822648ad36b2c767c0d15c33dbbcba7fb1ca2e5489bb0ffe1cafc4a3ff71,,,,,"DB00583,DB00152,DB00115,DB00126,DB00163","DB00583,DB00152,DB00115,DB00126,DB00163",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Elevated urine 5-oxoproline,NA,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
920,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,,,,,,,,,,,,,,,,,,,,Decreased blood free carnitine,HP:0008315,,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,
921,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,Sodium Bicarbonate,,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/26669244/",
922,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,high-anion gap acidosis,HP:0001941*,,http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract,
923,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,dorzolamide+acetazolamide,,DB00869+DB00819,DB00869 + DB00819,14e2a66435960bede166016ae6e1ce9f44d2690cef9ea823f277327bd00e8ebd,,,,,"DB00869,DB00819","DB00869,DB00819",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,cystoid macular edema,HP:0011505,,https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract,
924,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,erythropoietin + iron+folic acid + vitamin B12,,DB00016+DB01592+DB00158+DB00165,DB00016 + DB01592 + DB00158 + DB00165,ad6578000018db642a0813987755950ddab640bc3d430dc13ba5dbdc4a801fd9,,,,,"DB00016,DB01592,DB00158,DB00165","DB00016,DB01592,DB00158,DB00165",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,anaemia,HP:0001903,,"http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract,https://link.springer.com/content/pdf/10.1007%2Fs10545-005-0156-0.pdf",
925,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,"It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622",GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,CarnitineÂ +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",DB00583+DB00130+DB09393,DB00583 + DB00130 + DB09393,5e34832864f55a7696367285109a61f410973bc9bcb2dbcef9ae5e007ffa15f5,,,,,"DB00583,DB00130,DB09393","DB00583,DB00130,DB09393",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Brain damage,HP:0001298,Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622,https://www.ncbi.nlm.nih.gov/pubmed/23326493,
926,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Cerebral palsy,HP:0100021,"Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918",https://www.ncbi.nlm.nih.gov/pubmed/10630918,
927,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234*,,,
928,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,Carnitine+ Riboflavin+baclofen,,DB00583+DB00130+DB00181,DB00583 + DB00130 + DB00181,8a6405f06d478a0cea25afe7f348f802b7e36fc3daaea682cc4eb559884563c7,,,,,"DB00583,DB00130,DB00181","DB00583,DB00130,DB00181",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Disease progression,HP:0003676,,"https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract",
929,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234*,,https://www.sciencedirect.com/science/article/pii/S0387760405001439?via%3Dihub,
930,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Metabolic acidosis,HP:0001942,,,
931,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen,,DB00583+DB00679+DB01563+DB00181,DB00583 + DB00679 + DB01563 + DB00181,4947ffaad4434bb054eaf943aa57514279f0f12f0b88eae9dfb97f4c70f4de2d,,,,,"DB00583,DB00679,DB01563,DB00181","DB00583,DB00679,DB01563,DB00181",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Dystonia,HP:0001332,The phenotype has been reported in association to treatment with baclofen as,https://www.ncbi.nlm.nih.gov/pubmed/8881997,
932,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,chlorpromazine,,DB00477,DB00477,d1a2c04a61c91aef138ad149b3c95e590cd1e66b7a2acc6f7a94893e6f27bf37,DB00477,DB00477,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperpyrexia in case of acute encephalopathic crises(Fever)*,HP:0001945*,,https://www.ncbi.nlm.nih.gov/pubmed/10222465,
933,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,Carnitine+Riboflavin+L-Arginine+clofibrate,The combination was accompanied by Low L-lysine diet,DB00583+DB00130+DB00125+DB00636,DB00583 + DB00130 + DB00125 + DB00636,6e753d9c6e6ec14adce3ed1cefc7b2c92268534825d6744ff2da524b8af76f73,,,,,"DB00583,DB00130,DB00125,DB00636","DB00583,DB00130,DB00125,DB00636",,,ECO:0005542,ECO:0005542,,,Functional interaction (B),B,Glutaric acidemia,HP:0003530,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,https://www.ncbi.nlm.nih.gov/pubmed/20923787,
934,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Carnitine+ riboflavin,Synergism inmproves results,DB00583+DB00140,DB00583 + DB00140,650f11b7e6f4777f00adca00b7917adc93c6bc3fa59a316e4ef42c82577b9fdc,,,,,"DB00583,DB00140","DB00583,DB00140",,,ECO:0000352,ECO:0000352,,,Functional interaction (B)+Direct Interaction (A),B,High serum creatine kinase,HP:0003236,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,"https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract",
935,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Muscle weakness,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/10723193,
936,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234,,https://www.ncbi.nlm.nih.gov/pubmed/10723193,
937,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Carnitine+ riboflavin+Coenzyme Q,,DB00583+DB00140+DB09270,DB00583 + DB00140 + DB09270,11206d52bacc0dd8486f1255d886b9b83ba197524527d61fedff15baddf2c298,,,,,"DB00583,DB00140,DB09270","DB00583,DB00140,DB09270",,,ECO:0000352,ECO:0000352,,,Functional interaction (B)+Direct Interaction (A)+symptomatic,A,Dysphagia,HP:0002015,,https://www.ncbi.nlm.nih.gov/pubmed/26236614,
938,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Difficulty walking,HP:0002355,,,
939,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234,,https://www.ncbi.nlm.nih.gov/pubmed/10723193,
940,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Glycine+Riboflavin+Carnitine,,DB00145+DB00140+DB00583,DB00145 + DB00140 + DB00583,7cfddedaefee3e74fea3c0426b9903e35e4cec0da84039dee7b8c5e4b0246848,,,,,"DB00145,DB00140,DB00583","DB00145,DB00140,DB00583",,,ECO:0000352,ECO:0000352,,,Symptomatic (C)+Direct Interaction (A)+Functional interaction (B),C,Muscle weakness,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/3229565,
941,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,"sodium-d,l-3-hydroxybutyrate",,CHEBI:113373,CHEBI:113373,f9013acf5797722338d82172bac7001402845cead1ecb2bb15b3f83682b5a7df,CHEBI:113373,,CHEBI_113373,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,progressive leukodystrophy,HP:0002415,,"https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract",
942,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,paralysis,HP:0003470,,https://www.ncbi.nlm.nih.gov/pubmed/12727399,
943,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,cardiomyopathy,HP:0001638,,https://www.ncbi.nlm.nih.gov/pubmed/12727399,
944,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,Impaired myocardial contractility,HP:0006670,,https://www.ncbi.nlm.nih.gov/pubmed/12727399,
945,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,Direct Intercation (activity modification)*,,,HP:0006670,,https://www.ncbi.nlm.nih.gov/pubmed/10581232,
946,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,
947,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,
948,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,
949,231690,,Number Sign,231690,GLUTARIC ACIDURIA III; GA3,GA III;; GLUTARYL-CoA OXIDASE DEFICIENCY,,Glutaric acidemia type III,,SUGCT,SUGCT,succinate-hydroxymethylglutarate coA-transferase,b512eaa65cbec4557828616db1d43cbeebf11345ee9adbb652f36253a132a201,2.8.3.13,2.8.3.13,,Metronidazole,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:00007121,ECO:00007121,,,Functional intercation ( Mechanistic B),C,Cyclic vomiting (Vomiting)*,HP:0002013,,https://www.ncbi.nlm.nih.gov/pubmed/28766179,
950,231690,,Number Sign,231690,GLUTARIC ACIDURIA III; GA3,GA III;; GLUTARYL-CoA OXIDASE DEFICIENCY,,Glutaric acidemia type III,,SUGCT,SUGCT,succinate-hydroxymethylglutarate coA-transferase,b512eaa65cbec4557828616db1d43cbeebf11345ee9adbb652f36253a132a201,2.8.3.13,2.8.3.13,,,,,,,,,,,,,,,,,,,,,Bacterial glutric acid production,NA,,,
951,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,l-glutamine,,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,ECO:0007121,ECO:0007121,,,Functional intercation ( Mechanistic B),B,Abnormal plasma glutamine levels,HP:0010903,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192420/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495849/",
952,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Low CSF glutamine level,HP:0030980*,,,
953,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,unalertness,HP:0002329,,,
954,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Lack of emotional expressions,HP:0030213,,,
955,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Abnormal EEG results,HP:0002353,,,
956,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Low brain glutamine concentration,HP:0030980,,,
957,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,Symptomatic (C),,Secondary NAD+ deficiencyÂ in leucocytes,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pubmed/25896882/",
958,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Nicotinamide,,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),C,Secondary NAD+ deficiencyÂ in leucocytes,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/25896882/",
959,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Vitamin C+Vitamin E+Selenium,,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/26984560,https://www.ncbi.nlm.nih.gov/pubmed/25896882/",
960,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Citric acid+Sodium citrate+ Potassium citrate,,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Metabolic acidosis,HP:0001942,,https://www.ncbi.nlm.nih.gov/pubmed/26984560,
961,229100,229100,Number Sign,229100,GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY,FORMIMINOTRANSFERASE DEFICIENCY;; FORMIMINOGLUTAMIC ACIDURIA;; FIGLU-URIA,,Glutamate formiminotransferase deficiency,The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726,FTCD,FTCD,formiminotransferase cyclodeaminase,fa3eaef7b61a25a93d5ae56c2f7a94a76809cfbe6c062feb39afaaa767a93501,6.3.1.2,6.3.1.2,,pyridoxine +folic acid,,DB00165+DB00158,DB00165 + DB00158,3c0930810a383d269d2952caae6c609ecf08a455e5358398a34518d835c35883,,,,,"DB00165,DB00158","DB00165,DB00158",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Megaloblastic anemia,HP:0001889,,https://www.ncbi.nlm.nih.gov/pubmed/5301410,
962,606824,,Number Sign,606824,GLUCOSE/GALACTOSE MALABSORPTION; GGM,MONOSACCHARIDE MALABSORPTION; GM,,Glucose-galactose malabsorption,Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187,SLC5A1,SLC5A1,sodium/glucose cotransporter protein called SGLT1,1c2c7c79d7ca7ca5975f200df167478430149d67daee923b3d8f9d2f685e274e,6.3.1.2,6.3.1.2,,Fractose +Carbohydrate free formula,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Watery Diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/",
963,606824,,Number Sign,606824,GLUCOSE/GALACTOSE MALABSORPTION; GGM,MONOSACCHARIDE MALABSORPTION; GM,,Glucose-galactose malabsorption,,SLC5A1,SLC5A1,sodium/glucose cotransporter protein called SGLT1,1c2c7c79d7ca7ca5975f200df167478430149d67daee923b3d8f9d2f685e274e,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Dehydration,HP:0001944,,,
964,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitorsâfor example, topiramate, zonisamide, and acetazolamideâmay increase risk of nonâanion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract",SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,UX007 (triheptanoin),,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,Symptomatic (C),C,seizures,HP:0001250,,"https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,ECO:0007121/ECO:0005542",
965,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,EEG with focal spike waves,HP:0011197,,,
966,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Nonepileptic paroxysmal abnormalities,NA,,,
967,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/",
968,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,C,movement disorders,HP:0100022,,,
969,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Dyskinesia,HP:0100660,,http://medwiekurozwoj.pl/articles/2015-4-7.pdf,
970,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,AAV-GLUT1,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,Abnormal CSF glucose levels,HP:0031884,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,
971,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Abnormal motor function,HP:0004302,,,
972,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,,,,,,,,,,,,,,,,,,,,Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia),HP:0007166,,,
973,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,Rofecoxib,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,DB00533,DB00533,ff321d767684cde091e0c67da04440b914856f6f1938068a32dd01aa979fd9fe,DB00533,DB00533,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Refractory hypokalemia,HP:0002900*,,"https://www.ncbi.nlm.nih.gov/pubmed/12141411,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub",
974,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Abnormally reduced levels of aldosterone,HP:0004319,,,
975,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,,,Abnormal serum renin level,HP:0040084,,,
976,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,,,,,,,
977,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,Indometacin/Amiloride/Eplerenone+Potassium,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",(DB00328/DB00594/DB00700)+DB00761,(DB00328 / DB00594 / DB00700) + DB00761,1a8db6aa750b8f1d42ae71169258db54bd12fd30097e42e497b586ce27512706,"(DB00328,DB00594,DB00700)",DB00594,,"(DB00328,DB00700)",DB00761,DB00761,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Refractory hypokalemia,HP:0002900*,,"https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/",
978,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,Indometacin,,(DB00328/DB00594/DB00700)+DB00761,(DB00328 / DB00594 / DB00700) + DB00761,1a8db6aa750b8f1d42ae71169258db54bd12fd30097e42e497b586ce27512706,"(DB00328,DB00594,DB00700)",DB00594,,"(DB00328,DB00700)",DB00761,DB00761,,,,,,,,,developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/25852896/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/",
979,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,,,high plasma RAAS activity,HP:0000847*,,,
980,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Abnormally reduced levels of aldosterone,HP:0004319,,https://www.ncbi.nlm.nih.gov/pubmed/25012174,
981,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Abnormal serum renin level,HP:0040084,,https://www.ncbi.nlm.nih.gov/pubmed/25012174,
982,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,Magnesium,,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,hypomagnesemia,HP:0002917,"In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,
983,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,,,,,,,,,,,,,,,,,,,,chondrocalcinosis,HP:0000934,,,
984,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,Potassium chloride,,DB00761,DB00761,67f1e0b55afe5c60ce17dcb742c8ee747c1e0593a6d968a63548f2028bdaab68,DB00761,DB00761,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,hypokalemia,HP:0002900,,,
985,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Taliglucerase alfa,,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Hepatomegaly,HP:0002240,,"https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27839981",
986,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Splenomegaly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018",
987,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
988,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,low mean hemoglobin concentration,HP:0025547,,,
989,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,low bone marrow fat fraction value,NA,,https://www.ncbi.nlm.nih.gov/pubmed/30066229,
990,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,ImiglucÃ©rase (ISU302),,DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,primary low heamoglobin level,HP:0001903*,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/30066229",
991,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
992,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,splenomegaly,HP:0001744,,,
993,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,,
994,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,high angiotensin- converting enzyme,HP:0000841,,,
995,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*,HP:0004356,,,
996,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,"elevated Chemokine Ligand (CCL-18) Level [ng,mL]",NA,,,
997,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,prGCD,,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Trial is no longer available,NA,,"https://clinicaltrials.gov/ct2/show/NCT00705939,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt",
998,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,,,,,
999,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Eliglustat tartrate,,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,Low mean hemoglobin level,HP:0001903,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622",
1000,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,,
1001,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,,
1002,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Splenomegaly,HP:0001744,,,
1003,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Low lumbar spine bone mineral density(bnormality of bone mineral density)*,HP:0004348,,,
1004,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,N-acetylcysteine,,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Oxidative stress,HP:0025464,,"https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/?term=N-acetylcysteine+in+treating+Gauchers",
1005,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Low blood glutathione redox ratios,MP:0012604*,,,
1006,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Inflammation,HP:0012649,,https://www.ncbi.nlm.nih.gov/pubmed/23860343,
1007,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,concentration of myo-inositol in brain,HP:0025460,,,
1008,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,concentration of TNF-alpha in plasma,HP:0011118*,,,
1009,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Elelyso,,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,ECO:0000352/ ECO:0007121,"ECO:0000352,ECO:0007121",,,Direct interaction ( Mechanistic A),A,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7",
1010,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Splenomegaly,HP:0001744,,,
1011,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
1012,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,anaemia,HP:0001903,,,
1013,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Velaglucerase alfa,,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,changes in lumbar spine (LS),HP:0100712,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797",
1014,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,abnormality in bone mineral density,HP:0004348,,,
1015,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,anaemia,HP:0001903,,,
1016,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
1017,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,hepatosplenomegaly,HP:0001433,,,
1018,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,growth faliure,HP:0001510,,,
1019,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,avascular osteonecrosis,HP:0010885,,https://www.ncbi.nlm.nih.gov/pubmed/29503270,
1020,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Bone pain,HP:0002653,,https://www.ncbi.nlm.nih.gov/pubmed/29503270,
1021,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Ambroxol,The drug was used in a pilot study.,DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction (A),A,Anemia,done,,"https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17,https://www.ncbi.nlm.nih.gov/pubmed/23085429",
1022,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Splenomegaly,HP:0001744,,https://www.ncbi.nlm.nih.gov/pubmed/23085429,
1023,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Thrombocytpenia,HP:0001873,,https://www.ncbi.nlm.nih.gov/pubmed/23085429,
1024,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,https://www.ncbi.nlm.nih.gov/pubmed/23085429,
1025,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Miglustat (NB-DNJ)(OGT 918),,,,,,,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,Functional interaction(Mechanistic B),B,Splenomegly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/11227045,https://www.ncbi.nlm.nih.gov/pubmed/12064906,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716",
1026,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,hepatomegly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070",
1027,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,High chitotriosidase level,NA,,,
1028,230900,,Number Sign,230900,"GAUCHER DISEASE, TYPE II","GD II;; GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE",,Gaucher disease type 2,"By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.",GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Glucocerebrosidase+ gadolinium-diethylenetriamine penta-acetic acid,The treatment was done via convection-enhanced delivery,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,ECO:0007121/ ECO:0000352,"ECO:0007121,ECO:0000352",,,Direct interaction ( Mechanistic A) ERT,A,No result is  added,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809",
1029,230900,,Number Sign,230900,"GAUCHER DISEASE, TYPE II","GD II;; GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE",,Gaucher disease type 2,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,,done,,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,
1030,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Miglustat (Substrate reduction therapy)+imiglucerase,,DB00419+DB00053,DB00419 + DB00053,51bdf6bb3ec01460f1435d4730dae65a179de75a0147a4ffa717a8e1214c126a,,,,,"DB00419,DB00053","DB00419,DB00053",,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B)+Direct interaction (Mechanistic A),B,neuropathy,HP:0009830,,"https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1",
1031,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,generalized tonic-clonic seizures,HP:0002069,,,
1032,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,speech impairment,HP:0002167,,,
1033,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,Eliglustat(Substrate reduction therapy),,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,ECO:0007121,ECO:0007121,CYP2D6,,Functional interaction(Mechanistic B),B,abnormal glucocerebroside level,HP:0003656,,"https://www.ncbi.nlm.nih.gov/pubmed/29680197,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012",
1034,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,Hepatosplenomegaly,HP:0001433,,https://www.ncbi.nlm.nih.gov/pubmed/28935503,
1035,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
1036,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,low mean hemoglobin concentration,HP:0025547,,,
1037,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,velaglucerase alfa,,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Decreased hemoglobin,HP:0001903,,"https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all",
1038,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,,
1039,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,High spleen volume,HP:0001744,,,
1040,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,,,,,,,,,,,,,,,,,,,,high liver volume,HP:0002240,,,
1041,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,pyridoxine,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Cystathioninuria,HP:0003153,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897",
1042,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,,,,,,,,,,,,,,,,,,,,Tremor,HP:0001337,,,
1043,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,,,,,,,,,,,,,,,,,,,,Impaired fine motor skillls,HP:0007010,,,
1044,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,,,,,,,,,,,,,,,,,,,,EEG abnormality,HP:0002353,,,
1045,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,,,,,,,,,,,,,,,,,,,,High total homocysteine level,HP:0010919,,,
1046,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,flumazenil,,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,Symptomatic (C),C,unalertness,HP:0002329,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352",
1047,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,EEG abnormality,HP:0002353,,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,
1048,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,Functional motor deficit,HP:0004302,,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,
1049,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,excessive adventitious movements,HP:0100022*,,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,
1050,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,hypersomnolence,HP:0100786,,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,
1051,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,Oculomotor apraxia,HP:0000657,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,
1052,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,Developmental delay,HP:0012758,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,
1053,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,Phenobarbital/clonazepam/valproate/ midazolam,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",DB01174/DB01068/DB00313/DB00683,DB01174 / DB01068 / DB00313 / DB00683,5b3829335f50b39cc21a56f9e991ece77fabacec528a40c389b5e209b02047ff,"DB01174,DB01068,DB00313,DB00683","DB01174,DB01068,DB00313,DB00683",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,
1054,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,rapamycin,,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,ECO:0007764/ECO:0005542,"ECO:0007764,ECO:0005542",,,Symptomatic (C),C,elevated CSF GHB levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/",
1055,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,,,,,,,,,,,,,,,,,,,,oxidative stress,HP:0025464,,,
1056,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,rAAV-PPCR,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,edematous,HP:0000969,,"https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/",
1057,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,,,,,,,,,,,,,,,,,,,,infertility,HP:0000789,,,
1058,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,,,,,,,,,,,,,,,,,,,,incoordination,HP:0002311,,,
1059,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,,,,,,,,,,,,,,,,,,,,gait abnormality,HP:0001288,,,
1060,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,,,,,,,,,,,,,,,,,,,,,,,,
1061,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,N-octyl-4-epi-Î²-valienamine (NOEV),,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all,,Functional interaction(Mechanistic B),B,"Low Î²-gal activity (Abnormal enzyme,coenzyme activity )*",,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,
1062,230200,230200,Number Sign,230200,GALACTOKINASE DEFICIENCY,GALK DEFICIENCY;; GALACTOSEMIA II,,Galactokinase deficiency,,GALK1,GALK1,galactokinase 1,edfaddb12a00796b20a59ed295aa2a16983295c3bcbc0e298f1254835fabf836,2.7.1.6,2.7.1.6,,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,
1063,606812,,Number Sign,606812,FUMARASE DEFICIENCY; FMRD,FUMARIC ACIDURIA,,Fumarase deficiency,"The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812",FH,FH,"Fumarate hydratase, mitochondrial",40f9a301bd7696f1ff675b402e57eaf49d1189c6251954af0e2caa42c3b1a02d,4.2.1.2,4.2.1.2,,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,
1064,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,antisense oligonucleotide (VMO AED cocktail),,NA,,,,,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,Direct interaction ( Mechanistic A),A,Abnormal fukutin mRNA expression,HP:0030098,,"https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908,https://www.ncbi.nlm.nih.gov/pubmed/26259553",
1065,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,,,,,,,,,,,,,,,,,,,,pathogenic exon trapping,NA,,,
1066,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,AAV9-MCK-fukutin,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,Imapired muscle function,HP:0011804,,https://academic.oup.com/hmg/article/22/15/3003/652530,
1067,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,Corticosteroid,,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Muscle weakness,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/21726969,
1068,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,,,,,,,,,,,,,,,,,,,,Muscle necrosis,HP:0003713,,,
1069,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,,,,,,,,,,,,,,,,,,,,Muscle inflammation,HP:0100614,,,
1070,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,recombinant canine Î±-l-fucosidase enzyme,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,High level of fucosyl-linked oligosaccharide accumulation,HP:0100614,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",
1071,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Neuronal vacuolation,NA,,,
1072,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,PyramidalÂ neuronÂ loss,HP:0002062*,,,
1073,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Astrocytosis,MP:0003354,,,
1074,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Microgliosis,HP:0100708,,,
1075,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Purkinji cells apoptosis,MP:0000880,,,
1076,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,OligodendrocyteÂ loss,HP:0100709,,,
1077,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Hypomyelination,MP:0013438,,,
1078,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,LysosomalÂ expansion inÂ neuronsÂ of deep cortex,HP:0004356*,,,
1079,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,AstrocytosisÂ inÂ cerebral cortex,HP:0002446,,,
1080,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression,NA,,,
1081,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,,,,,,,,,,,,,,,,,,,,Abnormal neurololgical function,HP:0000707,,,
1082,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,Tocilizumab,,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Arthritis,HP:0001369,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/,
1083,229700,,Number Sign,229700,"FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D",,,"Fructose-1,6-bisphosphatase deficiency","The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9",FBP1,FBP1,"Fructose-1,6-bisphosphatase 1",2af4dad1db9b1bf79da3b3893477a1067bd2b4cef5a98f748bcfc46cf56ebe08,3.1.3.11,3.1.3.11,,Glucose,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/29203193,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus",
1084,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146",LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,statin,,DB00175,DB00175,d31fa496b3e1f971be70434217e8047ef375f89af3b12e73b64c8cefb3ad1aa9,DB00175,DB00175,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),B,decreased cholesterol absorption,MP:0002647,,https://www.ncbi.nlm.nih.gov/pubmed/24636183,
1085,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),The drug was accomapined with fat-restricted diet,C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,ECO:0000352,ECO:0000352,,,,,Abnormal lipoprotein profile,HP:0010979,,https://www.ncbi.nlm.nih.gov/pubmed/23522979,
1086,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Abnormal renal function,HP:0012211,,https://www.ncbi.nlm.nih.gov/pubmed/23522979,
1087,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Proteinuria,HP:0000093,,https://www.ncbi.nlm.nih.gov/pubmed/23522979,
1088,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Low serum HDL-cholesterol,HP:0003233,,https://www.ncbi.nlm.nih.gov/pubmed/23522979,
1089,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,r LCAT,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,,,Abnormal lipoprotein profile,HP:0010979,,https://www.ncbi.nlm.nih.gov/pubmed/20605907,
1090,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Low HDL-C  level,HP:0003233,,https://www.ncbi.nlm.nih.gov/pubmed/20605907,
1091,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,baclofen/tizanidine/trihexyphenidyl/benzodiazepine/dantrolene,,DB00182/DB00697/DB00376/DB12537/DB01219,DB00182 / DB00697 / DB00376 / DB12537 / DB01219,08c214003c71e6f8119bea13050b14b59459aea91999a3b551e7a598fca187cf,"DB00182,DB00697,DB00376,DB12537,DB01219","DB00182,DB00697,DB00376,DB12537,DB01219",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/21735565,
1092,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,spasticity,HP:0001257,,https://www.ncbi.nlm.nih.gov/pubmed/21735565,
1093,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,botulinum toxin,,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,abnormal muscular co-contraction,HP:0001257,,https://www.ncbi.nlm.nih.gov/pubmed/21735565,
1094,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,Nimodipine,,DB00393,DB00393,d0e57aca42d512727b33735654750b60e83b57417c7edc03c44bdd35e5855e0d,DB00393,DB00393,,,,,,,ECO:0000305/ECO:0001565,"ECO:0000305,ECO:0001565",,,Direct interaction ( Mechanistic A),,Abnormality of circulating enzyme level,HP:0011021,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,
1095,616896,,Number Sign,616896,MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14,,,Fatal infantile encephalomyopathy,,OPA1,OPA1,mitochondrial dynamin like GTPase,8c185cea397cefe05a1e4fb116497d5b9d180d3ef5e3e1ec51170fac5455fd63,2.3.1.43,2.3.1.43,,No treatment is available in DDIEM,,DB00393,DB00393,d0e57aca42d512727b33735654750b60e83b57417c7edc03c44bdd35e5855e0d,DB00393,DB00393,,,,,,,,,,,,,,HP:0011021,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,
1096,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,,NA,,,,,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,Direct interaction ( Mechanistic A) ERT,A,Delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1097,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,High cermaide level,MP:0020582,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",
1098,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,High intracellular cermaid level,MP:0020582*,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1099,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,Abnormal spleen size,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1100,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,abnormal sphingosine level(Abnormality of lipid metabolism)*,MP:0009587,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1101,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,high plasma MCP-1,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1102,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,High macrophage infiltration into tissues(Abnormal inflammatory response)*,HP:0012647*,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1103,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1104,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,Joint inflammation,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1105,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,Amitriptyline,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.",,,,,,,,,,,,ECO:0000305/ECO:0005542,"ECO:0000305,ECO:0005542",,,,,Abnormal pulmonary ceramide level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18376404,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",
1106,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,,,,,,,,,,,,,,,,,,,,,,,,
1107,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncooked Cornstarch,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,https://www.ncbi.nlm.nih.gov/pubmed/7564233/",
1108,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Vitamin D,,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Short stature,HP:0004322,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,
1109,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,phosphorus,,DB14151,DB14151,be7969895fb0f5c6847d1e95ee9308f3a095a9e9395150489e03df8ba80a2af0,DB14151,DB14151,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Rickets,HP:0002748,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,
1110,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,bicarbonate,,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Renal tubular acidosis,HP:0001947,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,
1111,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Insulin,,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Diabetes mellitus,HP:0000819,,"http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/23456528",
1112,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,ISIS 703802 (AKCEA-ANGPTL3-LRx),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic(C),C,high fasting triglycerides,HP:0002155*,,"https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/23456528",
1113,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Metreleptin(A-100),,DB09046,DB09046,1a517f379389e13ad177a97ed71c30d24e12c060e8c593686602eb3ca271ad94,DB09046,DB09046,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,Symptomatic(C),C,abnormal free fatty acid levels,HP:0040300,,"https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25734254",
1114,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,high facial soft tissue volume,HP:0000287,,https://www.ncbi.nlm.nih.gov/pubmed/28993984,
1115,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,abnormal fasting glucose,MP:0013277,,"https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826",
1116,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,high  HbA1c levels,HP:0040217,,,
1117,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Albiglutide (glucagon-like peptide-1 receptor agonist),,DB09043,DB09043,a9bfbb9ad22610a5e7b86d90e9c133de63a8f5e248549d5ac376ad129988f4f3,DB09043,DB09043,,,,,,,,,,,Symptomatic (C),C,abnormal fasting glucose,MP:0013277,,,
1118,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,high  HbA1c levels,HP:0040217,,,
1119,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,volanesorsen (IONIS-APOCIIIRx),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Abnormal fasting triglycerides,HP:0002155*,,"https://clinicaltrials.gov/ct2/show/NCT02300233,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2",
1120,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Obeticholic Acid,,DB05990,DB05990,5ae68e2f089e8813114eb6689c739e28ef7eed31279def478f19c58e028193ca,DB05990,DB05990,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Hepatic steatosis,HP:0001397,,https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,
1121,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,High liver triglyceride level(hyperlipidemia)*,HP:0003077*,,,
1122,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Gemcabene,,DB05123,DB05123,2b9e9729f24d96e3ec7a2062f7c7c0659acdf5f035650f7750c31728a7fba63c,DB05123,DB05123,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Hypertriglyceridemia,HP:0002155,,https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,
1123,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,Hepatic steatosis,HP:0001397,,,
1124,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,fibrates + omega-3 fatty acids (OMG-3),Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,DB00636Â +DB11133,DB00636 + DB11133,c0d3e606bb58b12e43fe893c6646630d0a3cb9bfc9f8aa62e381b4398681311a,,,,,"DB00636,DB11133","DB00636,DB11133",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglyceridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/27710244,
1125,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,,,,,,,,,,,,,,,,,,,,,,,,
1126,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,recombinant humanÂ LCAT (ACP-501),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,anemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1",
1127,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Abnormal lecithin:cholesterol acyltransferase activity,MP:0011598,,,
1128,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,abnormal plasma lipids levels,HP:0003119,,,
1129,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,low HDL level,HP:0003233,,,
1130,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,low HDL-C level,HP:0003233,,,
1131,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Abnormal cholesterol efflux from cells,MP:0003193,,,
1132,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,dyslipidemia,MP:0003949,,,
1133,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,low APO A level,HP:0025201*,,,
1134,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,Low Apo B protein level,HP:0025201*,,,
1135,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,,,,,,,,,,,,,,,,,,,,proteinuria,HP:0000093,,,
1136,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Captopril,,DB01197,DB01197,3c8d1cdfa5d7eae0a7ed8072dc18cfc49bf2a7f83409f9c71cb7742bd0ea81be,DB01197,DB01197,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertension,HP:0000822,,https://www.ncbi.nlm.nih.gov/pubmed/23391322,
1137,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Thiazide,,DB01324,DB01324,220a0c5acbf784f3ffab6250232a8f228a59e8fdd431a6ae0acc2e73ec19d03b,DB01324,DB01324,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Oedema,HP:0000969,,,
1138,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Probenecid,,DB01032,DB01032,2eaf2c7a70dc6dbae04804ddaf804322045de4d452b206ddf563c955877393ec,DB01032,DB01032,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pubmed/8842764",
1139,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Probenecid+Allopurinol,,DB01032+DB00437,DB01032 + DB00437,086a1fa338dfeb1b1a0fa473ad50163f4b54bc57b80a2dcfab09c598787d3367,,,,,"DB01032,DB00437","DB01032,DB00437",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Hyperurecemia,HP:0002149,,https://www.ncbi.nlm.nih.gov/pubmed/8842764,
1140,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Allopurinol,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651",
1141,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,,,,,,,,,,,,,,,,,,,,Mortality,HP:0040006,,https://www.ncbi.nlm.nih.gov/pubmed/12205338,
1142,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,,,,,,,,,,,,,,,,,,,,Disaess progression(Progressive)*,HP:0003676,,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,
1143,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Allopurinal+Benzbromarone,,DB00437+DB12319,DB00437 + DB12319,2fc403f863cf86f34c01c21c9be2941ebdab5a370b373b3c229d513dd188b060,,,,,"DB00437,DB12319","DB00437,DB12319",,,ECO:0000352,ECO:0000352,,,,,Hyperurecemia,HP:0002149,,https://www.ncbi.nlm.nih.gov/pubmed/9678437,
1144,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,"In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511",CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,Cinacalcet,,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,,,Hypercalcemia,HP:0003072,,"https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/16882283/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",
1145,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,,,,,,,,,,,,,,,,,,,,Elevated circulating parathyroid hormone level,HP:0003165,,"https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/",
1146,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,,,,,,,,,,,,,,,,,,,,Impaired renal uric acid clearance,HP:0004732,,https://www.ncbi.nlm.nih.gov/pubmed/28459040,
1147,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,,,,,,,,,,,,,,,,,,,,Polydipsia,HP:0001959,,https://www.ncbi.nlm.nih.gov/pubmed/28459040,
1148,145981,,Number Sign,145981,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2","FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II",,Familial hypocalciuric hypercalcemia type 2,,GNA11,GNA11,guanine nucleotide-binding proteinÂ (GÎ±11),46e2c268ba2563c9de64deab1ac7ef8ac2557ec540ff356ac866fa5bb398db23,P21278,,P21278,Cinacalcet,,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,high serum ionized calcium concentrations,HP:0003072*,,"https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/28833550",
1149,145981,,Number Sign,145981,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2","FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II",,Familial hypocalciuric hypercalcemia type 2,,GNA11,GNA11,guanine nucleotide-binding proteinÂ (GÎ±11),46e2c268ba2563c9de64deab1ac7ef8ac2557ec540ff356ac866fa5bb398db23,P21278,,P21278,,,,,,,,,,,,,,,,,,,,abnormal parathyroid hormone level,HP:0003165,,,
1150,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,Cinacalcet,,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,high serum ionized calcium concentrations,HP:0003072*,,"https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://academic.oup.com/jcem/article/100/7/2515/2829587",
1151,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,,,,,,,,,,,,,,,,,,,,abnormal parathyroid hormone level,HP:0003165,,,
1152,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,,,,,,,,,,,,,,,,,,,,low calcium urine excretion,HP:0003127,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,
1153,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,Gemfibrozil,,,,,,,,,,,,,,,,,,,,HP:0003127,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,
1154,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,,,,,
1155,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,fenofibrate,,,,,,,,,,,,,,,,,,,,,,,
1156,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,,,,,
1157,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,Niacin,,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction (Mechanistic A),A,hypoalphalipoproteinemia,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10",
1158,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,Gemfibrozil,,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),A,Low HDL cholesterol concentration,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10",
1159,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,fenofibrate,,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,,,,,Direct interaction ( Mechanistic A),A,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10",
1160,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,Atorvastatin,,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,Direct interaction ( Mechanistic A),A,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3",
1161,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"CER 001, a recombinant high-density lipoprotein (HDL)",,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,low  plasma cholesterol,HP:0003146,,"https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8",
1162,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiency,,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,low unesterified cholesterol,HP:0003107*,,,
1163,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,Fabrazyme ( agalsidase beta),,DB00103,DB00103,79dd432a3b190cdfcbbf5d9cd7daaf60890ec1bbd24bd6ab89acaf5926de95d4,DB00103,DB00103,,,,,,,,,,,Direct interaction (Mechanistic A),A,Abnormal kidney function,HP:0012211,,"https://fabrydiseasenews.com/prx-102-pegunigalsidase-alfa/,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03180840?cond=fabry+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",
1164,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,REPLAGAL (Agalsidase Alfa),,DB00103,DB00103,79dd432a3b190cdfcbbf5d9cd7daaf60890ec1bbd24bd6ab89acaf5926de95d4,DB00103,DB00103,,,,,,,,,,,Direct interaction (Mechanistic A),A,cardiomegaly,HP:0001640,,"https://fabrydiseasenews.com/prx-102-pegunigalsidase-alfa/,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03180840?cond=fabry+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",
1165,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,low renal glomerular filtration rate,HP:0012213,,,
1166,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,pain,HP:0012531,,,
1167,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,pegunigalsidase alfa ( PRX-102),,NA,,,,,,,,,,,,,,,Direct interaction (Mechanistic A),A,,done,,,
1168,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,migalastat hydrochloride (AT1001),,DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,,,,,Direct interaction (Mechanistic A),A,,done,,,
1169,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,Carbamazepine,,DB00564,DB00564,d7432f727b8e4d8a7e02cf9e041ae6a05684d37d649a8d66c2081dea81a7aebc,DB00564,DB00564,,,,,,,,,,,Symptomatic (C),C,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/books/NBK6803/,
1170,249900,,Number Sign,249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATOR DEFICIENCY;; SAPOSIN B DEFICIENCY,,Encephalopathy due to prosaposin deficiency,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,7.6.2.1,7.6.2.1,,NA,,DB00564,DB00564,d7432f727b8e4d8a7e02cf9e041ae6a05684d37d649a8d66c2081dea81a7aebc,DB00564,DB00564,,,,,,,,,,,,,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/8370580,https://www.omim.org/entry/611721",
1171,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,vitamin D,,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,,,,,Symptomatic (C),C,concommitant low vit D level,HP:0100512*,,"https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=24137761&dopt=abstractplus,https://www.omim.org/entry/611721",
1172,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Afamelanotide (Scenesse),,DB04931,DB04931,5f32666b0e51dace64dd70db686cc214256e5ad5ed3a5b06fb93bab008250600,DB04931,DB04931,,,,,,,,,,,Symptomatic (C),C,Erythema,HP:0010783,,"https://www.karger.com/Article/Abstract/362174,https://www.omim.org/entry/611721",
1173,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Cutaneous photosensitivity,HP:0000992,,,
1174,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,corticosteroids,,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,,,,,Symptomatic (C),C,Pain,HP:0012531,,https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2444,
1175,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Pruritus,HP:0000989,,,
1176,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,zinc,,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,Symptomatic (C),C,Increased ROS formation,HP:0025464,,"http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract,https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0846.2011.00586.x",
1177,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Î²-carotene,,DB06755,DB06755,1655cf3e02a610000fa34728036de9e5ddeb4c6c0b23919f6affc0b796640c6b,DB06755,DB06755,,,,,,,,,,,Symptomatic (C),C,intolerance to sunlight,HP:0000992,,"http://www.bloodjournal.org/content/120/23/4496.long?sso-checked=true,https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0846.2011.00586.x",
1178,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Pain in the skin,HP:0025280*,,,
1179,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Cholestyramine,,DB01432,DB01432,99cdf2f21fcc72a3fb2865acd9480a160747f28c850655d0d48dcf1c14efa723,DB01432,DB01432,,,,,,,,,,,Symptomatic (C),C,Abnormal  protoporphyrin enterhepatic circulation,HP:0012187,,,
1180,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,activated charcoal,,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,Symptomatic (C),C,Hepatic involvement,HP:0001410,,,
1181,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,hemin,,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,Functional interaction (B),B,Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*,HP:0010472*,,,
1182,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,cysteine hydrochloride,,DB00151,DB00151,f4a3b70861186a8191ed47b3b2c65115e5f04d82475df026af1be8f7d9fb8159,DB00151,DB00151,,,,,,,,,,,Symptomatic (C),C,photosensitivity,HP:0000992,,https://clinicaltrials.gov/ct2/show/NCT00004831,
1183,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Isoniazid,,DB00951,DB00951,5135c377c53c781a3543872d45c849ab29cb39030e601326261c04d9b75871cc,DB00951,DB00951,,,,,,,,,,,Symptomatic (C),C,,done,,https://clinicaltrials.gov/ct2/show/NCT01550705,
1184,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Iron,,DB01592,DB01592,f3a10486a1ac3d6f8a96ed9a44748e3af2046be5171b04b2a9825d9e53243dc3,DB01592,DB01592,,,,,,,,,,,Symptomatic (C),C,high erythrocyte protoporphyrin levels,HP:0012187,,https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10,
1185,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic uroporphyria associated with myeloid malignancy,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,NA,,DB01592,DB01592,f3a10486a1ac3d6f8a96ed9a44748e3af2046be5171b04b2a9825d9e53243dc3,DB01592,DB01592,,,,,,,,,,,,,,done,,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,
1186,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Acetylcysteine,,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,Functional interaction (Mechanistic B),B,high Lactic acid,HP:0003648,,"https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub",
1187,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,neomycin,,DB00994,DB00994,84ba0ddc899e90ea80b3558b68d013230a5208a08a6b28292b40d20c7fafce12,DB00994,DB00994,,,,,,,,,,,Functional interaction (Mechanistic B),B,abnormal thiosulfates level,HP:0011943,,"https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub",
1188,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Metronidazole,,DB00916,DB00916,79846491de3f471f18c6f5a94dca029d0821623cf02f5eb17b5047963fd340aa,DB00916,DB00916,,,,,,,,,,,Functional interaction (Mechanistic B),B,Hypotonia,MP:0004144,,"https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub",
1189,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,diarrhea,HP:0002014,,,
1190,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,high EMA levels,HP:0003219,,,
1191,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Ascorbic acid,,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,,,,,Supportive (C),C,Decreased activity of cytochrome C oxidase in muscle tissue,HP:0003688,,,
1192,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Supportive (C),C,,done,,,
1193,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,rifampicin,,DB01045,DB01045,490f0717aaac2f1972b8c1719e961d1bdb7c60fffc8ef5d3e7003545a1039e87,DB01045,DB01045,,,,,,,,,,,Symptomatic (C),C,pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533671/,https://emedicine.medscape.com/article/173517-treatment",
1194,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,hyperbilirunbinemia,HP:0002904,,,
1195,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,elevated serum concentrations of bile acids,HP:0012202,,,
1196,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,UDCA,,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,,,,,Symptomatic (C),C,high serum alkaline phosphatase,HP:0003155,,,
1197,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,hyperbilirunbinemia,HP:0002904,,,
1198,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,elevated serum concentrations of bile acids,HP:0012202,,,
1199,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,High biliary cholesterol saturation index,NA,,,
1200,608799,,Number Sign,608799,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E",CDG Ie; CDGIe,,DPM1-CDG (CDG-Ie),,DPM1,DPM1,dolichol-P-mannose synthase 1,b773b155ddcb516cf5362a5d343e120d248839d5cd0c5840d35c986824cf0202,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,,done,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,
1201,615042,,Number Sign,615042,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U",CDG Iu; CDGIu,,DPM2-CDG,,DPM2,DPM2,dolichyl-phosphate mannosyltransferase subunit 2,4983bad482a07e1405069670c34280fef81663c6d4fef19ac3b60a2f38970216,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,,done,,,
1202,612937,,Number Sign,612937,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DPM3-RELATED;; CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O;; CDG Io; CDGIo;; CDG1(DPM3)",,DPM3-CDG (CDG-Io),,DPM3,DPM3,dolichyl-phosphate mannosyltransferase subunit 3,a3ad9b9f9a686daf48b067c277d740720c63b7647531cd4359702b364d210ca0,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,,done,,,
1203,179850,,Number Sign,179850,DOWLING-DEGOS DISEASE 1; DDD1,DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES,,Dowling-Degos disease,,KRT5/POGLUT1,"KRT5,POGLUT1",keratin 5/protein O-glucosyltransferase,136e1b3e218315d92ce0e4910f8ec541cf01021bc68ea21440812274d36a1491,7.6.2.1,7.6.2.1,,hydroquinone,,DB09526,DB09526,38c541b8e70bbbf34db26e7ddc20aa7c904ad684846cc2f57b852e9cd0788f26,DB09526,DB09526,,,,,,,,,,,Symptomatic (C),C,,done,,"https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1204,179850,,Number Sign,179850,DOWLING-DEGOS DISEASE 1; DDD1,DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES,,Dowling-Degos disease,,KRT5/POGLUT1,"KRT5,POGLUT1",keratin 5/protein O-glucosyltransferase,136e1b3e218315d92ce0e4910f8ec541cf01021bc68ea21440812274d36a1491,7.6.2.1,7.6.2.1,,retinoids,,DB02699,DB02699,961358b93f85b62e2ca432a15e13ec38a7b5d03a96853d26672a0d58f0d70d8a,DB02699,DB02699,,,,,,,,,,,Symptomatic (C),C,,done,,"https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1205,179850,,Number Sign,179850,DOWLING-DEGOS DISEASE 1; DDD1,DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES,,Dowling-Degos disease,,KRT5/POGLUT1,"KRT5,POGLUT1",keratin 5/protein O-glucosyltransferase,136e1b3e218315d92ce0e4910f8ec541cf01021bc68ea21440812274d36a1491,7.6.2.1,7.6.2.1,,steroids,,DB14657,DB14657,18f7c2550f5280d0d752b5b77d57a2ba6f0ca71e89be2798258c5787e4505a14,DB14657,DB14657,,,,,,,,,,,Symptomatic (C),C,,done,,"https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1206,179850,,Number Sign,179850,DOWLING-DEGOS DISEASE 1; DDD1,DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES,,Dowling-Degos disease,,KRT5/POGLUT1,"KRT5,POGLUT1",keratin 5/protein O-glucosyltransferase,136e1b3e218315d92ce0e4910f8ec541cf01021bc68ea21440812274d36a1491,7.6.2.1,7.6.2.1,,"tretinoin,",,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,,,,,Symptomatic (C),C,,done,,"https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1207,223360,,Number Sign,223360,ORTHOSTATIC HYPOTENSION 1; ORTHYP1,"DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL;; NOREPINEPHRINE DEFICIENCY;; NORADRENALINE DEFICIENCY",,Dopamine beta hydroxylase deficiency,,DBH,DBH,dopamine beta (Î²)-hydroxylase,c0d0848916a51126275a1226a107d62354d0cefe727b99c917dba88b8ae748d7,7.6.2.1,7.6.2.1,,droxidopa,,DB06262,DB06262,56df5a8da214638477d2d0a34f74a5a116d1462023085f75a22129bc0bf0e135,DB06262,DB06262,,,,,,,,,,,Functional interaction (Mechanistic B),B,orthostatic hypotension,HP:0001278,,"https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1208,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,levedopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,Functional interaction (Mechanistic B),B,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1209,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,carbidopa,,DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,,,,,Functional interaction (Mechanistic B),B,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1210,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,selegiline+L-dopa,,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,Functional interaction (Mechanistic B),B,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.sciencedirect.com/science/article/pii/S0887899410000287?via%3Dihub,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/",
1211,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,lack of eye contact,HP:0000817,,,
1212,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Delayed motor skills,HP:0002194,,,
1213,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Lack of head suuport,,,,
1214,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Delayed mental development,HP:0001263,,,
1215,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,lack of gross motor function,HP:0002194,,,
1216,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,5âhydroxytryptophan,,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,,,,,Functional interaction (Mechanistic B),B,Depression,HP:0000716,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117403/,
1217,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,,,,,,,,,,,,,,,,,,,,Serotonin deficiency,HP:0003117*,,,
1218,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,D-galactose,,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,Functional interaction (Mechanistic B),B,"""abnormal alanine transaminase,""",HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675745/",
1219,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,abnormal aspartate transaminase,HP:0002910,,,
1220,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,abnormal activated partial thromboplastin time,HP:0003645,,,
1221,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,abnormal Antithrombin-III levels,HP:0001976,,,
1222,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,,,,,,,,,,,,,,,,,,,,abnormal nucleotide sugars,,,,
1223,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,Fucose,,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,Functional interaction (Mechanistic B),B,defected phagocytic function,HP:0010977,,,
1224,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,low neutrophil count,HP:0001875,,,
1225,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,recurrent infection,HP:0002719,,,
1226,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,abnormal expression of E- and P-selectin ligands,NA,,,
1227,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,atypical psychomotor development,HP:0001263*,,,
1228,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,Q96A29,,Q96A29,vigabatrin,,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,Symptomatic (C),C,seizures,HP:0001250,,"https://www.sciencedirect.com/science/article/pii/S1096719213002278?via%3Dihub,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/",
1229,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,Q96A29,,Q96A29,clonazepam,,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,,,,,Symptomatic (C),C,,done,,"https://www.sciencedirect.com/science/article/pii/S1096719213002278?via%3Dihub,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/",
1230,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,Dipsogenic diabetes insipidus,,???,???,??,e270aeb347f2165574c3a5c5bf11d038bcd3acd5abfdb5ae8a1b52d91cb842f0,Q96A29,,Q96A29,desmopressin,,DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,,,,,Symptomatic (C),C,polyuria,HP:0000103,,"https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/",
1231,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,Dipsogenic diabetes insipidus,,???,???,??,e270aeb347f2165574c3a5c5bf11d038bcd3acd5abfdb5ae8a1b52d91cb842f0,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,affected functional activity,HP:0025142*,,,
1232,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,Q96A29,,Q96A29,uridine triacetate,,DB09144,DB09144,440fb1c050f1ba7bf4971a696a78852d6ee6bd1c41a83aae02605bb37880978d,DB09144,DB09144,,,,,,,,,,,Functional interaction(Mechanistic B),B,,done,,https://www.sciencedirect.com/science/article/pii/S0041008X18302709?via%3Dihub,
1233,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,developmental delay,HP:0001263,,"https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14",
1234,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,BH4,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,Functional interaction (Mechanistic B),B,developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1235,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,Functional interaction (Mechanistic B),B,receptive language abnormality,HP:0010863*,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1236,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,L-dopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,Functional interaction (Mechanistic B),B,unalertencess,HP:0002329*,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1237,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,carbidopa,,DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,,,,,Functional interaction (Mechanistic B),B,unresponsiveness,HP:0004372,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1238,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,5-hydroxytryptophan,,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,,,,,Functional interaction (Mechanistic B),B,abnormal blood Phe levels,HP:0010893,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1239,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,entacapone,,DB00494,DB00494,11625d24c6472a531c4bbbdb6bea193ee8357d1cdf9a2b375d44382faf825226,DB00494,DB00494,,,,,,,,,,,Supportive (C),C,high plasma phenylalanine level,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1240,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,selegiline,,DB01037,DB01037,644e539a884ff99a911c1461dfac19cb760ef8d267eb5e251485358b02f6d6df,DB01037,DB01037,,,,,,,,,,,Supportive (C),C,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292",
1241,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,pramipexole,,DB00413,DB00413,290d325ba989b4fff91dd03ea4802da44c13419e775c00006b58d6a058ac79d4,DB00413,DB00413,,,,,,,,,,,Supportive (C),C,dopamine deficiency,HP:0012656,,"https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.sciencedirect.com/science/article/pii/S1096719212000170?via%3Dihub,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub",
1242,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,movement disability,HP:0100022,,,
1243,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,behavioral disability,HP:0000708,,,
1244,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,hyperprolactinemia,HP:0000870,,,
1245,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,Q96A29,,Q96A29,rotigotine,,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,Functional interaction (B),B,parkinsonian symptoms,HP:0001300,,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub,
1246,222748,,Number Sign,222748,DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD,DIHYDROPYRIMIDINURIA;; DPYS DEFICIENCY;; DPH DEFICIENCY,,Dihydropyrimidinase deficiency,,DPYS,DPYS,dihydropyrimidinase,37bc07b207a99262f09e5fa9bea99ca067b39876b3e11db1433a4471b1c9b598,Q96A29,,Q96A29,NA,,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,,,,done,,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub,
1247,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,Riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,Direct interaction ( Mechanistic A),A,exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub",
1248,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,biotin,,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,,,,,Supportive (C),C,mitochondrial proliferation in the muscle.,HP:0003200,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub",
1249,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,coenzyme Q,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,Supportive (C),C,myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub",
1250,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,carnitine,,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,,,,,Supportive (C),C,high lactic acid level,HP:0003648,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub",
1251,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,Thiamine,,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,,,,,Supportive (C),C,recurrent vomiting,HP:0002572,,"https://www.ncbi.nlm.nih.gov/books/NBK220444/,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub",
1252,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,sodium dichloroacetate,,DB08809,DB08809,71802b7b681b44ab3ed9d0b44efa6ba19246ead16dace1ff0c9770fb7d25a678,DB08809,DB08809,,,,,,,,,,,Supportive (C),C,muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/books/NBK220444/",
1253,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,Encephalopathy,HP:0001298,,,
1254,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,Lipoic acid,,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,,,,,Symptomatic (C),C,lactic acidemia,HP:0003128*,,,
1255,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,pyruvic acidemia,HP:0001941,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,
1256,222730,,Number Sign,222730,DICARBOXYLIC AMINOACIDURIA; DCBXA,GLUTAMATE-ASPARTATE TRANSPORT DEFECT,,Dicarboxylic aminoaciduria,,SLC1A1,SLC1A1,solute carrier family 1 member 1,84d57e1c0f0cecf4ec54bc126d608776fd8469d17f142672531096b9e36f0c9f,Q96A29,,Q96A29,NA,,,,,,,,,,,,,,,,,,,,done,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,
1257,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,levetiracetam,,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,Symptomatic (C),C,Epileptic seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/",
1258,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,olanzapine,,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,,,,,Symptomatic (C),C,psychosis,HP:0000709,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/",
1259,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,haloperidol,,DB00502,DB00502,c03f213a9af50389d04c2a012b86e721621460df242555065daf1851fcde6e97,DB00502,DB00502,,,,,,,,,,,Symptomatic (C),C,hallucinatory-paranoid state,HP:0011999*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/",
1260,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,levomepromazine,,DB01403,DB01403,490348cfd42c08fef4ec8c82b8a8568ea65b05dee235096a4b8d99cbf392afd3,DB01403,DB01403,,,,,,,,,,,Symptomatic (C),C,auditory hallucinations,HP:0008765,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/",
1261,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,elicited hyperactivity,HP:0000752,,,
1262,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,perampanel,,DB08883,DB08883,fe228167ceb5a8d853ece56c0579ab7adf47ab79df2efc63d820119756651f6b,DB08883,DB08883,,,,,,,,,,,Symptomatic (C),C,Diminished intellectual abilities,HP:0001249,,,
1263,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,myoclonic seizures,HP:0002123,,,
1264,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,Q96A29,,Q96A29,,,,,,,,,,,,,,,,,,,,inability to walk,HP:0002540,,,
1265,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,Q96A29,,Q96A29,riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,Functional interaction(Mechanistic B),B,High desmosterol levelsÂ (Abnormality of cholesterol metabolism)*,HP:0003107*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,
1266,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,Q96A29,,Q96A29,nicotinamide,,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,,,,,Functional interaction(Mechanistic B),B,"High desmosterol,cholesterol ratio (Abnormality of cholesterol metabolism)*",HP:0003107*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,
1267,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,Q96A29,,Q96A29,thiamine,,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,,,,,Functional interaction(Mechanistic B),B,,done,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,
1268,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,Q96A29,,Q96A29,cholesterol,,DB04540,DB04540,35d8d2e536310c7ee95cf58f43abb43574e00c3fcc4be87e1443448125e7a2e7,DB04540,DB04540,,,,,,,,,,,Functional interaction(Mechanistic B),B,High desmosterol levelsÂ (Abnormality of cholesterol metabolism)*,HP:0003107*,,https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6,
1269,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,L-leucine,,DB00149,DB00149,0ab0e4635f785428b642513a35aa1de824a96f5a9002b3ceec83ccc40aa51fe9,DB00149,DB00149,,,,,,,ECO:0007121/ECO:0005542/ECO:0000352,"ECO:0007121,ECO:0005542,ECO:0000352",,,Functional interaction(Mechanistic B),B,low heamoglobin leval,HP:0001903,,"https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294",
1270,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,Defect in protein synthesis (Abnormality of circulating protein level)*,HP:0010876*,,,
1271,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,Decreased red blood cell production,HP:0012133*,,https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4,
1272,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Antithymocyte globulin+Cyclosporine,,DB00098+DB00091,DB00098 + DB00091,c344136a5c9639c06b73479b19bb5da9553e14e73b250de8a062479209afd68c,,,,,"DB00098,DB00091","DB00098,DB00091",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Pure red bllod cell aplasia,HP:0012410,,https://clinicaltrials.gov/ct2/show/NCT00001749,
1273,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Rituximab,,DB00073,DB00073,b6ad43e0794f0e25752143cc390b9c74dd387c0ab16f94cb2491cb43a2c010a8,DB00073,DB00073,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,low RBC count,HP:0001877,,https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156,
1274,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Daclizumab,,DB00111,DB00111,3a119e9c3f78fcad08e0c4a20a4f2b46d086c4c17746dcf9afed38af04dfa75c,DB00111,DB00111,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,NA,,,https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1,
1275,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,lenalidomide,,DB00480,DB00480,4c9822a75b067e7e9b548521f4c40a7aa62f6b12e480199afc343541eaf4c8f6,DB00480,DB00480,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,,done,,https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9,
1276,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,prednisolone,,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,low hb level,HP:0001903,,"https://link.springer.com/article/10.1007%2Fs12185-016-2044-9,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+features%2C+mutations+and+treatment+of+104+patients+of+Diamond-Blackfan+anemia+in+China%3A+a+single-center+retrospective+study,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632",
1277,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,low quality of ife,HP:0025142*,,,
1278,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,Pathological apoptosis,NA,,,
1279,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,erythroid progenitor depletion,HP:0025034*,,,
1280,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,premature differentiation of erythroid cells,HP:0012130*,,,
1281,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Prednisone +Cyclosporine,,DB00635+DB00091,DB00635 + DB00091,cff51f590b9aab5047fe4ecad59b94f622e16f1ea2615a4a8fd063f05a7c91a2,,,,,"DB00635,DB00091","DB00635,DB00091",,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,low Hb level,HP:0001903,,https://link.springer.com/article/10.1007%2Fs12185-016-2044-9,
1282,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Metoclopramide,,DB01233,DB01233,8f4199ed3e9676670d7de1d9828519772dc66334e1bc8d3e042d2a8244732536,DB01233,DB01233,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),,low Hb level,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655",
1283,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,Reduced hematocrit,HP:0031851,,,
1284,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Metoclopramide+prednisolone,,DB01233+DB00635,DB01233 + DB00635,0996df2ba4f7c62ba3b541137288ab6cc941cc6d98ad430389e16780689c904c,,,,,"DB01233,DB00635","DB01233,DB00635",,,ECO:0000352,ECO:0000352,,,,,low Hb level,HP:0001903,,https://www.ncbi.nlm.nih.gov/pubmed/24744655,
1285,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,Eltrombopag,,DB06210,DB06210,3b49c8d5051311812e28f412a50f7faf6bbdaef12a2d953de7528a2716de4042,DB06210,DB06210,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),,low Hb level,HP:0001903,,"http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587",
1286,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,,
1287,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,vitamin B6,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,high ornithine level,HP:0012026,,"https://www.ncbi.nlm.nih.gov/pubmed/29757052,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911",
1288,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,lysine supplementation,,DB00123,DB00123,ddfbdace28c1f9f81f233925d671c7da70607547088b3a060bd544b81ef7e66d,DB00123,DB00123,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,cystoid macular edema,HP:0011505,,"https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract",
1289,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,,,,,,,,,,,,,,,,,,,,low visual acuity,HP:0007663,,,
1290,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,topical NSAIDs +systemic CAI,,DB00586+DB00311,DB00586 + DB00311,b29ba3c629450dee9b9853db863f2c46f369146adf1469a2847cc23dc0851c9f,,,,,"DB00586,DB00311","DB00586,DB00311",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,cystoid macular edema,HP:0011505,,https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract,
1291,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,Intravitreal bevacizumab,,DB00112,DB00112,d19137cecbc7955778ca2c83c3c0dafe91fa290e6003d7722e34c59412b184e5,DB00112,DB00112,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,choroidal neovascularization,HP:0011506,,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,
1292,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,,,,,,,,,,,,,,,,,,,,decreased visual acuity,HP:0007663,,,
1293,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,,,,,,,,,,,,,,,,,,,,abnormal central vision,HP:0000504,,,
1294,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,Gene therapy *,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,,done,,"https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1",
1295,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,creatine-monohydrate,,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Extrapyramidal movement disorders,HP:0002071,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971",
1296,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,l-ornithine,,DB00129,DB00129,c1d52e31c66fc159a26d79a88cb74151502b862d82633d79fe195678b2837322,DB00129,DB00129,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Epileptic seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/11749046,
1297,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,Slow background activity in the EEG(EEG abnormality)*,HP:0002353*,,,
1298,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*,HP:0002453*,,,
1299,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,sodium benzoate+ornithin +carnitine,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoateÂ did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785",DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,High CSF guanidinoacetate levels,NA,,https://www.ncbi.nlm.nih.gov/pubmed/24071436,
1300,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,High plasma guanidinoacetate levels,NA,,https://www.ncbi.nlm.nih.gov/pubmed/24071436,
1301,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,Creatine+l-ornithine,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),,Epilepsy,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/24268530,
1302,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,low urinary creatine excretion,HP:0012113,,https://www.ncbi.nlm.nih.gov/pubmed/16855203,
1303,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,low brain creatine phosphate,NA,,https://www.ncbi.nlm.nih.gov/pubmed/16855203,
1304,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,low cerebral creatine,HP:0025051,,https://www.ncbi.nlm.nih.gov/pubmed/16855203,
1305,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,High plasma guanidinoacetate levels,NA,,https://www.ncbi.nlm.nih.gov/pubmed/16855203,
1306,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,abnormal coordination of movements,HP:0011443,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency",
1307,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,EC,,,,,,,,,,,,,,,,,,,,behavioralÂ abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203",
1308,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Tetrahydrobiopterin,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,Functional interaction(Mechanistic B),B,high serum phenylalanine,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/9667588,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES,https://www.sciencedirect.com/science/article/pii/S1096719205003057?via%3Dihub",
1309,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,L-dopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/12391354,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",
1310,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,benserazide,,DB12783,DB12783,af40e9d2d42c7675f2e5e0fe71508a5758ad995404ebb5fc6f0e7cad71a0a976,DB12783,DB12783,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,oromandibular dystonia,HP:0012048,,"https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346",
1311,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,5-hydroxytryptophane,,DB04159,DB04159,e704b6192e65cfb3fe694c24098aeada3ff2985e19be31fe1ea973a3ed522e03,DB04159,DB04159,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,spasticity,HP:0001257,,,
1312,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,,,,,,,,,,,,,,,,,,,,abnormal motor development,HP:0001270,,,
1313,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,,,,,,,,,,,,,,,,,,,,Sleep disturbance,HP:0002360,,,
1314,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,,,,,,,,,,,,,,,,,,,,Defected neurotransmitter homeostasis in the CNS,HP:0012535,,https://www.ncbi.nlm.nih.gov/pubmed/22729819,
1315,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,depletion of cerebral folate,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179",
1316,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,,,,,,,,,,,,,,,,,,,,abnormal folate homeostasis in the CNS,HP:0012335,,,
1317,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Amantadine,,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,levodopaâinduced choreic dyskinesia(Dyskinesia)*,HP:0100660*,,https://www.ncbi.nlm.nih.gov/pubmed/15389992,
1318,215140,,Number Sign,215140,GREENBERG DYSPLASIA; GRBGD,"HYDROPS-ECTOPIC CALCIFICATION-MOTH-EATEN SKELETAL DYSPLASIA;; HEM SKELETAL DYSPLASIA;; MOTH-EATEN SKELETAL DYSPLASIA;; CHONDRODYSTROPHY, HYDROPIC AND PRENATALLY LETHAL TYPE",,Greenberg dysplasia,,LBR,LBR,lamin B receptor,da519e2dbaa197f50ee710f838bd1a41ba2a87fc480c1ab0c9ccb5e7a5a5107e,Q14739,,Q14739,No treatment is available in DDIEM,,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,,,,,,,,HP:0100660*,,https://www.ncbi.nlm.nih.gov/pubmed/15389992,
1319,603358,603358,Number Sign,603358,GRACILE SYNDROME,"GROWTH RETARDATION, AMINO ACIDURIA, CHOLESTASIS, IRON OVERLOAD, LACTIC ACIDOSIS, AND EARLY DEATH;; FINNISH LETHAL NEONATAL METABOLIC SYNDROME; FLNMS;; LACTIC ACIDOSIS, FINNISH, WITH HEPATIC HEMOSIDEROSIS;; FELLMAN SYNDROME",,GRACILE syndrome,,BCS1L,BCS1L,ubiquinol-cytochrome c reductase complex chaperone,e24029ff6960f0803aa1392f17b9bba8a081111c7c22640b4ee18f5c60df23c8,Q9Y276,,Q9Y276,Sodium bicarbonate,,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,lactic acidosis,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/15389992,https://www.ncbi.nlm.nih.gov/pubmed/22970607,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",
1320,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,Gangliosides,,DB12351,DB12351,1a0df9fbdd70d2ef2fed47efad22dbadd5103a65c8c794dbdf28311e4a6cd5ef,DB12351,DB12351,,,,,,,EC0:0007121,EC0:0007121,,,Direct action (Mechanistic A) Replacement,A,Delayed Develoment,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/15389992,https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",
1321,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,CoQ10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,defect in eye contect,HP:0000817,,"https://www.ncbi.nlm.nih.gov/pubmed/15389992,https://www.ncbi.nlm.nih.gov/pubmed/22990144,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",
1322,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,,,,,,,,,,,,,,,,,,,,abnormal interactivity,HP:0012433,,,
1323,230500,,Number Sign,230500,"GM1-GANGLIOSIDOSIS, TYPE I","GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I;; GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1;; BETA-GALACTOSIDASE-1 DEFICIENCY;; GLB1 DEFICIENCY","GM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED",GM1 gangliosidosis type 1,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,5aR)-5a-C-Pentyl-4-epi-isofagomine,,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction ( Mechanistic A),A,Neurologic abnormalities,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/27750150,
1324,230500,,Number Sign,230500,"GM1-GANGLIOSIDOSIS, TYPE I","GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I;; GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1;; BETA-GALACTOSIDASE-1 DEFICIENCY;; GLB1 DEFICIENCY","GM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED",GM1 gangliosidosis type 1,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,purified recombinant human -GalWT,,NA,,,,,,,,,,,ECO:0001565+ECO:0005542,"ECO:0001565,ECO:0005542",,,Direct interaction ( Mechanistic A),A,Decreased beta-galactosidase activity,HP:0008166,,https://www.ncbi.nlm.nih.gov/pubmed/26766614,
1325,230600,,Number Sign,230600,"GM1-GANGLIOSIDOSIS, TYPE II","GANGLIOSIDOSIS, GENERALIZED GM1, JUVENILE TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 2","GANGLIOSIDOSIS, GENERALIZED GM1, LATE-INFANTILE TYPE, INCLUDED",GM1 gangliosidosis type 2,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,6S-NBI-DGJ,,PubChem:CID 76070514,PubChem:CID 76070514,33a6428b19e237bda98927c09285f2b77fc4c8c52f476e81c2e742a85838d698,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction ( Mechanistic A),A,Brain pathology,HP:0001298,,https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract,
1326,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,Allopregnanolone+2-hydroxypropyl-Î²-cyclodextrin,,DB11859+DB15146,DB11859 + DB15146,1c7edabf91f10f1b61ca2ad764738908c7e09d3077c6d4d11e1fb3e4bbe3bc55,,,,,"DB11859,DB15146","DB11859,DB15146",,,ECO:0005542,ECO:0005542,,,Symptomativc (C),C,high intraneuronal GSL storage,NA,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,
1327,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,,,,,,,,,,,,,,,,,,,,elevated intraneuronal cholesterol,NA,,,
1328,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,AAV-treatedÂ Î²gal,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct action (Mechanistic A) Replacement,A,Abnormally decreased rate of beta-galactosidase activity,HP:0008166,,https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract,
1329,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,miglustat,,DB00419,DB00419,a47e10902853c2689213c0aa7da671fa33498cddf871edae57b1524b9caabad1,DB00419,DB00419,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,High ganglioside accumulation,NA,,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,
1330,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,EC,,,,,,,,,,,,,,,,,,,,ataxic gait,HP:0002066,,,
1331,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC2 protein,f8d36cad5c786369bb4b9b1112bb7f706c527af88c98851f18e5be7a46ff93fa,Q9VQ62,,Q9VQ62,2-hydroxypropyl-beta-cyclodextrin,,DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,HP:0003107*,,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,
1332,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC2 protein,f8d36cad5c786369bb4b9b1112bb7f706c527af88c98851f18e5be7a46ff93fa,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,High intraneuronal GSL storage,NA,,,
1333,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC2 protein,f8d36cad5c786369bb4b9b1112bb7f706c527af88c98851f18e5be7a46ff93fa,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,HP:0003119*,,,
1334,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,N-butyldeoxynojirimycin +allopregnanolone,,DB00419Â +DB11859,DB00419 + DB11859,37bfa20d42e4aa5dbb8e6e37858970f92f897390e572fa1e6c2744b971feb8e2,,,,,"DB00419,DB11859","DB00419,DB11859",,,ECO:0005542,ECO:0005542,,,Functional interaction (B),B,elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*,HP:0003107*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736622/,
1335,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,ECO:0007121/ECO:0000352/ECO:0005542,"ECO:0007121,ECO:0000352,ECO:0005542",,,Functional interaction (B),B,High intraneuronal GSL storage,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844",
1336,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,HP:0003119*,,,
1337,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Neurodegeneration,HP:0002180,,,
1338,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Poor swallowing,HP:0002015,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,
1339,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Cognitive impairment,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,
1340,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Fine motor impairment,HP:0007010,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,
1341,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Liver injury,HP:0001392,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,
1342,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Cholesterol sequestration (Abnormality of cholesterol metabolism)*,HP:0003107*,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,
1343,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Reduced life span (Mortality)*,HP:0040006*,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,
1344,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,Miglustat + Allopregnanolone+Cyclodextrin,,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,ECO:0005542,ECO:0005542,,,Functional interaction(Mechanistic B),B,Motor function impairment,HP:0002275,,https://www.ncbi.nlm.nih.gov/pubmed/23948640,
1345,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Cerebeller neurodegeneration( neurodegeneration)*,HP:0002180*,,https://www.ncbi.nlm.nih.gov/pubmed/25400034,
1346,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Abnormality of lipid metabolism,HP:0003119,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,
1347,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Splenomegaly,HP:0001744,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,
1348,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Increased number of splenic myeloid cells,NA,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,
1349,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,,,,,
1350,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,(Trimethoprim+Sulfamethoxazole)+Acitretin,,(DB00440+DB01015)+DB00459,(DB00440 + DB01015) + DB00459,23a0f4b029f47fa8586e2131cd2e014fe159b4ac93aeaa0c302f9e6fb3065ba2,,,,,"(DB00440,DB01015),DB00459",DB00459,,"(DB00440,DB01015)",ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Palmoplantar keratoderma,HP:0000982,,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,
1351,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Periodontitis,HP:0000704,,,
1352,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,Acitretin,,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Periodontitis,HP:0000704,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,
1353,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,etretinate,,DB00926,DB00926,21280346c8f4a95b457ffe02a7287c89f735cbcb08c492ddf69859485cf2a463,DB00926,DB00926,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Keratoderma,HP:0000982,,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,
1354,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Aggressive periodontitis(Sever periodontitis),HP:0000166,,,
1355,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,cathepsin C,c96299bbcd262e876470d16244377a6e56f889dfe2e649b01a30d23d2f7bc839,Q9VQ62,,Q9VQ62,salicylic acid+urea,,DB00936+DB03904,DB00936 + DB03904,f56178fcba0fd1fb795da6da8773fec2be6bf2b5e1aae45c7f81a2fd898996b2,,,,,"DB00936,DB03904","DB00936,DB03904",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Palmoplantar hyperkeratosis,HP:0000972,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,
1356,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),dee316cbf84ee82969ac0642059e18d451ab1eab620078c834d329da8e3545f8,Q9VQ62,,Q9VQ62,Niacin,,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Chronic diarrhea,HP:0002028,,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,
1357,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),dee316cbf84ee82969ac0642059e18d451ab1eab620078c834d329da8e3545f8,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Hypoalbuminemia,HP:0003073,,,
1358,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),dee316cbf84ee82969ac0642059e18d451ab1eab620078c834d329da8e3545f8,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,Exfoliative erythema,HP:0001019,,,
1359,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,Ascorbic acid,,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (Mechanistic A),A,Low activity of the immature 4-HPPD enzyme,NA,,"https://www.degruyter.com/view/j/jpem.2016.29.issue-1/jpem-2015-0132/jpem-2015-0132.xml,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf",
1360,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,N-acetyl-L-cysteine,,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,"secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*",HP:0001939*,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,
1361,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,pyroglutamic aciduria(Organic aciduria)*,HP:0001992*,,,
1362,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,metabolic acidosis,HP:0001942,,,
1363,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,decreased appetite,HP:0004396,,,
1364,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,Medium-chain triglyceride oil,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,failure to thrive,HP:0001508,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,
1365,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,growth delay,HP:0001510,,,
1366,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,hemolytic anemia,HP:0001878,,,
1367,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,,,,,,,,,,,,,,,,,,,,"low Î²2 microglobulin,creatinine ratio",NA,,,
1368,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,phosphate,,DB14573,DB14573,e3e6683b28e33eaa8e55b0e6a51e3c0059dca7a04015fd40fbb890b95a1a55e7,DB14573,DB14573,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypophosphatemia,HP:0002148,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,
1369,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,sodium bicarbonate,,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,metabolic acidosis,HP:0001942,,,
1370,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,Q9VQ62,,Q9VQ62,Nitisinone (NTBC),,DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (A),A,Extreme frailty (Fatigue)*,HP:0012378*,,"https://pubs.acs.org/doi/abs/10.1021/bi1008112,https://www.ncbi.nlm.nih.gov/pubmed/20677779",
1371,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,Pantoprazole,,DB00213,DB00213,324b88440d34dee63a069bd2b9f08e92a5a95b726cf3b1ab7475f0c16718df80,DB00213,DB00213,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,High serum ferritin,HP:0003281,,"https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580",
1372,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,,,,,
1373,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,,,,,
1374,602390,,Number Sign,602390,"HEMOCHROMATOSIS, TYPE 2A; HFE2A",,"HEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED;; HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED",Hemochromatosis type 2,,HJV/HAMP,"HJV,HAMP",hemojuvelin/hepcidin,b4315f8b7b3872ab484f7d04e94430a6e7f353baaab498692c917c88fc44bbef,Q30201,,Q30201,Deferoxamine,,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/17124037",
1375,602390,,Number Sign,602390,"HEMOCHROMATOSIS, TYPE 2A; HFE2A",,"HEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED;; HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED",Hemochromatosis type 2,,HJV/HAMP,"HJV,HAMP",hemojuvelin/hepcidin,b4315f8b7b3872ab484f7d04e94430a6e7f353baaab498692c917c88fc44bbef,Q30201,,Q30201,hepcidin,,NA,,,,,,,,,,,ECO:0007764,ECO:0007764,,,Direct interaction ( Mechanistic A),A,Increased plasma iron concentration(Increased serum iron),HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives,http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true",
1376,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,Deferoxamine,,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://link.springer.com/article/10.1007%2Fs12185-017-2365-3,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789",
1377,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,hepcidin,,NA,,,,,,,,,,,ECO:0007764,ECO:0007764,,,Functional interaction(Mechanistic B),B,Increased plasma iron concentration(Increased serum iron),HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789",
1378,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,LJPC-401(Synthetic human hepcidin),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,High serum iron,HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789",
1379,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,Deferiprone (L1),,DB08826,DB08826,ecac33e809e84cbd68c4ad875f2d52e72c6fc8367bdeabc70a344a6582d0858a,DB08826,DB08826,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,elevated liver iron concentration,HP:0040134,,"https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39",
1380,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,Nifedipine,,DB01115,DB01115,2a3c3d72dc2507fe9bee48e2502b8ef0f3f4f1ad00867294ea36c87c0822ed7f,DB01115,DB01115,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30,
1381,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,flavanols,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34,
1382,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),C,High atherogenic lipoprotein(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/22798447,http://www.malacards.org/card/hepatic_lipase_deficiency",
1383,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*,HP:0003119*,,,
1384,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,,,,,,,,,,,,,,,,,,,,High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*,HP:0003119*,,,
1385,613521,,Asterisk,613521,UROPORPHYRINOGEN DECARBOXYLASE; UROD,,,Hepatoerythropoietic porphyria,,UROD,UROD,uroporphyrinogen decarboxylase,d89f20618d1fca0e3ca0669761f6c65589929fadd24bba042d43a567d931f5cd,4.1.1.37,4.1.1.37,,Hemin,,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,Functional interaction (mechanistic B),B,Acute episodic abdominal pain,HP:0002574,,https://www.ncbi.nlm.nih.gov/pubmed/24652768,
1386,613521,,Asterisk,613521,UROPORPHYRINOGEN DECARBOXYLASE; UROD,,,Hepatoerythropoietic porphyria,,UROD,UROD,uroporphyrinogen decarboxylase,d89f20618d1fca0e3ca0669761f6c65589929fadd24bba042d43a567d931f5cd,4.1.1.37,4.1.1.37,,,,,,,,,,,,,,,,,,,,,Low pancreatic zymogens,NA,,,
1387,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,Chloroquine,,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,ECO:0000352,ECO:0000352,C282Y/H63D  heterozygosity or compound heterozygosity,C282Y(Homozygous mutation),Functional interaction (mechanistic B),,Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*,HP:0010472*,,"https://www.ncbi.nlm.nih.gov/pubmed/12622622,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/7324107",
1388,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,Increased liver iron level,HP:0012465,,"https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.sciencedirect.com/science/article/pii/S0022202X15441491",
1389,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,https://www.ncbi.nlm.nih.gov/pubmed/4739135,
1390,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,Increased serum ferritin,HP:0003281,,https://www.ncbi.nlm.nih.gov/pubmed/4739135,
1391,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,Elevated transferrin saturation,HP:0012463,,https://www.ncbi.nlm.nih.gov/pubmed/4739135,
1392,176100,,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED","PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,,,,,,,,,,,,,,,,,,,,Increased serum iron,HP:0003452,,,
1393,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,asfotase alfa,,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Defect of bone mineralisation,HP:0004348,,"https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537",
1394,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,growth delay,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub",
1395,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,poor skeletal mineralization,HP:0006462,,https://www.ncbi.nlm.nih.gov/pubmed/30083035,
1396,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,respiratory insufficiency,HP:0002093,,https://www.ncbi.nlm.nih.gov/pubmed/30083035,
1397,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,rickets,HP:0002748,,https://cdn.intechopen.com/pdfs/56869.pdf,
1398,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,gross motor dysfunction,HP:0007015,,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,
1399,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,fine motor dysfunction,HP:0007010,,,
1400,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,cognitive impairment,HP:0100543,,,
1401,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,muscle weakness,HP:0001324,,,
1402,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,fatigue,HP:0012378,,,
1403,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,delayed growth(stature),HP:0000002,,,
1404,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,,,,,Direct interaction ( Mechanistic A),A,secondary hyperparathyrodism,HP:0000867,,https://cdn.intechopen.com/pdfs/56869.pdf,
1405,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,NSAID,,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Lower limb pain,HP:0012514,,"https://www.ncbi.nlm.nih.gov/pubmed/16803637,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582",
1406,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Abnormal prostaglandin level,HP:0011023,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,
1407,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,
1408,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Muscle weakness,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,
1409,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Abnormal walking distance,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,
1410,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,,
1411,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Teriparatide,,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,D378V /G339R/E191K/A176T/V423A,N461L,Functional interaction(Mechinistic B),B,stress fractures(Pathologic fracture)*,HP:0002756*,,"https://link.springer.com/article/10.1007%2Fs00198-015-3272-1,https://www.ncbi.nlm.nih.gov/pubmed/27042741,https://link.springer.com/article/10.1007%2Fs00223-011-9562-5",
1412,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,Ala176Thr/Val423Ala/Val522Ala,,,,metatarsal stress fractures,HP:0001832,,https://www.ncbi.nlm.nih.gov/pubmed/20089612,
1413,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,compound heterozygotes for a p.G339R and p.E191KÂ ALPLÂ mutation,,,,proximal femur pseudofractures,HP:0100036,,"https://academic.oup.com/jcem/article/95/12/5174/2835157,https://www.ncbi.nlm.nih.gov/pubmed/20739387",
1414,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,High bone turnover markers,HP:0003260*,,,
1415,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,defect in skeletal mineralization,HP:0006462,,,
1416,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Pain,HP:0012531,,,
1417,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,mobility problems,HP:0001376,,,
1418,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,High urine phosphoethanolamine,HP:0003239,,https://www.ncbi.nlm.nih.gov/pubmed/20089612,
1419,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,High serum pyridoxal 5'-phosphate,NA,,https://www.ncbi.nlm.nih.gov/pubmed/20089612,
1420,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin B6,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Seizure,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract,
1421,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,BPS804 (setrusumab),,DB14778,DB14778,d97d983858dc6a85a79c82a3f439fcdf6ee671db03598832193c3cd74bde365a,DB14778,DB14778,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,bone weakness,HP:0002749,,"https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/",
1422,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,bone fructure,HP:0002757,,,
1423,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,low bone formation biomarkers,HP:0031429,,,
1424,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,low bone mineral density,HP:0004349,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,
1425,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,Vitamin A,,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Fat soluble vitamin  Malabsorption,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038",
1426,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Progressive ataxic retinopathy,HP:0000488,,https://www.ncbi.nlm.nih.gov/pubmed/26086616,
1427,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,Vitamin E,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Central nervous degeneration,HP:0007009,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038",
1428,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Retinal degeneration,HP:0000546,,,
1429,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Neuromuscular degeneration,HP:0002180,,,
1430,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,,
1431,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Progressive ataxic neuropathy,HP:0003434,,https://www.ncbi.nlm.nih.gov/pubmed/26086616,
1432,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,Vitamin A,,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),C,Fat soluble vitamin  Malabsorption (Fat malabsorption)*,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038",
1433,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Progressive ataxic retinopathy,HP:0000488,,https://www.ncbi.nlm.nih.gov/pubmed/26086616,
1434,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,Vitamin E,,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),C,Central nervous degeneration,HP:0007009,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038",
1435,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Retinal degeneration,HP:0000546,,,
1436,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Neuromuscular degeneration,HP:0002180,,,
1437,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,,
1438,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Progressive ataxic neuropathy,HP:0003434,,https://www.sciencedirect.com/science/article/pii/S0891584915002671?via%3Dihub,
1439,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,3.1.3.1,3.1.3.1,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0003434,,"https://link.springer.com/article/10.1007%2Fs11010-011-1147-0,https://www.ncbi.nlm.nih.gov/pubmed/28285122",
1440,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,https://link.springer.com/article/10.1023%2FA%3A1023811019023,
1441,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0736574803001461,
1442,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,,
1443,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,Vitamen B6,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),C,Seizures,HP:0001250,,https://link.springer.com/article/10.1007%2Fs10545-013-9660-9,
1444,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,Pyridoxine phosphate,,DB02209,DB02209,cb21ff1e3834345abf422c955689bf96a485c83a86e138f945a6d20a59935ab1,DB02209,DB02209,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(C),C,Seizures,HP:0001250,,https://link.springer.com/article/10.1007%2Fs10545-013-9660-9,
1445,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,olanzapine,,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,behavioural disturbance,HP:0000708,,https://www.sciencedirect.com/science/article/pii/S0387760417300086?via%3Dihub,
1446,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,lithium,,DB14507,DB14507,0952a37ef98709b89910d807b9944108664d234d76b1822b18096068328ab59a,DB14507,DB14507,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,psychotic  disorder,HP:0000725,,,
1447,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,green tea extract,,DB14307,DB14307,a3f42d09b866035b6717e4b96d6039ab415cc23e3d7a5d6167b7957b7c8de639,DB14307,DB14307,,,,,,,ECO:0000352,ECO:0000352,,,Supportive (C),C,Oxidative Stress,HP:0025464,,"https://www.sciencedirect.com/science/article/pii/S075333221630645X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/24980685",
1448,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,Vitamin D,,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),A,schizophrenia,HP:0100753,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044915/,
1449,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,Î±-Tocopherol+ascorbic acid,TÎ±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,impairment of reference,,,https://www.sciencedirect.com/science/article/pii/S0166432805003657,
1450,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,C,working spatial memoryÂ impairment*,HP:0002354,,https://www.sciencedirect.com/science/article/pii/S0166432805003657,
1451,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,,
1452,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,cerebral cortex acetylcholinesterase inhibition,NA,,,
1453,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,"""hippocampal Na+, K+-ATPaseÂ reduced activity""",NA,,,
1454,239510,,Number Sign,239510,"HYPERPROLINEMIA, TYPE II; HYRPRO2",HPII;; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE DEFICIENCY,,Hyperprolinemia type 2,,ALDH4A1,ALDH4A1,Î1-pyrroline 5-carboxylate dehydrogenase,16130b49e5865728dc21dcfcd547498a5468317685ff2d6a59c2b95efb363cc2,3.1.3.1,3.1.3.1,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,NA,,,
1455,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,Protein and phenylalanine restriction should be maintained in order to avoid disease progression.,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,Tetrahydrobiopterin,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),B,Muscular hypotonia,HP:0001252,,https://link.springer.com/article/10.1007%2Fs10545-012-9506-x,
1456,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Dystonia,HP:0001332,,,
1457,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/9585615,https://www.ncbi.nlm.nih.gov/pubmed/24204001",
1458,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,Growth failure,HP:0001510,,https://www.ncbi.nlm.nih.gov/pubmed/9760199,
1459,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,,,,,,,,,,,,,,,,,,,,High urinary levels of primapterin (7-biopterin),NA,,https://www.ncbi.nlm.nih.gov/pubmed/24204001,
1460,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,3.1.3.1,3.1.3.1,,Salfonylureas,,DB01124,DB01124,0ad4ddcac409ec127b2a4a30aee705c2cd5bb1f4541bf111d75e4d2171488665,DB01124,DB01124,,,,,,,ECO:0005542,ECO:0005542,,,Symptomatic (C),,PCBD1-diabetes (Noninsulin-dependent diabetes)*,HP:0005978*,,https://www.ncbi.nlm.nih.gov/pubmed/24848070,
1461,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in our patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,botulinum toxin,,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Delayed motor development,HP:0001270,,https://www.ncbi.nlm.nih.gov/pubmed/23570448,
1462,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,valproate+carbamazepine,,DB00313+DB00564,DB00313 + DB00564,c6e9b056eef426486b1fd24405f26f60b1ddc961400e456d079e3c602a7e0d8f,,,,,"DB00313,DB00564","DB00313,DB00564",,,,,,,Symptomatic (C),C,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/23570448,
1463,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Generalized tonic convulsions,HP:0010818,,https://www.ncbi.nlm.nih.gov/pubmed/23570448,
1464,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,Valproic acid+Lysin restricted diet,The drug was accompanied with lysin restricted diet,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C)+Dietry restriction,,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/23570448,
1465,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,pyridoxine,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,"""No remarkable clinical improvement was observed and therefore, treatment was discontinued""",,,https://www.ncbi.nlm.nih.gov/pubmed/23890588,
1466,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,rosuvastatin,,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:00007121,ECO:00007121,,,Symptomatic (C),C,hypertriglyceridemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23323877",
1467,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High LDL level,HP:0003141,,,
1468,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High total cholesterol,HP:0003124,,,
1469,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High Apoliporprotein B level(Abnormal abpolipoprotein level)*,HP:0025201*,,,
1470,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,fenofibrates,,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,ECO:00007121,ECO:00007121,,,Functional interaction (B),B,hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622",
1471,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High level of very low-density lipoprotein,HP:0003362,,,
1472,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High total cholesterol,HP:0003124,,,
1473,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Low HDL-cholesterol,HP:0003233,,,
1474,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,nicotinic acid,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,hypertriglyceridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/1894760,
1475,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High total plasma cholesterol,HP:0003124,,,
1476,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Elevated LDL-C level,HP:0003141,,,
1477,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High VLDL-triglycerides,HP:0003362,,,
1478,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Low HDL-C,HP:0003233,,,
1479,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"strong statins (atorvastatin, pitavastatin, and rosuvastatin",,DB01076Â or DB08860 or DB01098,DB01076 or DB08860 or DB01098,905041f8cb092cda36593dff4630e0452efe1622eb2276a924c4b81bfdb72cdf,"DB01076,DB08860,DB01098","DB01076,DB08860,DB01098",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hypertriglyceridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/22129523,
1480,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Gemfibrozil,,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0000352/ ECO:0007121,"ECO:0000352,ECO:0007121",,,Functional interaction (B),B,Tuberoeruptive xanthomas,HP:0001013*,"The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860","https://www.ncbi.nlm.nih.gov/pubmed/2702860,https://www.ncbi.nlm.nih.gov/pubmed/2681858",
1481,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Hyperchylomicronemia,HP:0012238,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,
1482,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High total plasma cholesterol leve,,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,
1483,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Elevated LDL-C level,HP:0003141,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,
1484,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High VLDL-triglycerides,HP:0003362,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,
1485,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Low HDL-C,HP:0003233,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,
1486,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Rosuvastatin+Pravastatin,,DB01098Â +DB00175,DB01098 + DB00175,47be8dbad4d21c7f7abd5a8da79a0b39c5af2b2f3e8f617c547d527d0fec83e2,,,,,"DB01098,DB00175","DB01098,DB00175",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,hypertriglycernemia,HP:0002155,,https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2,
1487,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,torcetrapib/atorvastatin,Study was terminated due to safety issues.,DB06281+ DB01076,DB06281 + DB01076,be90b560d5db4ed9c4bdd8fe031bc8d0321f607a9c68e3cb80a81ea407df90ba,,,,,"DB06281,DB01076","DB06281,DB01076",,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,,,,https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3,
1488,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,simvastatin,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",
1489,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High VLDL triglycerides,,,,
1490,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,gemfibrozil,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",
1491,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High VLDL triglycerides,NA,,,
1492,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,lovastatin,,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",
1493,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,clofibrate,,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593",
1494,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,lovastatin and clofibrate,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,DB00227+DB00636,DB00227 + DB00636,ebe11f6032da4ec7cd62232ee034ce4a0429c7f10f18081a76b28a34b32dbce2,,,,,"DB00227,DB00636","DB00227,DB00636",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,hypercholesterolemia,HP:0003124,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593",
1495,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Fenofibrate,,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Hypertriglyceridemia,HP:0002155,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293",
1496,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Niacin,,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Hypertriglyceridemia,HP:0002156,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293",
1497,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Fish oil,,DB13961,DB13961,a1f114161df905ead8073e35b571aebc7d01d63c91b1461750961e3e35a3e669,DB13961,DB13961,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglyceridemia,HP:0002157,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract",
1498,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,fenofibrate + atorvastatin,,DB13873+ DB01076,DB13873 + DB01076,ab3545e1ccbf433d4356f659d0d8279f75fb2a01e2e5a3a85eae219e87482e29,,,,,"DB13873,DB01076","DB13873,DB01076",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,xanthomas,HP:0000991,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293",
1499,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,stenotic coronary atherosclerosis,HP:0001677,,,
1500,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,angina pectoris,HP:0001681,,,
1501,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Atrovastatin,,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,ECO:0000352,ECO:0000352,,,,,High serum total cholesterol,HP:0001681,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract",
1502,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High serum triglyceride,,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract",
1503,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High remnant-like particle (RLP)-cholesterol,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,
1504,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,High remnant-like particle (RLP)-TG,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,
1505,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,"Elevated very low-density lipoprotein (VLDL)-cholesterol,serum TG ratio",,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,
1506,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,,,,,,,,,,,,,,,,,,,,Increaed apolipoprotein B level,,,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,
1507,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,probucol,,DB01599,DB01599,05376f8286d603d41a72cb424df20acf941f34da18505574bfdb7f7e3b796d96,DB01599,DB01599,,,,,,,ECO:0005542,ECO:0005542,,,,,Atherosclerosis,HP:0002621,,https://www.ncbi.nlm.nih.gov/pubmed/9185508,
1508,617347,,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED",Hyperlipidemia type 3,,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,Q6Q788,,Q6Q788,Bezafibrate/ atorvastatin,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",DB01393/DB01076,DB01393 / DB01076,fefc87183c114df83fad9fc94b40dbb5592ec54bcab3071c80b69696d34b9dbc,"DB01393,DB01076","DB01393,DB01076",,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),,Atherogenic dyslipidemia(Dyslipidemia)*,HP:0003119*,,https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract,
1509,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,"Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/",GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,diazoxide,,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/23295286,https://www.ncbi.nlm.nih.gov/pubmed/20936362,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/?term=Hyperinsulinism+Hyperammonemia+Syndrome%2C+a+Rare+Clinical+Constellation",
1510,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,,,,,,,,,,,,,,,,,,,,epileptic seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/,https://www.ncbi.nlm.nih.gov/pubmed/28621098",
1511,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,,,,,,,,,,,,,,,,,,,,Hyperinsulinism,HP:0000842,,https://www.ncbi.nlm.nih.gov/pubmed/10969108,
1512,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,Carglumic acid + diazoxide+ Glucose,,DB06775+DB01119+DB01914,DB06775 + DB01119 + DB01914,3a11d0c7d259945cc14c3c834cddf696a2f316788d86bbd276a0cf1797968562,,,,,"DB06775,DB01119,DB01914","DB06775,DB01119,DB01914",,,ECO:0000352,ECO:0000352,,,,,hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/26962538,
1513,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,Levetiracetam,,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,,,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/26962538,
1514,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,,,,,,,,,,,,,,,,,,,,Hyperammonemia,HP:0001987,,https://www.ncbi.nlm.nih.gov/pubmed/10969108,
1515,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,diazoxide,,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,T65I,GK-Y214C(De novo muttation),Functional interaction (B),B,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/15277402,https://www.ncbi.nlm.nih.gov/pubmed/19336674",
1516,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,(Val455Met) at codon 455,,,,"https:,www.ncbi.nlm.nih.gov,pubmed,19336674",HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448",
1517,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,M197I,Y214C,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1518,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,A456V,ins454A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1519,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,W99R,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1520,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,S64Y,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1521,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,V452L,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1522,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,,,,,,,,,,,,,,,,M197I,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,
1523,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,Octreotide,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,,,,,,,,,,,ECO:0007121,ECO:0007121,G68V,,Functional interaction (B),B,Hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,
1524,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,Dextrose +Diazoxide,,DB09341+DB01119,DB09341 + DB01119,9bb504c3a2d85188e2c90bd8d7a0edb612d953ce46e42623454969e68f560268,,,,,"DB09341,DB01119","DB09341,DB01119",,,ECO:0000352,ECO:0000352,W99L,,Functional interaction (B),B,Hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,
1525,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hyperglycerolemia (Isolated glycerol kinase deficiency),,GK,GK,Glycerol kinase,c3e7e4cc9b8354aed11ae511c8456b4a16e9f085a19cc04075cf8df2e20ecc0a,2.7.1.30,2.7.1.30,,Rosuvastatin,,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/",
1526,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,PIGM,GPI mannosyltransferase 1,aa60de0635c3629d8d6cbef7740f8ae3da8edc011cd2d2436954d8d62a90b113,2.7.1.30,2.7.1.30,,Antithrombotic agents,,B01,B01,83aa02054b48cae0a7a624c2800c41da465f3514b70a09550457ecd74267ff0b,B01,,,B01,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Thrombosis,HP:0001977,,https://www.ncbi.nlm.nih.gov/pubmed/16767100,
1527,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,PIGM,GPI mannosyltransferase 1,aa60de0635c3629d8d6cbef7740f8ae3da8edc011cd2d2436954d8d62a90b113,2.7.1.30,2.7.1.30,,Sodium phenylbutyrate,,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/17442906,
1528,237400,,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,Hyperbetaalaninemia,,?????,?????,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.7.1.30,2.7.1.30,,Taurine,,DB01956,DB01956,e2c35ccb93ffade0cbb9686ed721b0a3a2b9e0bc72b4e19db7c29c4ec1dba1b0,DB01956,DB01956,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),,mitochondrial toxicity*,HP:0012103,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097872/,https://link.springer.com/article/10.1007%2Fs00726-017-2462-x",
1529,237400,,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,Hyperbetaalaninemia,,?????,?????,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.7.1.30,2.7.1.30,,Pyridoxine,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500",
1530,237400,,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,Hyperbetaalaninemia,,?????,?????,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.7.1.30,2.7.1.30,,,,,,,,,,,,,,,,,,,,,somnolence,HP:0002360,,https://www.ncbi.nlm.nih.gov/pubmed/7936305,
1531,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,anti-TNF-alpha (Adalimumab)+Etanercept,,DB00051+DB00005,DB00051 + DB00005,079a8c32a567d5da45511c5462944d43b3daeea685a701ac87ef56bd8ae63e46,,,,,"DB00051,DB00005","DB00051,DB00005",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,periodic fever,HP:0001954,,https://www.ncbi.nlm.nih.gov/pubmed/24935455,
1532,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Abnormality of immune system physiology,HP:0010978,,https://www.ncbi.nlm.nih.gov/pubmed/24935455,
1533,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,Anakinra,,DB00026,DB00026,5e71f801220feda13941c6cb41b2f9d50b040b99a73461c19aa223396944edaf,DB00026,DB00026,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/",
1534,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,joint swelling,HP:0001386,,,
1535,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,Canakinumab,,DB06168,DB06168,beb9e5b81bcf66f6d85baf3cbba13cd41cb6a815a35bfea4b8e1b7ff0511dbdb,DB06168,DB06168,,,,,,,ECO:0000352,ECO:0000352,,,,,Fever,HP:0001945,,"https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/",
1536,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,High serum amyloid A protein,NA,,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,
1537,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Elevated C-reactive protein,HP:0011227,,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,
1538,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,prednisolone + azathioprine + immunoglobulins,,DB00860+DB00993+DB00028,DB00860 + DB00993 + DB00028,8b58b6d1d67c7792a60e3f5f365cdd6038769fe7683b3b5d20c4215925880692,,,,,"DB00860,DB00993,DB00028","DB00860,DB00993,DB00028",,,ECO:0000352,ECO:0000352,compound V377I and I126T mutations,,Symptomatic (C),C,periodic fever,HP:0001954,,https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract,
1539,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,Thalidomide,,DB01041,DB01041,95fdada91a05dc6af4aead5ec1a49f066392d411cfc9abb67523dc647c5ba069,DB01041,DB01041,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Limited Efficacy of the drug.,HP:0001954,,https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract,
1540,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,steroids + simvastatin,,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Periodic fever,HP:0001954,,https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract,
1541,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,Infliximab,,DB00065,DB00065,7765e08cdc99e4767116cc9af1c36b2de6865467f2f4486b8e5b04dc12637e85,DB00065,DB00065,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Nummular keratitis(keratitis)*,HP:0000491,,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,
1542,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Corneal scar,HP:0000559,,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,
1543,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Decreased visual acuity,HP:0007663,,,
1544,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,tocilizumab,,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Fever,HP:0001945,,"https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243",
1545,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Fatigue,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,
1546,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Pain,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,
1547,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Oral ulceration,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,
1548,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,Anakinra+ tocilizumab,,,,,,,,,,,,,ECO:0001565/ECO:0000352,"ECO:0001565,ECO:0000352",,,,,Inflammation,,,https://www.ncbi.nlm.nih.gov/pubmed/25173351,
1549,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,2.7.1.36,2.7.1.36,,Niacin,,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,dermatitis,HP:0011123,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2019216/pdf/archdisch01582-0040.pdf,
1550,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,diarrhoea,HP:0002014,,https://www.ncbi.nlm.nih.gov/pubmed/14169454,
1551,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,dementia,HP:0000726,,https://www.ncbi.nlm.nih.gov/pubmed/17334708,
1552,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,2.7.1.36,2.7.1.36,,ascorbic acid,,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,,HP:0000726,,https://www.ncbi.nlm.nih.gov/pubmed/10540864,
1553,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,Laronidase,,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction (A),A,Low Forced Vital Capacity,HP:0002111,,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,
1554,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,"High Apnea,Hypopnea Index(sleep apnea)*",HP:0010535*,,,
1555,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Decreased pulmonary function,HP:0005952,,,
1556,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,,
1557,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Limitation of the Joint range of motion,HP:0001376,,,
1558,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Six Minute Walk Test,NA,,,
1559,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,Nanotechnology-based gene therapy,,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction (A),A,Low IDUA activity(Abnormal enzyme activity)*,HP:0012379,,https://www.ncbi.nlm.nih.gov/pubmed/29122734,
1560,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,,,,,
1561,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,GNeo-IDUA,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (A),A,neurodegenerative astrogliosis,HP:0002180*,,https://www.ncbi.nlm.nih.gov/pubmed/28958576,
1562,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,glycosaminoglycan accumulation,HP:0004371,,,
1563,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,Laronidase (IRT),,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (A),A,Hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=132&Disease(s)/group%20of%20diseases=Mucopolysaccharidosis-type-1&title=Mucopolysaccharidosis%20type%201&search=Disease_Search_Simple&ChdId=0,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1",
1564,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Abnormality of joint mobility,HP:0011729,,,
1565,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Sleep apnea,HP:0010535,,,
1566,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Nocturnal hypopnea,HP:0002877,,,
1567,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Abnormal apneaâhypopnea index,NA,,,
1568,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Urinary glycosaminoglycan excretion,HP:0003541,,,
1569,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,photophobia,HP:0000613,,,
1570,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,conjunctival irritation,HP:0030953,,,
1571,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,impaired Visual acuity,HP:0007663,,,
1572,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,low exercise endurance,NA,,,
1573,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,tricuspid regurgitation,HP:0005180,,,
1574,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,pulmonary regurgitation,HP:0010444,,,
1575,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,dyspnea at rest,HP:0012763,,,
1576,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,pitting edema,HP:0000969,,,
1577,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,low quality of sleep,HP:0002360,,,
1578,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Daytime somnolence,HP:0002189,,,
1579,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,white matter abnormalities,HP:0002500,,https://www.ncbi.nlm.nih.gov/pubmed/19748810,
1580,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,brain ventricular dilatation,HP:0002119,,,
1581,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,brain MRI abnormalities,HP:0002500,,,
1582,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,Gene therapy,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction (A),A,Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*,HP:0004356,,"https://www.ncbi.nlm.nih.gov/pubmed/8700879,https://www.ncbi.nlm.nih.gov/pubmed/30081189",
1583,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,Gene therapy,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (A),A,ventricular hypertrophy,HP:0001714,,"https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189",
1584,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,"cardiac dilation, Heart enlargment, cardimegaly",HP:0001640,,,
1585,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,left ventricularc contractility abnormalities,HP:0006670*,,,
1586,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUAgene,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,2.7.1.36,2.7.1.36,,,,,,,,,,,,,,,,,,,,,Left ventricle dysfunction,HP:0030872,,,
1587,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,,DB04789 + DB00200 +DB00165+ DB06756,DB04789 + DB00200 + DB00165 + DB06756,cc0685b76815ebe5c1c8f1867b59541c328b34ba15aa2454e2656e71531a6439,,,,,"DB04789,DB00200,DB00165,DB06756","DB04789,DB00200,DB00165,DB06756",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Abnormal Folate level,HP:0040087,,https://www.ncbi.nlm.nih.gov/pubmed/11916316,
1588,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,Abnormal serum Methylfolate Level,NA,,,
1589,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Betaine+Folinic acid,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",DB06756+DB00650,DB06756 + DB00650,f6abbfdcd45773b2171439108039d119470dc004c99e5d1a724d91296b8e3b31,,,,,"DB06756,DB00650","DB06756,DB00650",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Abnormality of homocysteine metabolism,HP:0010919,,https://www.ncbi.nlm.nih.gov/pubmed/25024447,
1590,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,,,,,,,,,,,,,,,,,,,,low muscle tone,HP:0001290,,,
1591,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Topiramate,,DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/25024447,
1592,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"Betaine, Folic acid, Vitamin B6 , Vitamin B12",,DB06756+DB00158+DB00165+DB00115,DB06756 + DB00158 + DB00165 + DB00115,a3270ee06456b40d51341486b949645237dc5be36e9bb6feb6b0dfdb63ad152c,,,,,"DB06756,DB00158,DB00165,DB00115","DB06756,DB00158,DB00165,DB00115",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,High plasma homocysteine level(Abnormal homocysteine level)*,HP:0010919,,https://www.ncbi.nlm.nih.gov/pubmed/29246599,
1593,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Vitamin B+Betaine,"Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773",DB00165+DB6756,DB00165 + DB6756,8ac2f1c39c49a46e4b2abc975de8ccc1bfdef496ff29ea2aa9649775f3053d4a,,,,,"DB00165,DB6756","DB00165,DB6756",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),,Developmental abnormality,HP:0012759,,https://www.ncbi.nlm.nih.gov/pubmed/20356773,
1594,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,Pyridoxine,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542","""P49L, A114V, I278T, R266K, or R336H""","""R125Q, E176K, T191M, T262M, or G307S""",Functional interaction (B),B,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,HP:0012379*,,"https://www.ncbi.nlm.nih.gov/pubmed/29119254,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681",
1595,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,Î´-aminolevulinate,,DB00855,DB00855,bdc657f560d06262a8ba1a8cbc5799dc5b23348226409d565ee1035925d19702,DB00855,DB00855,,,,,,,ECO:0001565,ECO:0001565,R125Q,,Symptomatic (C),C,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,HP:0012379*,,"https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681",
1596,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,R266K,,,,Homocystinuria,HP:0002156,,,
1597,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,,H65R,,,,,,,
1598,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,S-Adenosylmethionine,,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction (A),A,"""The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.""",,,https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract,
1599,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,bortezomib,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,ECO:0005542,ECO:0005542,I278T,,Direct interaction (A),A,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,,,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,
1600,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,ONX-0912,,DB11991,DB11991,7a784d5ae86f72e3f18cfc49482833ce59550dba75ce45e72ce6c78b913d90d3,DB11991,DB11991,,,,,,,ECO:0005542,ECO:0005542,S466L /I278T,,Direct interaction (A),A,Abnormal Hcy level,HP:0010919*,,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,
1601,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,,,,,Homocystinuria,HP:0002156,,,
1602,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine/betaine,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",DB00165/DB06756,DB00165 / DB06756,0755377e352df328bfbf19894aa97ea4dd57f75ac4104c6e52efaac6bc623d0f,"DB00165,DB06756","DB00165,DB06756",,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,High total homocysteine levels,HP:0002160,,https://www.ncbi.nlm.nih.gov/pubmed/14739681,
1603,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,,,,,High total cysteine levels,HP:0010918,,,
1604,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,,,,,Low plasma serine levels,HP:0012279,,,
1605,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,,,,,,,,,,,,,,,,,,,,high blood S -adenosylhomocysteine level,NA,,,
1606,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,serine,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",DB00133,DB00133,c0d23226e9582983714d35d6d56065440bea047ae90f95c6635aae942f700144,DB00133,DB00133,,,,,,,ECO:0007764,ECO:0007764,,,Symptomatic (C),C,,NA,,,
1607,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,creatine/Creatine phosphate,,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechinistic B),B,muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172",
1608,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,Functional interaction (B),B,Low cerebral creatine content,HP:0012113*,,,
1609,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,Low developmental score,HP:0012759*,,,
1610,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,neurodevelopmental delay,HP:0012758,,,
1611,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/20682460,
1612,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,Low IQ score,HP:0001249,,,
1613,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,language impairment,HP:0002463,,https://www.ncbi.nlm.nih.gov/pubmed/23770102,
1614,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,behavior al abnormalities,HP:0000708,,,
1615,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,communicative skills abnormalities,HP:0002474*,,,
1616,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,psychomotor retardation,HP:0001263,,,
1617,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,,,,,,,,,,,,,,,,,,,,METABOLIC ENCEPHALOMYOPATHY,NA,,https://www.ncbi.nlm.nih.gov/pubmed/20625172,
1618,612933,,Number Sign,612933,GLYCOGEN STORAGE DISEASE XI; GSD11,GSD XI;; LACTATE DEHYDROGENASE A DEFICIENCY,,Lactate dehydrogenase A deficiency,,LDHA,LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1efb27da4b03aac4145900c1daa0fb13afba88954e2134a8ee522b9df451639e,1.1.1.27,1.1.1.27,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,NA,,https://www.ncbi.nlm.nih.gov/pubmed/20625172,
1619,614128,,Number Sign,614128,LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD,,,Lactate dehydrogenase deficiency,,LDHB/LDHA,"LDHB,LDHA","lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1efb27da4b03aac4145900c1daa0fb13afba88954e2134a8ee522b9df451639e,1.1.1.27,1.1.1.27,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,NA,,https://www.ncbi.nlm.nih.gov/pubmed/20625172,
1620,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,cholesterol,,DB04540,DB04540,35d8d2e536310c7ee95cf58f43abb43574e00c3fcc4be87e1443448125e7a2e7,DB04540,DB04540,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,Abnormal blood lathosterol level,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/24142275,
1621,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,Simvastatin,The drug has been reported to be unbeneficial in one patient .,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,p.K148E and p.D210E,,Functional interaction (B),B,Abnormal neurodevelopmental profile,HP:0012759,,,
1622,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,,,,,,,,,,,,,,,,,,,,developmental delay,HP:0001263,,,
1623,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,,,,,,,,,,,,,,,,,c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu),,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30097991,
1624,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,heptanoate,,CHEBI:32362,CHEBI:32362,4b49a1cef723433bb858ec2f03322aeba381e458cea8fb8e7d6ccbdaff2a4076,CHEBI:32362,,CHEBI_32362,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,elevation of creatine kinase,HP:0003236,,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,
1625,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Docosahexaenoic acid (DHA),Dietry treatment supplementation,DB03756,DB03756,16c5d8e3c2f1478a5f7643170003668626f452b44f7243f41dc742daab8d153f,DB03756,DB03756,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,metabolic acidosis,HP:0001942,,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,
1626,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,bezafibrate,,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0001565,ECO:0001565,c.1528Gâ>âC,c.1528Gâ>âC,Direct interaction ( Mechanistic A),A,Abnormal Fatty acid oxidation,HP:0004359*,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),
1627,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,C2129-2Aâ>âC,,,,Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity,NA,,,
1628,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,c. 1393_1479del-Del exon,,,,,,,,
1629,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,c.180â+â3Aâ>âG,,,,,,,,
1630,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,c.914Â Tâ>âA,,,,,,,,
1631,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,c.982Gâ>âA and c.1072Câ>âA,,,,,,,,
1632,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND1/MT-ND4L/MT-ND6,"MT-ND1,MT-ND4L,MT-ND6",mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6,3ad59e352a3baec4679dd9ff354f7fc1a087b007a7d559238b3a0657ec010276,4.2.1.17,"1.1.1.211,4.2.1.17",,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30107658,
1633,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,G11778A,,Functional interaction(Mechinistic B),B,Optic nerve damage,HP:0001138,,https://www.ncbi.nlm.nih.gov/pubmed/17296905,
1634,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Mitochondrial oxidative stress,HP:0012103,,,
1635,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)ï¼rAAV2-ND4))",,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,G11778A,,Direct interaction ( Mechanistic A),A,Abnormal visual acuity,HP:0030532,,"https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1",
1636,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,G11778A,,Direct interaction ( Mechanistic A),A,Low ATP synthesis,HP:0025464,,https://www.ncbi.nlm.nih.gov/pubmed/30208599,
1637,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Optic atrophy,HP:0000648,,,
1638,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,HP:0030534,,,
1639,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1640,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Idebenone,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121","""m.3460G>A, m.11778G>A, and m.14484T>C""",,Symptomatic (C),C,Abnormal visual acuity,HP:0030532,,"https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://www.ncbi.nlm.nih.gov/pubmed/11001192,https://www.ncbi.nlm.nih.gov/pubmed/17573650,https://www.ncbi.nlm.nih.gov/pubmed/21788663,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",
1641,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Abnormal retinal ganglion cell function,HP:0001112,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13",
1642,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Idebenone+Vitamin C+Vitamin B12,,DB09081+DB00126+DB00115,DB09081 + DB00126 + DB00115,212e4cce099decca0400320c49f275e248d9861dbc202e49f204147f7322e3bd,,,,,"DB09081,DB00126,DB00115","DB09081,DB00126,DB00115",,,ECO:0000352,ECO:0000352,,,,,Slow recovery,HP:0012823*,,"https://www.ncbi.nlm.nih.gov/pubmed/11001192/,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13",
1643,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,EPI-743(Vatiquinone),,DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13",
1644,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,HP:0030534,,,
1645,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Estrogens,,DB00783,DB00783,102bf3a48f5629450533d490b6f3cdafd4acafc04910d4d17440e7aa962a1c8d,DB00783,DB00783,,,,,,,ECO:0001565,ECO:0001565,,,Functional interaction(Mechinistic B),B,Mitochondrial dysfunction,HP:0003287,,https://www.ncbi.nlm.nih.gov/pubmed/20943885,
1646,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,elamipretide (MTP-131),,DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Excessive Reactive Oxidative System,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790",
1647,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Low ATP synthesis,HP:0025464,,,
1648,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Curcumin,,DB11672,DB11672,75495fe6add4f3e7ec689ed63fe192cec61e871e134d0fd3277a365ad0ad134d,DB11672,DB11672,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Oxidative stress,HP:0025464,,https://clinicaltrials.gov/ct2/show/NCT00528151,
1649,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Cyclosporine,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,DB00091,DB00091,13d35d65cb3bb074f90d6868ed89c129d48145825aea20089025fd435a5bf52d,DB00091,DB00091,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Disease progression,,,"https://www.ncbi.nlm.nih.gov/pubmed/24161764,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12",
1650,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteroid+Antiaggregates,,H02+B01A,H02 + B01A,a5ec57e88cb5d66bd6b9dc17b3e7ac187083877fe4bfb29b97d51caf826c403e,,,,,"H02,B01A",,,"H02,B01A",ECO:0000352,ECO:0000352,,,Symptomatic (C),,Large central visual field defect,HP:0001129,,"https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12",
1651,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1652,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1653,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1654,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type","Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/",LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,methylene blue,,DB09241,DB09241,cd6f137529c9886a5f82247ebaf4ca529fefa604daa656312db529260334cd8f,DB09241,DB09241,,,,,,,ECO:0001565,ECO:0001565,A354V,,Functional interaction (B),B,Low COX content and activity,NA,,https://www.ncbi.nlm.nih.gov/pubmed/22202226,
1655,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,A354V and C12775STOP,,,,acidotic crises,HP:0001941*,,,
1656,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,propionate,,DB03766,DB03766,429ffe8122c00772e3095dbc757b5ccb8f2447908143e18f816253bd8469bb21,DB03766,DB03766,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),C,Palmitate plus lactate-induced cell death,NA,,https://www.ncbi.nlm.nih.gov/pubmed/25835550,
1657,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),C,PL-induced cytotoxicity,NA,,https://www.ncbi.nlm.nih.gov/pubmed/25835550,
1658,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,Trolox ornithylamide hydrochloride,,,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),,Increased ROS production,HP:0025464,,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,
1659,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex I,HP:0011923,,,
1660,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex IV,HP:0008347,,,
1661,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1662,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Ecopipam ((PSYRX 101),,DB12273,DB12273,fc97ec403ea9c1721c4f7d10463041a1db67d448e4629ab43161b88137e33856,DB12273,DB12273,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Self-injurious Behavior,HP:0100716,,"https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/",
1663,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,sapropterin,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Behaviour abnormalities,HP:0100851,,https://clinicaltrials.gov/ct2/show/NCT00935753,
1664,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,aminomidazole carboxamide riboside,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,No result was added,,,https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4,
1665,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Hypoxanthine+ tetrahydrobiopterin,,DB04076+DB00360,DB04076 + DB00360,e10ffe12ea8f06f63494ac5b3af791d6c470f6133f6a081c1cada5ff932d1ca3,,,,,"DB04076,DB00360","DB04076,DB00360",,,ECO:0000352,ECO:0000352,,,Functional interaction (B),B,No result was accessible,,,https://www.ncbi.nlm.nih.gov/pubmed/3728152,
1666,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,SAM,,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0007121,ECO:0007121,,,,,Self-injurious behaviour,HP:0100716,,"https://www.ncbi.nlm.nih.gov/pubmed/16906475/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/",
1667,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Aggressive behavior,HP:0000718,,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,
1668,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1669,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Allopurinol,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperuricemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/",
1670,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,gouty arthritis,HP:0001997,,,
1671,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1672,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Baclofen,,DB00181,DB00181,283d4a5ab576ae808a0995e16fe21d81a8a4de4f3d61614edd1975a48037e4c1,DB00181,DB00181,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Spasticity,HP:0001257,,https://www.ncbi.nlm.nih.gov/pubmed/16549399,
1673,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,diazepam or alprazolam,,DB00829 or DB00404,DB00829 or DB00404,d31535d9b1caed200979c1bd39915bd5c013123f2b9204c2b9348d8a4811bee9,"DB00829,DB00404","DB00829,DB00404",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,anxiety,HP:0000739,,https://www.ncbi.nlm.nih.gov/pubmed/21126241,
1674,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,Spa,,,,Abnormal muscle tone,HP:0003808,,https://www.ncbi.nlm.nih.gov/pubmed/21126241,
1675,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Risperidone,,DB00734,DB00734,3386dc330cfd8bc8e3e77c8209b4c33d8c91496c09c526e583f1be47c58819dc,DB00734,DB00734,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Self-mutilation,HP:0000742,,https://www.ncbi.nlm.nih.gov/pubmed/8870064/,
1676,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Tetrabenazin,,DB04844,DB04844,3c691bde691be0bb10887f2109ce799a1166619ac2503e0085a835f70baa14ae,DB04844,DB04844,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Chorea,HP:0002072,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632",
1677,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,
1678,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,Carbidopaâlevodopa,,DB00190+DB01235,DB00190 + DB01235,a833b7564ae1ab0a9d22f26acf51f694431037621f537bac04993eae8f229885,,,,,"DB00190,DB01235","DB00190,DB01235",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,
1679,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Chorea,HP:0002072,,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,
1680,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,,,,,
1681,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,diazoxide,,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,E1506K,,Functional interaction (B),B,hypoglycemia,HP:0001943,,https://www.ncbi.nlm.nih.gov/pubmed/15356046,
1682,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,R1353H,,,,,,,,
1683,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,delSer1387,,,,,,,,
1684,613724,,Number Sign,613724,LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN,STEROL CARRIER PROTEIN 2 DEFICIENCY,,Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY),,SCP2,SCP2,sterol carrier protein 2,170522625b29ee7a1ef0982e1c33fd140870d731fbdb6b7e262ccc6dcd07a0b6,4.2.1.17,"1.1.1.211,4.2.1.17",,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16685654,
1685,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,acetazolamide,,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia ),HP:0002066*,,https://www.ncbi.nlm.nih.gov/pubmed/21749991,
1686,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Seizures,HP:0001250,,,
1687,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,glucocorticosteroid.,,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,spastic bladder,HP:0005340,,https://www.ncbi.nlm.nih.gov/pubmed/23644316,
1688,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Prednisolone,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,ECO:0000352/ECO:0007764,"ECO:0000352,ECO:0007764",,,Symptomatic (C),C,Myositis,HP:0100614,,"https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099",
1689,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Muscle weakness,HP:0001324,,,
1690,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Difficulty walking,HP:0002355,,,
1691,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Rapid progression,HP:0003678,,,
1692,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,rAAV-Fkrp,,,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A),A,Abnormal serum creatine kinase,HP:0040081,,"https://www.ncbi.nlm.nih.gov/pubmed/25048216,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302",
1693,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Muscle dystrophy,HP:0006785,,https://www.ncbi.nlm.nih.gov/pubmed/28107841,
1694,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,,,,,,,,,,,,,,,,,,,,Abnormal muscle function,HP:0011804,,,
1695,609308,,Number Sign,609308,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 11; LGMDR11;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2K; LGMD2K",,LGMD2K,,POMT1,POMT1,protein O-mannosyltransferase 1,c7f8ff87033b272860227f552819241c016e0fca894341285c3e08c74a60a022,2.4.1.109,2.4.1.109,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0011804,,https://www.ncbi.nlm.nih.gov/pubmed/17339125,
1696,611307,,Number Sign,611307,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L",,Limb-girdle muscular dystrophy type 2I (LGMD2I),,ANO5,ANO5,anoctamin 5,edacd0e23a519c1071120a82bd17a5efb3583aba8c0d520c1ba3f297e773bf0f,Q75V66,,Q75V66,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0011804,,https://www.ncbi.nlm.nih.gov/pubmed/17339125,
1697,253601,,Number Sign,253601,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 3; LGMD3",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B",,DYSF,DYSF,dysferlin,1805ac6983333359231feb5ac6a1abc39a425f5fcd774cefdd24cc6462b1e9b1,O75923,,O75923,Resolaris (ATYR1940),,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Abnormal muscle function,HP:0011804,,"https://clinicaltrials.gov/ct2/show/NCT02579239,https://musculardystrophynews.com/resolaris-atyr1940/,https://www.ncbi.nlm.nih.gov/pubmed/17339125",
1698,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,EC,AAV2 /1-mSeAP-propmyoD76A,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction ( Mechanistic B),B,Muscle atrophy,HP:0003797,,"https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125",
1699,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,EC,,,,,,,,,,,,,,,,,,,,abnormal muscle strenght,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A,
1700,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,EC,(r) AAV2/1-mediated calpain 3,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction ( Mechanistic B),,Low muscle mass,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",
1701,608099,,Number Sign,608099,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D;; DUCHENNE-LIKE AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, TYPE 2; DMDA2;; ADHALINOPATHY, PRIMARY",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D",,SGCA,SGCA,sarcoglycan alpha,842cd54aa7005064468652bc60f277a58b791db371ea81bba4c5fd0e90bdfcfa,Q16586,,Q16586,AAV2/1-MCK-Sgca,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction(Mechanistic A),A,Decreased muscle mass,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+Î±-sarcoglycan+deficiency,https://www.ncbi.nlm.nih.gov/pubmed/17339125",
1702,608896,,Asterisk,608896,"SARCOGLYCAN, GAMMA; SGCG","DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 35-KD",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C",,SGCG,SGCG,sarcoglycan gamma,eb776936c6a52d632a7fb1ead88eda8815e2f5f90251fefd3f7a8ed6b86bb29d,Q16586,,Q16586,,,,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15252120,https://www.ncbi.nlm.nih.gov/pubmed/16635485",
1703,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,Fenofibrate+Ï-3 fatty acids+EPA+DHA,Poor compliance to the treatment was noticed,DB01039+DB11133+DB00159 +DB03756,DB01039 + DB11133 + DB00159 + DB03756,72b61c38d6e676cffe014e9afb89ce70e0cccfe4f486b35c127c5d344c23313e,,,,,"DB01039,DB11133,DB00159,DB03756","DB01039,DB11133,DB00159,DB03756",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglycridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485",
1704,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,gemfibrozil+Ï-3 fatty acids,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",DB01241+DB11133,DB01241 + DB11133,8f5884bac439787a67097c69c67edfcd5d928a572e2bd2a37b3a1b2ce810a82e,,,,,"DB01241,DB11133","DB01241,DB11133",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglycridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/19820022,
1705,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,Insulin aspart+Fibrate(gemfibrozil)+ Ï-3 fatty acids,,DB01306+DB01241+DB11133,DB01306 + DB01241 + DB11133,678375cc4026977112d122e2dc7f43de1b5f4447b15fca0eb9e681f398c4f073,,,,,"DB01306,DB01241,DB11133","DB01306,DB01241,DB11133",,,ECO:0000352,ECO:0000352,W464X,,Symptomatic (C),C,Hypertriglycridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/19820022,
1706,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,,,,,,,,,,,,,,,,,,,,Hyperglycemia,HP:0003074,,,
1707,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,Metformin,A low fat regimen was added to metformin while treating the patient.,DB00331,DB00331,d056ae45d37c6e46046e3261b7b1c388af8a39d409eaa6caf8955e1f26e8277c,DB00331,DB00331,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypertriglycridemia,HP:0002155,,https://www.ncbi.nlm.nih.gov/pubmed/17994020/,
1708,614462,,Number Sign,614462,"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS",PYRUVATE DEHYDROGENASE LIPOIC ACID SYNTHETASE DEFICIENCY; PDHLD,,Lipoic acid synthetase deficiency,,LIAS,LIAS,lipoic acid synthetase,336baf56ca1cf9884a870e108ed4d86e41b121aecab300950098b617e853a008,2.8.1.8,2.8.1.8,,Topiramate+lamotrigine,,DB00273+DB00555,DB00273 + DB00555,b9a56afd3455e636c1ea14454da0a47ef94ff78d7dced696f889989c09267458,,,,,"DB00273,DB00555","DB00273,DB00555",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/24777537,
1709,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,Acitretin,,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Skin lesion,HP:0011122,,"https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532",
1710,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,Skin papules,HP:0200034,,,
1711,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,Mucosal lesions,,,,
1712,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,Hoarseness,HP:0001609,,"https://www.ncbi.nlm.nih.gov/pubmed/23259080/,https://www.ncbi.nlm.nih.gov/pubmed/18808438/",
1713,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,Elbow skin thickening,HP:0001072,,https://www.ncbi.nlm.nih.gov/pubmed/28681064,
1714,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,hyperkeratosis,HP:0000962,,,
1715,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,,,,,,,,,,,,,,,,,,,,verrucous lesions,HP:0012500,,,
1716,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,sodium bicarbonate,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Proximal tubular dysfunction,HP:0000114,,"https://www.ncbi.nlm.nih.gov/pubmed/12937245,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33",
1717,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,potassium bicarbonate,,DB11098,DB11098,99c93e7455a78824d81499f20c391ff8aa6048be5c1e071b2a842aff08583fc5,DB11098,DB11098,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33",
1718,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,Potassium citrate,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Metabolic acidosis (Hyperchloremic metabolic acidosis),HP:0004918,,https://www.ncbi.nlm.nih.gov/pubmed/20301653,
1719,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,,,,,,,,,,,,,,,,,,,,Hypokalemia,HP:0002900,,,
1720,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,phosphate+calcitriol,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB14573+DB00136,DB14573 + DB00136,97a3e9d877bccd9c942df123da571dc27ac9f8f93a241833174e40e2f124e28c,,,,,"DB14573,DB00136","DB14573,DB00136",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Renal rickets,HP:0002748,,https://www.ncbi.nlm.nih.gov/pubmed/20301653,
1721,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Hypophosphatemia,HP:0002148,,https://www.ncbi.nlm.nih.gov/pubmed/20301653,
1722,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,1-OH vitamin D,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperparathyrodism,HP:0000867,,"https://www.ncbi.nlm.nih.gov/pubmed/2017228,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33",
1723,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,pamidronate +growth hormone,,DB00282+DB00052,DB00282 + DB00052,23e8fee8c911ae066de3ac1d6590ba9e86e318f401a7c3a7127663b65e849e51,,,,,"DB00282,DB00052","DB00282,DB00052",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hypophosphatasia,HP:0002148,,https://www.ncbi.nlm.nih.gov/pubmed/19773212/,
1724,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,,,,,,,,,,,,,,,,,,,,Osteoporosis,HP:0000939,,,
1725,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,Thiazide,,DB01325,DB01325,218140bfb4aa9cf2acfbdbf3cf994ecb7422df77aedc77f45b82c7ed496f941f,DB01325,DB01325,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,High calcium excretion,HP:0002150,,https://www.ncbi.nlm.nih.gov/pubmed/26251718,
1726,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,secondary carnitine deficiency (Carnitine deficiency)*,HP:0003234,,"https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf,https://www.ncbi.nlm.nih.gov/books/NBK1480/",
1727,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,"General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/",SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Citrulline,"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650",DB00155,DB00155,f220a4f6ebbf26d38e30093b27cfa690c0d7ecacdd94dc8fd4976db62b0aed4b,DB00155,DB00155,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",
1728,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,corticosteroids(Amcinonide),"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*,HP:0010978,,https://www.ncbi.nlm.nih.gov/pubmed/28057010,
1729,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,cyclosporin,,DB00091,DB00091,13d35d65cb3bb074f90d6868ed89c129d48145825aea20089025fd435a5bf52d,DB00091,DB00091,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,,,,,
1730,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Alendronate,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Osteopenia,HP:0000938,,https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,
1731,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,ACEI (Benazepril),,DB00542,DB00542,319fb70aaaefde71913ae194827adc63b4824662d899ec62d1d9351723e1d9b6,DB00542,DB00542,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Kidney failure,HP:0000083,,,
1732,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,proteinuria,HP:0000093,,,
1733,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,hypertension,HP:0000822,,,
1734,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,sodium phenylbutyrate,Drug has no difference in terms of prognosis.,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/26865117,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535",
1735,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,sodium benzoate,Drug has no difference in terms of prognosis.,DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535",
1736,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Lysine,,DB00123,DB00123,ddfbdace28c1f9f81f233925d671c7da70607547088b3a060bd544b81ef7e66d,DB00123,DB00123,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,hypolysinemia,,,,
1737,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Lysine/Arginine/carnitine/Citrulline,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",DB00123/DB00125/DB00583,DB00123 / DB00125 / DB00583,155110350052021a097a15d4af37febf5999d53f44f0ed8a09b4a20b42cc8fca,"DB00123,DB00125,DB00583","DB00123,DB00125,DB00583",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,orotic aciduria,HP:0003218,The drug works through preventing the aciduria and the hyperammonemia rather than treating it.,https://www.ncbi.nlm.nih.gov/pubmed/25614305,
1738,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,Symptomatic (C),C,hypolysinemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535",
1739,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,intracellular defect of arginine,HP:0005961,,,
1740,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,hyperproteinemia,HP:0002152,,,
1741,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Growth hormone,,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,growth impairment,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/",
1742,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,Short stature,HP:0004322,,,
1743,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/28057010",
1744,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Sodium benzoate+ L-carnitine+ low dose citrulline,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,DB03793+DB00583+DB00155,DB03793 + DB00583 + DB00155,fa475ebf9e681771186325a2d773598150d24979e78ed2913c0157d73e1db6e2,,,,,"DB03793,DB00583,DB00155","DB03793,DB00583,DB00155",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,episodic behavioral abnormalities,HP:0000708,,https://www.ncbi.nlm.nih.gov/pubmed/27567650,
1745,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,social interaction defect,HP:0000735,,,
1746,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,lack eye-eye contact,HP:0000817,,,
1747,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,Hepatosplenomegaly,HP:0001433,,,
1748,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Azathioprine,,DB00993,DB00993,9cc88629a863a5b4624dcdb4e9555f1f32829311a490b2c7dd7ab7b0cdd88e06,DB00993,DB00993,,,,,,,ECO:0000352,ECO:0000352,,,,,,HP:0001433,,,
1749,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,,,,,
1750,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,,,,,
1751,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Sargramostim,,DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Pulmonary Alveolar Proteinosis,HP:0006517,,"https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/",
1752,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,Low pulmonary function,HP:0005952,,,
1753,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,rGM CSF,,DB05386,DB05386,cbe58720e48c0726a5bfcdce15a5c5b83399fad147b650d68ad6779adde0706b,DB05386,DB05386,,,,,,,,,,,Symptomatic (C),C,Pulmonary Alveolar Proteinosis,HP:0006517,,"https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527",
1754,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,,,,,,,,,,,,,,,,,,,,Low pulmonary function,HP:0005952,,,
1755,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,prednisolone+mycophenolate mofetil,,DB00860+DB00688,DB00860 + DB00688,ad0d467cd315ed5394c57672960e4f25f158361bd7f052555203dfe6ed5e58a8,,,,,"DB00860,DB00688","DB00860,DB00688",,,,,,,Symptomatic (C),C,membranoproliferative glomerulonephritis,HP:0000793,,https://www.ncbi.nlm.nih.gov/pubmed/28087478,
1756,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,Carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Functional interaction (B),B,High urinary malonic acid,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843",
1757,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,Mediumâchain triglycerides,,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,Functional interaction (B),B,High blood malonylcarnitine level,HP:0031544,,"https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843",
1758,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Low endurance,HP:0025142,,,
1759,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Failurre to thrive,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/28781843,
1760,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Cardiomyopathy progrssion,HP:0003679,,,
1761,614202,,Number Sign,614202,"MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15",,,MAN1B1-CDG,,MAN1B1,MAN1B1,mannosidase alpha class 1B member 1,8684d28c786ecaaee0c6ae544c9292c71eaecada039a8188bee8575ed73e1097,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,Symptomatic (C),C,,,,https://www.ncbi.nlm.nih.gov/pubmed/29908352,
1762,611722,,Number Sign,611722,"KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY",SAPOSIN A DEFICIENCY,,Krabbe disease atypical due to Saposin A deficiency,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,
1763,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,Folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,Symptomatic (C),C,Abnormal 5âMTHF(Low),,,"https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733",
1764,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,White matter alteration,,,,
1765,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,deambulation,,,,
1766,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,Growth Hormone,,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,,,,,Symptomatic (C),C,Short Stature,,,https://www.ncbi.nlm.nih.gov/pubmed/27718492,
1767,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,Symptomatic (C),C,Corneal Oedema,,,"https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",
1768,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Oxidative stress,,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,
1769,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,l-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Symptomatic(C),C,electron transfer within the respiratory chain,,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,
1770,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Myopathy,HP:0003198,,https://www.ncbi.nlm.nih.gov/pubmed/26884075,
1771,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,"dopamine, dobutamine, thiazide and milrinone",,DB00988+DB0084+DB00232+DB00235,DB00988 + DB0084 + DB00232 + DB00235,ff4de40c92295359317d4460c5368d43666b6d88865ca66fd94ef71a229b18e2,,,,,"DB00988,DB0084,DB00232,DB00235","DB00988,DB0084,DB00232,DB00235",,,,,,,Symptomatic(C),C,acute congestive heart failure,HP:0001635,,https://www.ncbi.nlm.nih.gov/pubmed/26884075,
1772,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,mitochonic acid 5,,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,Symptomatic (C),C,Mitochondrial dysfunction,HP:0003287,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,
1773,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Decreased cellular ATP level,HP:0011925*,,,
1774,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,
1775,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,Insuline,,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,,,,,Symptomatic (C),C,Diabetes mellitus,HP:0000819,,https://www.ncbi.nlm.nih.gov/pubmed/25092642,
1776,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,cysteamine bitartrate,,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,Symptomatic (C),C,,HP:0000819,,"https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4,https://clinicaltrials.gov/ct2/show/NCT02473445",
1777,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,Sodium Pyruvate,,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),,Elevated serum lactate level,HP:0002151,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445",
1778,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,"High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*",HP:0200125,,,
1779,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Increased lateral ventricular lactate level,NA,,,
1780,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,High serum GDF15 level,NA,,,
1781,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,
1782,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,
1783,609242,,Number Sign,609242,KANZAKI DISEASE,"ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET;; NAGA DEFICIENCY, TYPE II;; SCHINDLER DISEASE, TYPE II",,Kanzaki disease/schindler Disease type 2,,NAGA,NAGA,alpha-N-acetylgalactosaminidase,e1bc66017ff77da9dff9bfd69363bbb79ee406e7d2b958ca8632639009921c6e,4.1.1.9,4.1.1.9,,"iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)",,NA,,,,,,,,,,,,,,,Direct interaction (A),A,NA,,,,
1784,609242,,Number Sign,609242,KANZAKI DISEASE,"ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET;; NAGA DEFICIENCY, TYPE II;; SCHINDLER DISEASE, TYPE II",,Kanzaki disease/schindler Disease type 2,,NAGA,NAGA,alpha-N-acetylgalactosaminidase,e1bc66017ff77da9dff9bfd69363bbb79ee406e7d2b958ca8632639009921c6e,4.1.1.9,4.1.1.9,,1-deoxygalactonojirimycin (DGJ,,DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,,,,,Direct interaction (A),A,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/23045655,
1785,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,carglumic acid,,DB06775,DB06775,4232311e92dd47c3fa1cd15c2af2c63ef49708a80c82e3cc943e86fc4cfdfaf2,DB06775,DB06775,,,,,,,,,,,Symptomatic (C),C,acute hyperammonemia,,,https://www.ncbi.nlm.nih.gov/pubmed/21207059,
1786,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Symptomatic (C),C,High toxic acyl-CoA level,,,"https://www.ncbi.nlm.nih.gov/pubmed/21290185,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",
1787,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,L- glycine,,DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,,,,,Symptomatic (C),C,"""abnormal Na+,K+-ATPase activity""",,,"https://www.ncbi.nlm.nih.gov/pubmed/15624372,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",
1788,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,Symptomatic (C),C,Secondary carnitine deficiency,,,https://www.ncbi.nlm.nih.gov/pubmed/16602101,
1789,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,High 3-hydroxyisovaleric acid level (C5),,,https://www.ncbi.nlm.nih.gov/pubmed/17299485,
1790,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,metabolic stress,,,https://www.ncbi.nlm.nih.gov/pubmed/8804338,
1791,611283,,Number Sign,611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD,"IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY",,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,ACAD8,isobutyryl-CoA dehydrogenase,3635f69daf4aed89522045025cdbe0f13d5dd67ad828da07a18615b21fa50b06,4.1.1.9,4.1.1.9,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28053874,
1792,611283,,Number Sign,611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD,"IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY",,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,ACAD8,isobutyryl-CoA dehydrogenase,3635f69daf4aed89522045025cdbe0f13d5dd67ad828da07a18615b21fa50b06,4.1.1.9,4.1.1.9,,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Symptomatic (C),C,,,,https://www.babysfirsttest.org/newborn-screening/conditions/isobutyrylglycinuria,
1793,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,Vitamin B12,,DB00115,DB00115,09d1640c1033b1c7e861047a863362e2af2b6bc5ebb67876b539c3c7e3ffa46a,DB00115,DB00115,,,,,,,,,,,"Disease name: Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in life. https:,www.sciencedirect.com,science,article,pii,""S1096719207001667
Drug name:  Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https:"",www.sciencedirect.com,science,article,pii,""S0140673610609610?via%3Dihub
Mutation that didn't get benefits out the treatment: Homozygotes of R252W, IVS4-1GâA, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https:"",www.sciencedirect.com,science,article,pii,""S0022347699701381?via%3Dihub
Mutation improved by treatment: The serum Phe concentrations of patients have those mutaions never exceeded 20 mg"",""dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https:"",www.sciencedirect.com,science,article,pii,S0022347699701381?via%3Dihubhttps:,www.sciencedirect.com,science,article,pii,S0022347699701381?via%3Dihub",B,Low levels of serum vitamin B12,,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://rarediseases.info.nih.gov/diseases/3024/intrinsic-factor-deficiency#",
1794,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,High RBC's mean corpuscular volume,,,,
1795,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Low Hemoglobin concentration,,,,
1796,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal reticulocyte count,,,,
1797,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,Corticosteroid,,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,Symptomatic (C),C,Gastric mucosal atrophy,,,https://www.ncbi.nlm.nih.gov/pubmed/24424200,
1798,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,Recombinant human IGF1(Mecasermin),,DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,Direct interaction ( Mechanistic A),A,Low height velocity,,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306",
1799,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Low lean body mass,,,,
1800,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal linear growth (Low),,,,
1801,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,low insulin senstivity,,,,
1802,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal circulating GH level,,,,
1803,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal circulating IGFBP level,,,,
1804,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal circulating insulin level,,,,
1805,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Low body mass index,,,https://www.ncbi.nlm.nih.gov/pubmed/10770174,
1806,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal Body fat composition,,,,
1807,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,insulin resistance,,,,
1808,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,,,,,,,,,,,,,,,,,,,,Abnormal Si,,,,
1809,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,4.1.1.9,4.1.1.9,,IGFBP-3 (insulin-like growth factor binding protein-3),,DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,Supportive (C),C,hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/19627167,
1810,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,4.1.1.9,4.1.1.9,,phenytoin,,DB00252,DB00252,7355ede4950f929c039e58163d1daf16e75b5ea0f0e2193086b6c3e613e23110,DB00252,DB00252,,,,,,,,,,,Symptomatic (C),C,Seizures,,,https://www.ncbi.nlm.nih.gov/pubmed/20301746,
1811,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,4.1.1.9,4.1.1.9,,valproate,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,p.Y508C,Symptomatic (C),C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1812,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,4.1.1.9,4.1.1.9,,creatine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,Symptomatic (C),C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1813,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,4.1.1.9,4.1.1.9,,glutathione [Nâacetylâcysteine],,DB00143,DB00143,47128d69a6436e8bc030c60539ca77b0da944edbbd6b971074ad7717b1db1b54,DB00143,DB00143,,,,,,,,,,,Symptomatic (C),C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1814,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,4.1.1.9,4.1.1.9,,NAD+ [nicotinamide riboside],,DB00143,DB00143,47128d69a6436e8bc030c60539ca77b0da944edbbd6b971074ad7717b1db1b54,DB00143,DB00143,,,,,,,,,,,Symptomatic (C),C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1815,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)","The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/",NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction (B),B,,,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1816,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,Desipramine,,DB01151,DB01151,36798a080dc39909ba7a44f76f4ae4b38a64630581bea5a22cadc4f8bb511b8f,DB01151,DB01151,,,,,,,,,,,Symptomatic (C),C,,,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1817,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,D-PUFAs,,DB01151,DB01151,36798a080dc39909ba7a44f76f4ae4b38a64630581bea5a22cadc4f8bb511b8f,DB01151,DB01151,,,,,,,,,,,,,Chronic constipation,,,"http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/19304794/",
1818,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,,,,,,,,,,,,,,,,,,,,Bulbar dysfunction,,,,
1819,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,,,,,,,,,,,,,,,,,,,,Abnormal motor function,,,,
1820,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,,,,,,,,,,,,,,,,,,,,Defective eye motor function,,,,
1821,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,,,,,,,,,,,,,,,,,,,,Poor head control,,,,
1822,269920,,Number Sign,269920,INFANTILE SIALIC ACID STORAGE DISEASE; ISSD,"SIALURIA, INFANTILE FORM;; N-ACETYLNEURAMINIC ACID STORAGE DISEASE;; NANA STORAGE DISEASE; NSD",,Free sialic acid storage disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,,,,,,,,,,,,,,,,,Symptomatic (C),C,,,,https://www.ncbi.nlm.nih.gov/pubmed/20301643,
1823,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,Levetiracetam,,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,generalized tonic-clonic seizure,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/28662915,https://www.ncbi.nlm.nih.gov/pubmed/20301643",
1824,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,Phenobarbital,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,,,Seizures,,,https://www.ncbi.nlm.nih.gov/pubmed/12794688,
1825,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,,,,,,,,,,,,,,,,,,,,,,,,
1826,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,,,,,,,,,,,,,,,,,,,,,,,,
1827,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,ManNac (N-acetylmannosamine),,DB12536,DB12536,19405aa93bb2bbf18ee9664f0d2836ed598d9bf87edfebbbf2ebf6c0bfcbe702,DB12536,DB12536,,,,,,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,Decreased sialylation of muscle glycans,HP:0012350,,"https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927",
1828,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Low circulating levels of free sialic acids,HP:0012363,,,
1829,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Rimmed vacuoles,HP:0003805,,https://www.ncbi.nlm.nih.gov/pubmed/21517694,
1830,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Amyloid deposition,HP:0003216*,,https://www.ncbi.nlm.nih.gov/pubmed/21517694,
1831,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),,CHEBI:17012+DB12536,CHEBI:17012 + DB12536,1ee4ce78419fbf47e9341c2013d9573879a1cbb3218ad8db3174804bae6d0b1c,,,,,"CHEBI:17012,DB12536",DB12536,CHEBI_17012,,ECO:0007121,ECO:0007121,,,Functional interaction(Mechanistic B),B,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229",
1832,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Decreased sialylation of muscle glycans,HP:0012350,,,
1833,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,GNE gene lipoplex,,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction ( Mechanistic A),A,Decline of muscle strength (Muscle weakness),HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/21517694,
1834,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,Sialic acid,,CHEBI:17012,CHEBI:17012,d0e14b7fc3e352405716c3695a24532140cd82532f1ea97fefce1cff7857daa7,CHEBI:17012,,CHEBI_17012,,,,,,,,,,Functional interaction(Mechanistic B),B,Muscle weakness,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/21517694,
1835,252500,,Number Sign,252500,MUCOLIPIDOSIS II ALPHA/BETA,MUCOLIPIDOSIS II; ML II;; ML II ALPHA/BETA;; I-CELL DISEASE; ICD,,I cell disease,,GNPTAB,GNPTAB,(Î±) &(Î²)GlcNAc-1-phosphotransferas,c006250556b586a6a83267fa1c76f3af62b033b1ecb685bb54d495655c2b65f9,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,No treatment is available in DDIEM,,CHEBI:17012,CHEBI:17012,d0e14b7fc3e352405716c3695a24532140cd82532f1ea97fefce1cff7857daa7,CHEBI:17012,,CHEBI_17012,,,,,,,,,,,,,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/21517694,
1836,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,methylcobalamin,,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (Mechanistic B),B,Megalobalstic anaemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566",
1837,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Low level of serum B12,HP:0040126,,,
1838,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Neurological abnormalities,HP:0000707,,,
1839,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Normocytic anemia,HP:0001897,,"https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530",
1840,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Hyperammonemia,HP:0001987,,,
1841,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Increased liver enzyme activities,HP:0002910,,,
1842,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Abnormal methylmalonic acid level.,HP:0012120,,,
1843,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,,,,,,,,,,,,,,,,,,,,Hyperpigmentation,HP:0000953,,https://www.ncbi.nlm.nih.gov/pubmed/24222293,
1844,242600,242600,Number Sign,242600,IMINOGLYCINURIA,,,Iminoglycinuria,,SLC36A2 /SLC6A20/SLC6A19,"SLC36A2,SLC6A20,SLC6A19",solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19,32edfb4290a5c7f37848c48e31c682f40441ef9a6d1fc9b559674d8947a6be44,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0000953,,https://www.ncbi.nlm.nih.gov/pubmed/24222293,
1845,605637,,Number Sign,605637,"MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA","MYPOP;; MYOPATHY WITH CONGENITAL JOINT CONTRACTURES, OPHTHALMOPLEGIA, AND RIMMED VACUOLES;; INCLUSION BODY MYOPATHY 3, AUTOSOMAL DOMINANT, FORMERLY; IBM3, FORMERLY",,Inclusion body myopathy type 3,,MYH2,MYH2,myosin heavy chain 2,2091f9744d556c7e160085f9df23d3066594e864b405f4ce8e866628c5d7e411,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0000953,,https://www.ncbi.nlm.nih.gov/pubmed/24222293,
1846,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,EC:2.7.1.60,"3.2.1.183,2.7.1.60",,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0000953,,https://www.ncbi.nlm.nih.gov/pubmed/24222293,
1847,248510,,Number Sign,248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",BETA-MANNOSIDOSIS;; LYSOSOMAL BETA-MANNOSIDASE DEFICIENCY;; BETA-MANNOSIDASE DEFICIENCY,,Beta-mannosidosis,,MANBA,MANBA,mannosidase beta,bf89ccd68f6d15f301593d5ae826449f92327260c39d32e2a6d349815db98356,3.2.1.25,3.2.1.25,EC,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0000953,,https://www.ncbi.nlm.nih.gov/pubmed/24222293,
1848,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,Tauroursodeoxycholic acid,,DB08834,DB08834,21a431c60b3527945cb2c8797188e4496fdf35037b7454503d027df62bdc0d04,DB08834,DB08834,,,,,,,ECO:0005542,ECO:0005542,,,Functional intearction (Mecahnistic B),,ER (endoplasmic reticulum) stress,NA,,https://www.ncbi.nlm.nih.gov/pubmed/30420558,
1849,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,High triglyceride levels,HP:0002155,,,
1850,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,Muscle weakness,HP:0001324,,,
1851,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,bezafibrate,,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0005542,ECO:0005542,,,Functional intearction (Mecahnistic B),,Increased muscle lipid droplets,HP:0012240,,https://www.ncbi.nlm.nih.gov/pubmed/30420558,
1852,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,ER (endoplasmic reticulum) stress,NA,,,
1853,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,muscle weakness,HP:0001324,,,
1854,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,fiber necrosis,HP:0003713,,,
1855,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,,,,,,,,,,,,,,,,,,,,Myopathy,HP:0003198,,,
1856,550500,,Number Sign,550500,"MYOGLOBINURIA, RECURRENT",,,Myoglobinuria recurrent,,MT-CO1/MT-CO2/MT-CO3,"MT-CO1,MT-CO2,MT-CO3",Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3,efc819ecfc95950874b24fb75047360709d4ee1c7af8f39542687bc6ecea0a0e,P00414,1.9.3.1,"P00403,P00414",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0003198,,,
1857,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,"Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.",MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",Levetiracetam/Clonazepam/Zonisamide,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",DB01202/DB01068/DB00909,DB01202 / DB01068 / DB00909,5b37759a7630bfde9d160fdfc1e1079649a4825a4e435a81aa3567126adf4be1,"DB01202,DB01068,DB00909","DB01202,DB01068,DB00909",,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Myoclonic epliepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/14981187,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",
1858,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",Coenzyme Q10+L-carnitine+ lipoic acid,,DB09270+DB00583+ DB00166,DB09270 + DB00583 + DB00166,a82a7a6847c1cab2c36814ff22f93cfd415d5b654ca2891596ceca5fdeec25fb,,,,,"DB09270,DB00583,DB00166","DB09270,DB00583,DB00166",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Ankle weakness progression(Disease progression)*,HP:0003287,,https://www.ncbi.nlm.nih.gov/pubmed/17080429,
1859,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",,,,,,,,,,,,,,,,,,,,High resting plasma lactate concentration,HP:0003288,,https://www.ncbi.nlm.nih.gov/pubmed/17275787,
1860,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",Levetiracetam+ l-carnitine +CoQ10,,DB01202+DB00583+DB09270,DB01202 + DB00583 + DB09270,42ca91327c1669921d53dd0e207dd08ca4dceb72e32c238ca1a70bcf9faa0870,,,,,"DB01202,DB00583,DB09270","DB01202,DB00583,DB09270",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Myoclonus,HP:0002123,,https://www.ncbi.nlm.nih.gov/pubmed/17275787,
1861,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",,,,,,,,,,,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,,"https://www.ncbi.nlm.nih.gov/pubmed/28686997,https://link.springer.com/article/10.1007/s11940-011-0131-z",
1862,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",piracetam,,DB09210,DB09210,8ee096a00f28ec447d107f6d69a991017c968be0f92012a5f7dac48d685da58a,DB09210,DB09210,,,,,,,ECO:0000352,ECO:0000352,m.8344A > G,,Symptomatic (C),,Myoclonic seizures,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/28717435,https://link.springer.com/article/10.1007/s11940-011-0131-z",
1863,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414",Clonazepam,,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Asterixis-like movement(Abnormality of movement),HP:0100022,,https://www.ncbi.nlm.nih.gov/pubmed/1490314,
1864,601776,601776,Number Sign,601776,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1","EDSMC;; ADDUCTED THUMB, CLUBFOOT, AND PROGRESSIVE JOINT AND SKIN LAXITY SYNDROME;; EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY;; ADDUCTED THUMB-CLUBFOOT SYNDROME; ATCS;; DUNDAR SYNDROME;; ARTHROGRYPOSIS, DISTAL, WITH PECULIAR FACIES AND HYDRONEPHROSIS",,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1",,CHST14,CHST14,Dermatan-4-sulfotransferase-1,c10dbc3bc5764b00c110988af2c0900102f8990181b09add53a96440529463a3,2.8.2.35,2.8.2.35,,Magnesium,,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,constipation,HP:0002019,,https://www.ncbi.nlm.nih.gov/pubmed/21744491,
1865,300559,,Number Sign,300559,"GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D","GSD IXd;; MUSCLE PHOSPHORYLASE KINASE DEFICIENCY;; MUSCLE GLYCOGENOSIS, X-LINKED",,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,PHKA1,alpha subunit of muscle phosphorylase kinase,c11d5221b35a2e83c0f0a80e0e927f1a871844354ae56562aae92002447577ed,2.7.11.19,2.7.11.19,,cortisone,,DB14681,DB14681,6aaa696df62f8f21055a8e74cdbb67bc3cefa6271fd55579c3ae70046fcacd45,DB14681,DB14681,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Muscular hypotonia,HP:0001252,,https://www.ncbi.nlm.nih.gov/pubmed/15637709,
1866,300559,,Number Sign,300559,"GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D","GSD IXd;; MUSCLE PHOSPHORYLASE KINASE DEFICIENCY;; MUSCLE GLYCOGENOSIS, X-LINKED",,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,PHKA1,alpha subunit of muscle phosphorylase kinase,c11d5221b35a2e83c0f0a80e0e927f1a871844354ae56562aae92002447577ed,2.7.11.19,2.7.11.19,,Glucose,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Exercise intolerance,HP:0009020,,https://www.ncbi.nlm.nih.gov/pubmed/18401027,
1867,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,L-carnitine,,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,https://www.ncbi.nlm.nih.gov/pubmed/26006750,
1868,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,Riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,,
1869,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,Thiamine,,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,,
1870,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,Corticosteroid,,D07A,D07A,2cb015d1511207ad26a4d38b5c32d88029cf77233411add4a47ca8e56421499b,D07A,,,D07A,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Nummular eczema (Eczema)*,HP:0000964*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/,
1871,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,B-Blockers+Angiotensin-converting enzyme inhibitors,,C07+C09,C07 + C09,0dd6fd179ec7c4bd311f3450dcb680839eb067e81ce9c4a617e00808de939e4d,,,,,"C07,C09",,,"C07,C09",ECO:0000352,ECO:0000352,,,Symptomatic (C),,Cardiomyopathy,HP:0001638,,https://www.ncbi.nlm.nih.gov/pubmed/26067811,
1872,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,botulinum toxin,,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,strabismus,HP:0000486,,https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,
1873,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,,,,,,,,,,,,,,,,,,,,esotropia,HP:0000565,,,
1874,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,Ad5-LARGE-eGFP,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,Muscle dystrophy,HP:0003560,,https://www.ncbi.nlm.nih.gov/pubmed/15184894,
1875,236670,236670,Number Sign,236670,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT1-RELATED;; HYDROCEPHALUS, AGYRIA, AND RETINAL DYSPLASIA;; HARD SYNDROME;; CEREBROOCULAR DYSPLASIA-MUSCULAR DYSTROPHY SYNDROME;; COD-MD SYNDROME",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1",,POMT1,POMT1,protein O-mannosyltransferase 1,c7f8ff87033b272860227f552819241c016e0fca894341285c3e08c74a60a022,2.4.1.109,2.4.1.109,,Ad5-LARGE-eGFP,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,Muscle dystrophy,HP:0003560,,https://www.nature.com/articles/nm1059,
1876,613150,613150,Number Sign,613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,POMT2,Protein O-mannosyl-transferase 2,097ad49f5521518b32c2cca0cdf2be4bdbd4d20603044715ba88dbb9616ef8ab,2.4.1.109,2.4.1.109,,Diuretics,,C03,C03,0dfab5acbae0000ecfc55bf78f6be90842878115c5802d14dd7312bebc9e627a,C03,,,C03,,,,,ECO:0000352,ECO:0000352,,,Symptomatic ( C),C,congestive cardiac failure,HP:0001635,,https://www.ncbi.nlm.nih.gov/pubmed/28980384,
1877,613150,613150,Number Sign,613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,POMT2,Protein O-mannosyl-transferase 2,097ad49f5521518b32c2cca0cdf2be4bdbd4d20603044715ba88dbb9616ef8ab,2.4.1.109,2.4.1.109,,,,,,,,,,,,,,,,,,,,,tachypnea,HP:0002789,,,
1878,253800,253800,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4",,FKTN,FKTN,Fukutin,e2280cceba60a485896d6ee0ae5b4ef7286ded3d8716ea4b928b8c1a5a33c6a9,O75072,,O75072,Antisense oligonucleotide,,,,,,,,,,,,,ECO:0001565/ECO:0005542,"ECO:0001565,ECO:0005542",,,Direct interaction (Mechanistic A),A,Abnormal Fukutin function,NA,,https://www.ncbi.nlm.nih.gov/pubmed/21979053,
1879,613153,613153,Number Sign,613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,FKRP,Fukutin-related protein,8edd0c7b5b360f8dd25b7ceb32c870632438ef7f2899a90fd27fc4e8d271d442,Q9H9S5,,Q9H9S5,Adeno-associated Virus 9 Mediated FKRP Gene Therapy,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct intercation (Mechanistic A),,abnormal muscle function,HP:0011804,,https://www.sciencedirect.com/science/article/pii/S152500161632250X,
1880,613153,613153,Number Sign,613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,FKRP,Fukutin-related protein,8edd0c7b5b360f8dd25b7ceb32c870632438ef7f2899a90fd27fc4e8d271d442,Q9H9S5,,Q9H9S5,Ad5-LARGE-eGFP,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,Muscle dystrophy,HP:0003560,,https://www.nature.com/articles/nm1059,
1881,613154,613154,Number Sign,613154,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, LARGE-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6",,LARGE,LARGE,LARGE xylosyl- and glucuronyltransferase 1,4a75624094bb9c5b27b81c2ab5d84c7ce85379a40721abd66a3edc89426197ea,O95461,,O95461,Ad5-LARGE-eGFP,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,Muscle dystrophy,HP:0003560,,https://www.nature.com/articles/nm1059,
1882,614643,614643,Number Sign,614643,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, ISPD-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7",,ISPD,ISPD,D-ribitol-5-phosphate cytidylyltransferase,10bdf4c4f285c1ce6ee17dd5ee486693dfa59931fa716040f6879d4c1b29ca5c,2.7.7.40,2.7.7.40,,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,HP:0003560,,https://www.nature.com/articles/nm1059,
1883,614830,614830,Number Sign,614830,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GTDC2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8",,POMGNT2,POMGNT2,"Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2",d3af412b529d4c6d7f8bb5d14ba7576a6b23a1b3b47d909368684a75f49a6727,2.4.1.312,2.4.1.312,,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,HP:0003560,,https://www.nature.com/articles/nm1059,
1884,616538,616538,Number Sign,616538,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9","WALKER-WARBURG SYNDROME OR MUSCLE-EYE BRAIN DISEASE, DAG1-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9",,DAG1,DAG1,Dystroglycan,454bf13807a5c0a75636fd2014216e1277b482a1171ab578c58150092787fea9,Q14118,,Q14118,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,HP:0003560,,https://www.nature.com/articles/nm1059,
1885,615041,615041,Number Sign,615041,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, TMEM5-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10",,RXYLT1,RXYLT1,Ribitol-5-phosphate xylosyltransferase 1,d8d34cc8b62f435e85d09444b024d6f5fcce046c880d2ef74a2f8f841e0725ec,Q9Y2B1,,Q9Y2B1,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,,,HP:0003560,,https://www.nature.com/articles/nm1059,
1886,615181,615181,Number Sign,615181,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GALNT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11",,B3GALNT2,B3GALNT2,"UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2",f34c269281f61dc12a835c76d8f23c0b5bcb8b3f2f1e305d0de0d363a022e55e,2.4.1.313,2.4.1.313,,Phenobarbital,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/29273094,
1887,615249,615249,Number Sign,615249,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMK-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12",,POMK,POMK,Protein O-mannose kinase,dc1d24f7d7689be2947236a17fb249c84137b1f67a5d8dbc9725544beca83ae8,2.7.1.183,2.7.1.183,,No treatment is available in DDIEM,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,,,,,,,,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/29273094,
1888,615287,615287,Number Sign,615287,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GNT1-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13",,B4GAT1,B4GAT1,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,No treatment is available in DDIEM,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,,,,,,,,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/29273094,
1889,151800,,NULL,151800,"LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC",,Multiple symmetric lipomatosis,The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/,MTTK????,MTTK????,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,salbutamol,,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),C,Rapid progression in body fat mass( Abnormality of adipose tissue* ),HP:0009124*,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,
1890,272200,,Number Sign,272200,MULTIPLE SULFATASE DEFICIENCY; MSD,"MUCOSULFATIDOSIS;; SULFATIDOSIS, JUVENILE, AUSTIN TYPE",,Multiple sulfatase deficiency,,SUMF1,SUMF1,Formylglycine-generating enzyme,ddad1534997c2598bdbd497a3952e451b5f9f63e985e1642291441b812ad246b,1.8.3.7,1.8.3.7,,No treatment is available in DDIEM,,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,,,,,,,Low metabolic rate ( Abnormality of fatty acid metabolism)*,HP:0004359*,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,
1891,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,Dexamethasone,,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,ECO:0001565,ECO:0001565,,,Direct interaction( Mechanistic)>>>Activity modification,A,Abnormal cellular proliferation,HP:0031377,,"https://www.ncbi.nlm.nih.gov/pubmed/10947080,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",
1892,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,vandetanib,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,ECO:0007121,ECO:0007121,M918T,,Direct interaction (Mechanistis A)>>>Activity modification,A,low quality of life ( Constitutional symptom)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",
1893,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Pain,HP:0012531,,,
1894,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Objective response rate (ORR),NA,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,
1895,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,disease control rate(  Rapid disease progression),HP:0003678,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,
1896,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Short Progression-free survival,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22025146/,https://www.ncbi.nlm.nih.gov/pubmed/20371662/,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",
1897,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Elevated calcitonin,HP:0003528,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046",
1898,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Increased plasma CEA,HP:0031029,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046",
1899,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Bone pain,HP:0002653,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/,https://clinicaltrials.gov/ct2/show/NCT00514046",
1900,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Low skeletal muscle mass,HP:0003199,,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,
1901,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Weight loss,HP:0001824,,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,
1902,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Decreased adipose tissue,HP:0040063,,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,
1903,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,
1904,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,bortezomib + vandetanib,,DB00188+DB05294,DB00188 + DB05294,22f83ab11572b99f4651a2f912c9d37c16f8cfeccc93bc6a827a7ecf7282ccf7,,,,,"DB00188,DB05294","DB00188,DB05294",,,ECO:0007121,ECO:0007121,,,,,neoplastic growth,HP:0002664,,"https://www.ncbi.nlm.nih.gov/pubmed/18381602/,https://www.ncbi.nlm.nih.gov/pubmed/26170630,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",
1905,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,cabozantinib ( XL184),,DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,ECO:0007121,ECO:0007121,,,Direct interaction (Mechanistis A),,phospholylation of RET,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605",
1906,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Elevated calcitonin,HP:0003528,,,
1907,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Short Progression-free survival,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730",
1908,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,Low tumor response rate,NA,"The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501",,
1909,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,overall survival( premature death),MP:    ....,"Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/",,
1910,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,
1911,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,
1912,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,
1913,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,
1914,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,levetiracetam,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,
1915,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,topiramate,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
1916,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,oxcarbazepine,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Seizures,HP:0001250,,,
1917,300868,,Number Sign,300868,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2,"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 20; EIEE20;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 4; GPIBD4",,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 2,Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216,PIGA,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,22da0bb2fd3a94ca0f43e9aeeb0619bf5c68b6b0496b3b0e04a36197b3c55c48,2.4.1.198,2.4.1.198,,No medical treatment is availble in DDDIEM,,DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,,,,,,,,HP:0001250,,,
1918,300818,,Number Sign,300818,PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1,,,Paroxysmal nocturnal hemoglobinuria,PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949,PIGA,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,22da0bb2fd3a94ca0f43e9aeeb0619bf5c68b6b0496b3b0e04a36197b3c55c48,2.4.1.199,2.4.1.199,,Eculizumab,,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,Paroxysmal nocturnal hemoglobinuria,HP:0004818,,https://www.ncbi.nlm.nih.gov/pubmed/28516949,
1919,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Phenobarbital,Drugs has decreased rhe frequency of the tonic seizuress,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,
1920,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Clonzepam,Drugs has decreased rhe frequency of the tonic seizuress,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,
1921,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Potassium bromide,Drugs has decreased rhe frequency of the tonic seizuress,CHEBI:32030,CHEBI:32030,d48d05e725d73ea326f70f870fab57c6eb2a2947e5367197e9bd5486d5614ccf,CHEBI:32030,,CHEBI_32030,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,
1922,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,acetazolamide,,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),C,"""Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)""",HP:0002872*,,,
1923,248510,248510,Number Sign,248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",BETA-MANNOSIDOSIS;; LYSOSOMAL BETA-MANNOSIDASE DEFICIENCY;; BETA-MANNOSIDASE DEFICIENCY,,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",,MANBA,MANBA,Beta-mannosidase,94644c41f9880dc9478e8f8fc63d2bdc0175246a57a0d31c0c7867a5c87de1e2,3.2.1.25,3.2.1.25,,No medical treatment is available in DDIEM,,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,,,,,,,,HP:0002872*,,,
1924,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,"In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.",BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Natural osmolyte trimethylamine N-oxide (TMAO),,CHEBI:15724,CHEBI:15724,44eb303a64e5b597de9983ee80a31523772fc8e9c1ccc10fcbeec2b6d310e57c,CHEBI:15724,,CHEBI_15724,,,,,,ECO:0000352,ECO:0000352,F364C- alpha,A209D-alpha,Direct interaction( Mechanistic A),A,No phenotypes were mentioned in the study. In vitro Study.,HP:0002872*,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,
1925,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,,,,,,,,,,,,,,,,Y368C- alpha,,,,,,,,
1926,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,,,,,,,,,,,,,,,,Y393N- alpha,,,,,,,,
1927,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Norleucine,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,,,Branched-chain amino acid accumulation,HP:0008344,Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,
1928,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,,,,,,,,,,,,,,,,,,,,Encephalopathy,HP:0001298,"The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,
1929,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,,,,,,,,,,,,,,,,,,,,High Î±-ketoisocaproate level,NA,,,
1930,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ib,,BCKDHB,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",34bb8a3f0cdff01269838ceecbbf1a5135f8c33bf6b636c5eaf0e64b0af8107b,1.2.4.4,1.2.4.4,,Sodium phenylbutyrate,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic  A),A,High plasma branched chain keto acids,NA,,"https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799",
1931,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ib,,BCKDHB,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",34bb8a3f0cdff01269838ceecbbf1a5135f8c33bf6b636c5eaf0e64b0af8107b,1.2.4.4,1.2.4.4,,,,,,,,,,,,,,,,,,,,,High plasma branched chain amino acids,HP:0008344,,,
1932,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type II,,DBT,DBT,"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial",63b1c771f8947b9cd2157b2b8ea31efcc598ead581b2c0255da6899126199074,2.3.1.168,2.3.1.168,,Thiamine,,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction (Mechanistic B),B,High plasma branched chain amino acids,HP:0008344,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006,
1933,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,N-acetylcysteine +deferoxamine,,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,ECO:0000352,ECO:0000352,,,Symptomatic ( C),C,Memory impairment,HP:0002354,,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,
1934,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581",
1935,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Behavioural abnormalites,HP:0000708,,,
1936,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,cognitive imapirment,HP:0100543,,,
1937,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Learning impairment,HP:0001328,,,
1938,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,Riboflavin,,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (Mechanistic A),A,Exercise intolerance,HP:0003546,,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,
1939,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Mitochondrial proliferation in the muscle,HP:0003200,,,
1940,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Myopathy,HP:0003198,,,
1941,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,,,,,,,,,,,,,,,,,,,,Lactic acidosis,HP:0003128,,,
1942,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED",PHENYLKETONURIA,"Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub",PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,Tetrahydrobiopterin (sapropterin),,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,"P407S,A373T,R241C","Homozygotes of R252W ,Homozygotes of IVS4-1GâA ,Homozygotes of R413P",Direct interaction (Mechanistic A)>>Functional interaction( Functional complementation or a defective protein by stimulation),A,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",
1943,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED","HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,Tetrahydrobiopterin,,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction (Mechanistic A),A,Hyperphenylalaninemia,HP:0004923,,,
1944,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED","HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,Pegvaliase,,DB12839,DB12839,bf68275714e8f1adc53ed49e332120b42a92d5b072866e0613ce5a74f6af3e54,DB12839,DB12839,,,,,,,ECO:0007121+ECO:0005542,"ECO:0007121,ECO:0005542",,,Functional interaction ( Mechanistic B),B,Abnormal blood Phenylalanine levels,HP:0004923,,"https://www.sciencedirect.com/science/article/pii/S1096719218300210,https://www.sciencedirect.com/science/article/pii/S1525001605000845,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",
1945,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",
1946,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Vitamin B12+imipramine,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",DB00115+DB00458,DB00115 + DB00458,a94f3e3f7ee031ae53fd86bab25c5b58f28ed0d7e3cf476fc361409ff5879926,,,,,"DB00115,DB00458","DB00115,DB00458",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Diabetic polyneuropathy,HP:0001271,,https://www.ncbi.nlm.nih.gov/pubmed/28766015,
1947,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Prokinetic agents,,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Epigastric pain,HP:0410019,,https://www.ncbi.nlm.nih.gov/pubmed/28766015,
1948,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Acid regurgitation,HP:0002020,,,
1949,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,pregabalin,,DB00230,DB00230,465268e6188d99fe04e7f35af0afce31725c036f584899a741f34203de7dc38d,DB00230,DB00230,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neuropathic pain(Abnormality of pain sensation)*,HP:0010832*,,https://www.ncbi.nlm.nih.gov/pubmed/28766015,
1950,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,insulin,,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Diabetes,HP:0000819,"Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802",https://www.ncbi.nlm.nih.gov/pubmed/28756474,
1951,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,clonazepam,,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Involuntary movement,HP:0004305,,https://www.ncbi.nlm.nih.gov/pubmed/28756475,
1952,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Immunosuppressent +Carbonic anhydrase inhibitors,"The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.",L04+S01EC,L04 + S01EC,25cb721097bc18b8babbbb546737efd243e4b49c650cf59db78289e7701d108e,,,,,"L04,S01EC",,,"L04,S01EC",ECO:0000352,ECO:0000352,,,Symptomatic (C),,Macular cystoid changes,HP:0008028,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,
1953,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Triamcinolone acetonide,The drug was administered through intravitreal injection.,DB00620,DB00620,aceb2282ca3dc2d9e48b9a62c6c2ebc5c9926d969a8541e72d631f13cc666e4a,DB00620,DB00620,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Macular cystoid changes,HP:0011505,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,
1954,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Abnormal visual acuity,HP:0030532,,,
1955,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Intraretinal cystoid spaces (Retinal disease)*,HP:0000479*,,,
1956,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Non-steroidal anti-inflammatory agents,,M02AA,M02AA,028aa0edadc8fb72bc2fa2825a3abb4fefecacbd19e2d18dd9e079ccaba6846c,M02AA,,,M02AA,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Intraretinal cystoid spaces (Retinal disease)*,HP:0000479*,,https://www.ncbi.nlm.nih.gov/pubmed/23806424/,
1957,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Vitamins,,A11,A11,37b5be61fefd1edea7761c41767c6c4e8bda09d7e7b73002b6ef98b481bb68a5,A11,,,A11,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Malnutrition,HP:0004395,,,
1958,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,"MTTL1,MTTE,MTTK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine,,DB09270+A11EB+B02BA+ DB00583,DB09270 + A11EB + B02BA + DB00583,596ffc1f4b7ee7738d579680464e03d84daf73f9d03f62b4eebdb86768f34a73,,,,,"DB09270,A11EB,B02BA,DB00583","DB09270,DB00583",,"A11EB,B02BA",ECO:0000352,ECO:0000352,,,Symptomatic (C),,Mitochondrial dysfunction,HP:0003287,,,
1959,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS","MELAS syndrome can be caused by mutation in several genes, including MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000",MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/26823911,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118",
1960,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*,HP:0008972*,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/,
1961,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,arginine hydrochloride,,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Stroke-like episodes,HP:0002401,,"https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523",
1962,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Painful neuropathy(neuropathy)*,HP:0009830*,,,
1963,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Congestive heart failure,HP:0001635,,,
1964,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Pancreatic beta-cell dysfunction,HP:0006279,,,
1965,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Nicotinamide Riboside,,DB03227,DB03227,82435dc28985eea848a447ae2ad7c0f00d4219d1bd246cb036ff994edeb18815,DB03227,DB03227,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),,Muscle abnormality related to mitochondrial dysfunction,HP:0003800,,"https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2,http://ichgcp.net/clinical-trials-registry/NCT03432871",
1966,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Sodium Pyruvate,,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0007121,ECO:0007121,,,,,Elevated serum lactate level,HP:0002151,,https://www.ncbi.nlm.nih.gov/pubmed/30738201,
1967,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,"High lactate ,pyruvate ratio",NA,,,
1968,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Increased lateral ventricular lactate level,NA,,,
1969,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,High serum GDF15 level,NA,,,
1970,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Duloxetine,,DB00476,DB00476,9e638cc22e8ada9b06b373ac7b1a0dd2f6e8b8a89ac7ea830119149470414ee9,DB00476,DB00476,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Depression,HP:0000716,,https://www.ncbi.nlm.nih.gov/pubmed/29596118,
1971,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Taurine,,DB01956,DB01956,e2c35ccb93ffade0cbb9686ed721b0a3a2b9e0bc72b4e19db7c29c4ec1dba1b0,DB01956,DB01956,,,,,,,ECO:0000352,ECO:0000352,,,,,Oxidative stress,HP:0025464,,,
1972,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Mitochondrial dysfunction,HP:0003287,,,
1973,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Idebenone,,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),,Decreased activity of mitochondrial ATP synthase complex,HP:0011925,,"https://clinicaltrials.gov/ct2/show/NCT00887562,https://www.ncbi.nlm.nih.gov/pubmed/8757046",
1974,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Idebenone+Riboflavin,,DB09081+DB00140,DB09081 + DB00140,4972ea57eb644d98329ff8d20365dacd1e5daf6fe39faba1496cba9499b0e559,,,,,"DB09081,DB00140","DB09081,DB00140",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046",
1975,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Abnormal EEG (focal epileptiform activity),HP:0002353,,,
1976,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Hyperintensity of cerebral white matter on MRI,HP:0030890,,,
1977,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,,,,,,,,,,,,,,,,,,,,Stroke-like attacks,HP:0002401,,,
1978,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,"MTTL1,MTTQ,MTTH,MTTK,MTTC,MTTS1,MTND1,MTND5,MTND6,MTTS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,Idebenone+Coenzyme Q10,,DB09081+DB09270,DB09081 + DB09270,3898f75122df4adcec19acb5eda5edc015a70f7e191cb483747a9431860ec796,,,,,"DB09081,DB09270","DB09081,DB09270",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Abnormal EEG,HP:0002353,,https://www.sciencedirect.com/science/article/pii/0022510X89901123,
1979,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,Pyridoxine,,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,R229W,,Direct interaction ( Mechanistic A),,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,
1980,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,Clonic contractions,,There was partial improvement then patients died,,
1981,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,Lip-smacking automatisms(Epilepsy)*,HP:0001250,,,
1982,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1983,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1984,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1985,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1986,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1987,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,Pyridoxal phosphate,,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,ECO:0000352,ECO:0000352,,,Direct interaction ( Mechanistic A),,Siezures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/12747882,
1988,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,Developmental delay,HP:0001263,,,
1989,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,
1990,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,Phenobarbitone,,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Siezures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
1991,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,Folinic acid,,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Low total RBC folate level,HP:0040087,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
1992,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Bone marrow megaloblastic changes,HP:0001980,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
1993,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Low 5-MTHF level,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract",
1994,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Abscent 5-MTHF(Abnormal CSF metabolite level)*,HP:0025454*,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
1995,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Abnormal CSF folate level,HP:0012446,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
1996,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Megaloblastic anemia,HP:0001889,,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,
1997,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,,,,,
1998,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,,,,,
1999,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,Hydroxycobalamin + Folic acid,,DB00200+DB00158,DB00200 + DB00158,bc68f3adc5677a3e362d5e6039d3f3d63c1739de17bbe6d2508434f0a86176c0,,,,,"DB00200,DB00158","DB00200,DB00158",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Abnormal hemoglobin level,HP:0025546,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
2000,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,,,,,,,,,,,,,,,,,,,,Abnormal MCV level,HP:0025065,,,
2001,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,Phenobarbitone+levetiracetam,,DB01174+DB01202,DB01174 + DB01202,59709b84f52729770a9fd2d0a7bf0f754282c3510642d40ab5b7a0a043ccf628,,,,,"DB01174,DB01202","DB01174,DB01202",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,seizure,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/21310277,
2002,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Copper Histadine,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",DB01174+DB01202,DB01174 + DB01202,59709b84f52729770a9fd2d0a7bf0f754282c3510642d40ab5b7a0a043ccf628,,,,,"DB01174,DB01202","DB01174,DB01202",,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",G666R,2757delAG,Functional interaction( Mechanistic B),,Abnormal brain electrical activity,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1",
2003,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,N1304S,Del ex20â23,,,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/,
2004,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,"""IVS9,DS,+6TâG""",Q1385X,,,Neurological abnormalities.,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979",
2005,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Neurologic burden,HP:0002344,,https://clinicaltrials.gov/ct2/show/results/NCT00001262,
2006,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Rapid disease progression,HP:0003678,,https://www.ncbi.nlm.nih.gov/pubmed/30384011,
2007,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Eplieptic discharge (Interictal EEG abnormality)*,HP:0025373,,https://www.ncbi.nlm.nih.gov/pubmed/8223785,
2008,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Low muscular tone,HP:0001290,,,
2009,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Appendicular hyoptonia,HP:0012389,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,
2010,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Socio-cognitive abnormality(Neurodevelopmental abnormality)*,HP:0012759*,,,
2011,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Poor weight gain,HP:0001508,,,
2012,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Woolly hair,HP:0002224,,,
2013,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Hypopigmented skin,HP:0001010,,,
2014,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Thiuram + Copper Dimethyldithiocarbamate (Cu-DMDTC ),"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",DB13245+DB09130+CHEBI:84293,DB13245 + DB09130 + CHEBI:84293,d7c060bd822c9384dd782e524c06d917379bdc37ed2702caa0864cfcc59e2d7d,,,,,"DB13245,DB09130,CHEBI:84293","DB13245,DB09130",CHEBI_84293,,ECO:0005542,ECO:0005542,,,Functional interaction( Mechanistic B),,Low Brain Copper (Abnormal copper levels)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011",
2015,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Copper accumulation in kidney(Abnormal copper levels)*,HP:0010836*,,,
2016,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Copper nitrilotriacetate (Cu-NTA),,DB09130+CHEBI:25548,DB09130 + CHEBI:25548,41ffb8f8da0dbf9a1c2c49cefe6943a600378afbfb3838d61eabd64235443da5,,,,,"DB09130,CHEBI:25548",DB09130,CHEBI_25548,,ECO:0005542,ECO:0005542,,,Functional interaction( Mechanistic B),,Low survival rate (Mortality)*,HP:0040006*,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism,
2017,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Alpha-lipoic acid,"Due to its strong copper chelation capability, a copper salt should be added simultaneously",DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic (C),,Copper stroage abnormalities (Copper stroage abnormalities)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M",
2018,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Functional interaction( Mechanistic B),,Low life span (Mortality)*,HP:0040006*,,"https://www.ncbi.nlm.nih.gov/pubmed/30127521,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M",
2019,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,Direct interaction ( Mechanistic A),,Low brain copper levels (Abnormal copper levels)*,HP:0010836*,,https://www.ncbi.nlm.nih.gov/pubmed/30090842,
2020,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*,HP:0012535*,,,
2021,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Abnormal growth,HP:0001507,,,
2022,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Brain mitochondrial abnormalities (Mitochondrial dysfunction),HP:0003287*,,,
2023,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Behavioral abnormality,HP:0000708,,,
2024,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,,,,,,,,,,,,,,,,,,,,Neurological abnormalties,HP:0000707,,,
2025,249900,249900,Number Sign,249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATOR DEFICIENCY;; SAPOSIN B DEFICIENCY,,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,,PSAP,PSAP,Prosaposin,e38e3a0b3942f1718f3ea65419b9a3dda09953bf21d3e6f6ce819d60b65baea0,P07602,,P07602,No medical treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,HP:0000707,,,
2026,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,S-adenosylmethionine,,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction( Mechanistic B),,Poor appetite,HP:0004396,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2027,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Low IQ,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025",
2028,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Behavioural abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2029,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Abnormal Awake EEG,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025",
2030,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Delayed mylination,HP:0012449,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2031,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2032,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Hyperreflexia,HP:0001347,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2033,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Irritability,HP:0000737,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2034,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Foot clouns,HP:0011448,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2035,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Poor traction response,NA,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2036,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Poor weight gain,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2037,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Delayed motor milestone,HP:0001270,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2038,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormalities,HP:0012759,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2039,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Brain demylination,HP:0007266,,"https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A",
2040,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Valproic acid,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Myoclonic epilepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A",
2041,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,S-adenosylmethionine,,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B),,Poor appetite,HP:0004396,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2042,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Low IQ,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/27671892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025",
2043,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Behavioural abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/27671893,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2044,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Abnormal Awake EEG,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/27671894,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025",
2045,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Delayed development,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/27671895,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2046,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/27671896,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/",
2047,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Hyperreflexia,HP:0001347,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2048,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Irritability,HP:0000737,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2049,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Foot clouns,HP:0011448,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2050,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Poor traction response (Poor muscle tone)*,HP:0001290,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2051,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Poor weight gain,HP:0001508,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2052,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Delayed motor milestone,HP:0001270,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2053,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Neurodevelopmental abnormality,HP:0012759,,https://www.ncbi.nlm.nih.gov/pubmed/30389272,
2054,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,,,,,,,,,,,,,,,,,,,,Brain demylination,HP:0007266,,"https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A",
2055,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Valproic acid,,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Myoclonic epilepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A",
2056,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Hydroxicobalamin + betaine+ Folinic acid,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c),,Haemolysis,HP:0001878,,"https://www.ncbi.nlm.nih.gov/pubmed/24210589,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/",
2057,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/24210590,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.ncbi.nlm.nih.gov/pubmed/19821145",
2058,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,High urine methylmalonic acid level,HP:0012120,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,
2059,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Impaired renal function,HP:0012211,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,
2060,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,decreased glomerular filtration rate,HP:0012213,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,
2061,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Fatigue,HP:0012378,,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,
2062,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Anorexia,HP:0002039,,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,
2063,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Delirium,HP:0031258,,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,
2064,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Spasticity,HP:0001257,,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,
2065,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Lower limb hyperreflexia,HP:0002395,,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,
2066,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day),DB00200+DB06756+DB00650+A11EA,DB00200 + DB06756 + DB00650 + A11EA,3766322ddf58151727f9422ea3f645c2fe9161a1ec9cb35cda516c862e63d905,,,,,"DB00200,DB06756,DB00650,A11EA","DB00200,DB06756,DB00650",,A11EA,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,Psychiatric disturbances,HP:0000708,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,
2067,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Lower extremity weakness,HP:0007340,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,
2068,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Gait instability,HP:0002317,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,
2069,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2070,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Hydroxicobalamin + betaine+ carnitine,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c),,High urine methylmalonic acid level,HP:0012120,,"https://link.springer.com/article/10.1023/A:1005353530303,https://www.ncbi.nlm.nih.gov/pubmed/25511120",
2071,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,"https://link.springer.com/article/10.1023/A:1005353530304,https://www.ncbi.nlm.nih.gov/pubmed/25511120",
2072,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,High urine methylmalonic acid level,HP:0012120,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2073,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Abnormal brain stem auditory evoked potentials,HP:0006958,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2074,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Abnormal visual evoked potentials,HP:0000649,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2075,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Mental impairment,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2076,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Emotional lability,HP:0000712,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2077,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Psychiatric disturbances,HP:0000708,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2078,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Difficulty walking,HP:0002355,,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,
2079,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Dementia,HP:0000726,,https://www.ncbi.nlm.nih.gov/pubmed/17431913,
2080,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2081,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Hydroxicobalamin,,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),,Megaloblastic anemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913",
2082,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Methylmalonic aciduria,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913",
2083,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Elevated blood homocystine,HP:0002160,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,
2084,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Dementia,HP:0000726,,"https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120",
2085,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Myelopathy,HP:0002196,,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,
2086,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Gait instability,HP:0002317,,https://www.ncbi.nlm.nih.gov/pubmed/17431913,
2087,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Coumadin,,DB00682,DB00682,62aa94367de86d58ee9af6efff9cc00a45b7c1a21a2ea4d1896ae452a1f89458,DB00682,DB00682,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Deep venous thrombosis,HP:0002625,,https://www.ncbi.nlm.nih.gov/pubmed/11320193/,
2088,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Fluoxetine,,DB00472,DB00472,49364ceecbc7bb7f74d1a2853dec65abe9be41304aef496551b4f6652893cae5,DB00472,DB00472,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Emotional lability,HP:0000712,,https://www.ncbi.nlm.nih.gov/pubmed/25511120,
2089,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Poor eye contact,HP:0000817,,https://www.ncbi.nlm.nih.gov/pubmed/25511120,
2090,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,lorazepam,,DB00186,DB00186,5b85ccbd9dcc0c2b679cb7769a095a9de2345c006c12195d688d24fb6fc0ec6f,DB00186,DB00186,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Abnormal mental status,HP:0100543,,https://www.ncbi.nlm.nih.gov/pubmed/25511120,
2091,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Zonisamide,The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120,DB00909,DB00909,18de586f793c8d7432d331c9afe6dfcf1fcb41f7152cad42ef308d101c3060c9,DB00909,DB00909,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,sleep cycle disturbance,HP:0002360,,https://www.ncbi.nlm.nih.gov/pubmed/25511120,
2092,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Methylprednisolone sodium succinate +
Immune Globulin","Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",DB14644+DB00028,DB14644 + DB00028,b6b05e1366ceaa298aed959d7b3bfa931fd0d2471e75e86c01a8291a6420bb5a,,,,,"DB14644,DB00028","DB14644,DB00028",,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,"Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*","HP:0001298*,HP:0002960*","Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",https://www.ncbi.nlm.nih.gov/pubmed/25511120,
2093,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Risperidone,,DB00734,DB00734,3386dc330cfd8bc8e3e77c8209b4c33d8c91496c09c526e583f1be47c58819dc,DB00734,DB00734,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Psychiatric disturbance,HP:0000708,,https://www.ncbi.nlm.nih.gov/pubmed/17431913,
2094,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Hydroxicobalamin + betaine+Folinic acid+ carnitine,,DB00200+DB06756+DB00650+DB00583,DB00200 + DB06756 + DB00650 + DB00583,564819e8fa6cdc7a662745b83daf152c552a7057a07562eb6cb61f9eec78f834,,,,,"DB00200,DB06756,DB00650,DB00583","DB00200,DB06756,DB00650,DB00583",,,ECO:0000352,ECO:0000352,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,High urine methylmalonic acid level,HP:0012120,,https://www.ncbi.nlm.nih.gov/pubmed/18848477,
2095,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,https://www.ncbi.nlm.nih.gov/pubmed/18848477,
2096,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,Vatiquinone (Epi-743),,DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,ECO:0007121,ECO:0007121,,,Symptomatic (C),,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1",
2097,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2098,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2099,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2100,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,
2101,277410,,Number Sign,277410,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblD TYPE;; METHYLMALONIC ACIDURIA, cblH TYPE, FORMERLY;; METHYLMALONIC ACIDEMIA, cblH TYPE, FORMERLY","HOMOCYSTINURIA, cblD TYPE, VARIANT 1, INCLUDED;; METHYLMALONIC ACIDURIA, cblD TYPE, VARIANT 2, INCLUDED","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;",,C2orf25/MMADHC,"C2orf25,MMADHC","Methylmalonic aciduria and homocystinuria type D protein, mitochondrial",c078e7f188ee3b4d848889488761fabcc897ce61727ec2a8cf6b017c2e354245,Q9H3L0,,Q9H3L0,,,,,,,,,,,,,,,,,,,,,,,,
2102,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,Eculizumab,,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic (C),,Microhematuria,HP:0002907,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2103,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Microalbuminura,HP:0012594,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2104,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Anemia,HP:0001903,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2105,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2106,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Thrombotic microangiopathy,NA,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2107,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,Hydroxicobalamin,,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,Functional interaction(Mechanistic B),,Elevated plasma homocysteine concentration,HP:0002160,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2108,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Megaloblastic anemia,HP:0001889,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2109,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2110,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Granulocytopenia,HP:0001913,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2111,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Microhematuria,HP:0002907,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2112,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2113,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,Developmental delay,HP:0001263,,https://www.ncbi.nlm.nih.gov/pubmed/28210839,
2114,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,,,,,
2115,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,,,,,,,,,,,,,,,,,,,,,,,,
2116,236270,236270,Number Sign,236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblE COMPLEMENTATION TYPE;; VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE;; METHYLCOBALAMIN DEFICIENCY, cblE TYPE",,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,MTRR,Methionine synthase reductase,353c4ad43857fb31edfd977b8de50fef0674cacb7598a896e79d78b4f9d736e3,1.16.1.8,1.16.1.8,,Hydroxycobalamin,,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,,,,,,,
2117,236270,236270,Number Sign,236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblE COMPLEMENTATION TYPE;; VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE;; METHYLCOBALAMIN DEFICIENCY, cblE TYPE",,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,MTRR,Methionine synthase reductase,353c4ad43857fb31edfd977b8de50fef0674cacb7598a896e79d78b4f9d736e3,1.16.1.8,1.16.1.8,,,,,,,,,,,,,,,,,,,,,,,,,
2118,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,levodopa,,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(c),,Limb dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/30838265,
2119,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Axial dystonia,HP:0002530,,https://www.ncbi.nlm.nih.gov/pubmed/30838265,
2120,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Gait abnormality,HP:0001288,,https://www.ncbi.nlm.nih.gov/pubmed/30838265,
2121,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Parkinsonism,HP:0001300,,https://www.ncbi.nlm.nih.gov/pubmed/24943079,
2122,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Tremor,HP:0001337,,https://www.ncbi.nlm.nih.gov/pubmed/30941926,
2123,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Rigidity,HP:0002063,,https://www.ncbi.nlm.nih.gov/pubmed/30941926,
2124,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Bradykinesia,HP:0002067,,https://www.ncbi.nlm.nih.gov/pubmed/30941926,
2125,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,Phenytoin+oxcarbazepine+levetiracetam,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",DB00252+DB00776+ DB01202,DB00252 + DB00776 + DB01202,bf9b4958be979c4a6c5d145ce58a557c9836bf45156ad5f94ec054196f7ffe75,,,,,"DB00252,DB00776,DB01202","DB00252,DB00776,DB01202",,,ECO:0000352,ECO:0000352,,,Symptomatic(c),,Mitochondrial epilepsy(Epilepsy)*,HP:0001250*,,https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,
2126,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2127,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,coenzyme Q10,,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,Symptomatic (C),C,Mitochondrial myopathy,HP:0003737,,https://www.ncbi.nlm.nih.gov/pubmed/27442316,
2128,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,Low energy level,HP:0003473,,,
2129,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,prednisone,,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,Symptomatic (C),C,Inflammatory myopathy,HP:0009071,,https://www.ncbi.nlm.nih.gov/pubmed/25674260,
2130,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,dysphagia,HP:0002015,,,
2131,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2132,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,neck muscle weakness,HP:0000467,,,
2133,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2134,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,dysarthria,HP:0001260,,,
2135,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2136,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2137,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,
2138,258450,,Number Sign,258450,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,POLG,POLG,DNA polymerase subunit gamma-2,05ca22b9f15a9940d875945b3bbba14821ca93eecb651a7b2c8e9c2f553fe566,2.7.7.7,2.7.7.7,,levodopa,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(c),,Parkinsonism,HP:0001300,,https://www.ncbi.nlm.nih.gov/pubmed/12872260,
2139,609283,,Number Sign,609283,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,SLC25A4,SLC25A4,ADP/ATP translocase 1,3ba299a94b1a380dd555b61a544a885b0a16565a455b3c8691e10fb862205c14,P12235,,P12235,,,,,,,,,,,,,,,,,,,,,,,,
2140,616479,,Number Sign,616479,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,RNASEH1,RNASEH1,Ribonuclease H1,91deb5452e18b29f70319e80bc6672fb58aab312e38daa894f9bb4a350dfb8f8,3.1.26.4,3.1.26.4,,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,
2141,609286,,Number Sign,609286,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,TWNK,TWNK,"Twinkle protein, mitochondrial",9134aee3c28e981e7960ed4c82017c85369bd5c2afcd3f00fc573f5c62739de1,3.6.4.12,3.6.4.12,,Levodopa,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,Symptomatic(c),,Parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",
2142,617069,,Number Sign,617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,TK2,"Thymidine kinase 2, mitochondrial",d9b49c2facb54007cc8c7f4bd7acf15b82512be76500ecd24a8de6a105ae3542,2.7.1.21,2.7.1.21,,,,,,,,,,,,,,,,,,,,,,,,,
2143,617069,,Number Sign,617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,TK2,"Thymidine kinase 2, mitochondrial",d9b49c2facb54007cc8c7f4bd7acf15b82512be76500ecd24a8de6a105ae3542,2.7.1.21,2.7.1.21,,,,,,,,,,,,,,,,,,,,,,,,,
2144,617070,,Number Sign,617070,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,DGUOK,DGUOK,"Deoxyguanosine kinase, mitochondrial",109fec707f195cc06764d1cb304ea423e4d8093988104a24242677bbdf0e1920,2.7.1.113,2.7.1.113,,,,,,,,,,,,,,,,,,,,,,,,,
2145,613077,,Number Sign,613077,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,RRM2B,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B,12060fb8d515e9d5e2fd2631cb7e308570657ff4261d704c49c49281e8ffced9,1.17.4.1,1.17.4.1,,,,,,,,,,,,,,,,,,,,,,,,,
2146,618098,,Number Sign,618098,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,TOP3A,TOP3A,DNA topoisomerase 3-alpha,5119b72ceb81745461fc50d5d947c7637e19f46c5e39c9412b6e334b3decd1be,5.6.2.2,5.6.2.2,,,,,,,,,,,,,,,,,,,,,,,,,
2147,615156,,Number Sign,615156,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,DNA2,DNA2,DNA replication ATP-dependent helicase/nuclease DNA2,49165101c2efa3057c537686188ad7851b54c79672860fd927688f32250cbb47,3.1.-.-,"3.6.4.12,3.1.-.-",,Vitamin E+L-carnitine+Dichloroacetate+Creatine,,DB00163+DB00583+DB08809+DB00148,DB00163 + DB00583 + DB08809 + DB00148,903cace9e734a215ed260b48972258380ffa2d611967c0fcd32e3514eddc89c7,,,,,"DB00163,DB00583,DB08809,DB00148","DB00163,DB00583,DB08809,DB00148",,,ECO:0000352,ECO:0000352,,,Symptomatic(c),,Difficulty walking,HP:0002355,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/,
2148,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,Idebenone,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,,,High left ventricular mass index ( Left ventricular hypertrophy)*,HP:0001712*,,"https://www.ncbi.nlm.nih.gov/pubmed/11907009,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",
